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Chapter 1 
1. Introduction 
1.1 Medicinal Chemistry 
Medicinal chemistry is a scientific discipline at the intersection of chemistry and 
pharmacology, involved with designing, synthesizing and developing pharmaceutical drugs.1 
It is a highly interdisciplinary science combining organic chemistry with biochemistry, 
pharmacology, molecular biology and molecular modeling.2 The medicinal chemist attempts 
to design and synthesize a medicine or a pharmaceutically active compound, which has to 
satisfy the following criteria. It has to exert the intended effect without side effects and 
interactions with other drugs.3 
How many medicines fit these criteria? 
The short answer is none and there is no pharmaceutical compound on the market today 
which can completely satisfy all these conditions. Admittedly, some drugs come quite close to 
the ideal. For example, penicillin has been one of the most effective antibacterial agents ever 
discovered and has also been one of the safest. However, it still has some drawbacks, neither 
it has been able to kill all known bacteria nor it totally avoid allergic reactions. There are 
many patients who show an allergic reaction to penicillin and are required to take alternative 
antibacterial agents.3 
Why should drugs work? 
Indeed we take it for granted that they work, but why should chemicals some of which having 
remarkably simple structures, have such an important effect on a complicated and large 
structure such as a human body? The answer lies in the way, the human body operates. If we 
go to the molecular level of our body we would see a magnificent array of chemical reactions 
taking place, keeping the body healthy and functioning. Drugs which may be mere chemicals 
entering this world of chemical reactions with which they are interacting, can have an effect. 
However, the surprise might be their specific effects, which is the result of where they react in 
the body.3 
Where do drugs work?  
Since life is made up of cells, then quite clearly drugs must act on cells. The structure of a 
typical cell is shown in figure 1. The cell membrane, is a semipermeable lipid bilayer, which 
is separating the interior of a cell from the external environment.4 It contains a wide variety of 
biological molecules, primarily proteins and lipids, which are involved in a vast array of 
cellular processes such as cell adhesion, ion channel conductance and cell signaling. The two 
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layers of phospholipids, in the cell membrane are arranged in such a way that the hydrophobic 
tails point to each other and form a fatty hydrophobic centre, while the ionic (hydrophilic) 
head-groups are placed at the inner and outer surfaces of the cell membrane.3 
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The cell membrane does not only consist of phospholipids, but there are a large variety of 
proteins situated in the cell membrane (Figure 2). Some proteins lie on the surface of the 
membrane and other proteins are embedded in it with part of their structure exposed to outer 
or inner surface of the membrane. The structure of protein domains depends on the location 
where it is present. Portions of proteins embedded in the cell membrane have a large number 
of hydrophobic amino acids, whereas those portions, which stick out on the surface have a 
large number of hydrophilic amino acids. Different drugs act at different locations in the cell 
and there is no particular target site which can be pinpointed as the spot where drugs can act. 
Now it would be closer to understand how drugs work by classifying them with regard to the 
particular cell component they interact.3 
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Figure. 2 The position of proteins associated with the cell membrane
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Adapted from An introduction to medicinal chemistry, Graham L.. Patric, 1995, 1st edition
 
To understand this, we have to look at the molecular level and find out, which type of 
molecules in the cell are affected by drugs. There are three important molecular targets, 
namely lipids, proteins and nucleic acids.  
The number of drugs which interact with lipids are relatively small in general, they all act in 
the same way by disrupting the lipid structure of cell membranes. In order to understand how 
drugs interact with proteins, it is necessary to understand their structure. Proteins have four 
levels of structure which are primary, secondary, tertiary and quaternary. The primary 
structure is quite simple, in which the individual amino acids are linked through peptide 
bonds. The secondary structure consists of protein chain regions, ordered as α-helices and β-
sheets. The tertiary structure is the overall 3D shape of a protein. The tertiary structure of 
enzymes and receptors is crucial to their function and also to their interaction with drugs. 
Enzymes and receptors fold up on themselves to form more complex tertiary structures by van 
der Waals interaction, hydrogen bonding, ionic, covalent bonds and hydrophobic interactions. 
Quaternary structure is confined to those proteins which are made up of a number of protein 
subunits.3 
1.2 Drug action at receptors 
1.2.1 The receptor role 
Receptors are one of the major targets for drugs. Drugs which interact with receptors are 
amongst the most important in medicine and provide treatment for ailments such as pain, 
depression, Parkinson's disease, psychosis, heart failure, asthma, and many other problems.3 
What are these receptors and what do they do? 
Cells are all individual, yet in a complex organism such as human body, they have to get 
along with their neighbors. There has to be some sort of communication system. 
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Communication is essential to make sure that all the body's organs to function in a 
coordinated and controlled fashion. Control and communication comes primarily from the 
central nervous system (CNS) which receives and sends messages via a vast network of 
nerves. The nerves do not connect directly to their target cells and they stop just a short 
distance away from the cell surface. The distance is about 100 Å, but it is a space which the 
electrical impulse is unable to jump. Therefore, there should be a way of carrying the message 
across the gap between the nerve ending and the cell. This is done by the release of a chemical 
messenger (neurotransmitter) from the nerve cell. Once released, this neurotransmitter can 
diffuse across the gap to the target cell, where it can bind and interact with a specific protein 
(receptor) embedded in the cell membrane. It is noteworthy to remember that the 
communication system depends crucially on a chemical messenger. Since a chemical process 
is involved, it should be possible for other chemicals (drugs) to interfere or to take part in the 
process.3 
1.2.2 Neurotransmitters 
Neurotransmitters are chemicals which relay, amplify and modulate signals between a neuron 
and another cell.3 There are a large variety of neurotransmitters and many of them are quite 
simple molecules. Neurotransmitters include compounds such as acetylcholine, noradrenaline, 
dopamine, γ-aminobutyric acid (GABA), serotonin, histamine and even glycine.3 
In general, a nerve releases only one type of neurotransmitter and the receptor, which awaits it 
on the target cell, will be specific for that messenger. However, this does not mean that the 
target cell has only one type of receptor protein. Each target cell has a large number of nerves 
communicating with it and they do not all use the same neurotransmitter. (From one and the 
same nerve cell, also more than one neurotransmitter can be released). Therefore, the target 
cell will also have other types of receptors specific for those neurotransmitters. When the 
neurotransmitter is released it will interact with a receptor and a message is received. The cell 
responds to that message, changes its internal chemistry and a biological response results 
accordingly.3 
Communication is clearly essential for the normal working of the human body and if it 
becomes faulty then it leads to diseases such as depression, heart problems, schizophrenia, 
muscle fatigue and many other problems. 
What sort of things could go wrong? 
One problem would be if too many messengers were released, the target cell could become 
over stimulated. Alternatively, if too few messengers were sent out the activation level of the 
target cell could become too low. At this point drugs can play a role by either substituting 
 5 
messengers (if there is a lack of the body's own messengers) or by blocking the receptors for 
the physiological (natural) messengers (if there are too many host messengers). Drugs of the 
former type are known as agonists and those of the latter type are known as antagonists.3 
What determines whether a drug is an agonist or an antagonist and is it possible to predict 
whether a new drug will act as one or the other? 
In order to answer that, we have to understand what happens at the molecular level when a 
small molecule such as a drug or a neurotransmitter interacts with a receptor protein. Let us 
look at receptors, when one of the body's own neurotransmitters interacts with it.3 
1.3 Receptors 
A receptor is a protein molecule, embedded in either the plasma membrane or cytoplasm of a 
cell, to which a mobile signaling molecule may attach. A molecule which binds to a receptor 
is called a "ligand," and it may be a neurotransmitter, a hormone, a pharmaceutical drug, or a 
toxin. It is embedded within the cell membrane with part of its structure facing outside of the 
cell. The protein surface has a complicated 3D shape with a specific area, which has the 
correct shape to accept the incoming messenger. This area is known as the binding site and it 
is analogous to the active site of an enzyme. When the chemical messenger fits into this site, it 
'switches on' the receptor molecule and a message is received (Figure 3).3 
Receptor
Messenger
Receptor
Induced fit
CellCellCell
Messenger
Receptor
Messenger
Receptor
Cell
Membrane
Cell
Membrane
Cell
Membrane
Figure 3. Binding of a messenger to a receptor
message
Adapted from An introduction to medicinal chemistry, Graham L. Patric 1995 1st edition
 
Receptors can be regarded as the sensing elements in the system of chemical communication 
that coordinate the function of all the different cells in the body, the chemical messengers 
being hormones or transmitter substances. Many therapeutically useful synthetic drugs act, 
either as agonists or antagonists, on receptors for endogenous mediators.3 
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1.3.1 Receptor families 
In terms of both molecular structure and nature of the transduction mechanism, we can 
distinguish four receptor types (Figure 4).4 
      (A) Direct ligand gated channel type (type 1)         (B) G-protein coupled type (type 2) 
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    Figure 4. General structure of four receptor super families  
    Adapted from Pharmacology, fourth edition, Churchill, livingstone Inc. 1995 
 
Type 1: receptors for fast neurotransmitters, coupled directly to an ion channel, example the 
nicotinic acetylcholine receptor, the GABAA receptor, the glutamate receptor.  
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Type 2: receptors for many hormones and slow transmitters, coupled to effector system via a 
G-protein, example, the muscarinic acetylcholine receptor (mAChR), noradrenergic receptors 
and histamine receptors.  
Type 3: receptors for insulin and various growth factors, which are directly linked to tyrosine 
kinase.  
Type 4: receptors for steroid hormones, thyroid hormone and other agents such as retinoic 
acid and vitamin D.  
Receptors of the first three categories are membrane proteins, whereas the steroid receptors 
are intracellular proteins. The molecular organization of these four types of receptors is shown 
in fig 4. With in the same family of GPCRs, the sequence varies in particular regions and 
lengths of intracellular and extracellular loops, but the overall structural patterns of the 
receptors are consistent. The identification of these superfamilies represents a major step 
forward in understanding how drugs act.4 
1.4 G-protein coupled receptors  
G-protein coupled receptors (GPCRs) comprise one of the largest superfamilies of human 
genome.5 The recent achievement of human genome project has revealed that there are 
approximately 900 GPCR genes in the human genome.6 Most of these genes are identified on 
the basis of sequence homology to known GPCR genes. For most of these receptors natural 
ligands have been identified. However the ligands for some receptors have not yet been 
identified and they are, therefore reffered to as orphan GPCRs. Orphan GPCR research is 
therefore important from the perspctives of both basic and applied science. The identification 
of ligands for orphan GPCRs should yield important clues as to their physiological functions 
and will help determine weather they are suitable as drug targets.  The identification of 
ligands for orphan GPCRs is expected to lead to the discovery of new regulatory mechanism 
of human body. Further more, GPCRs have been historically proven to be the most successful 
targets in the field of drug discovery.5 
G-protein coupled receptors (GPCRs), also known as seven-transmembrane domain receptors, 
7TM receptors or hepta helical receptors, consist of a large protein family of transmembrane 
receptors that sense molecules outside the cell and activate inside signal transduction 
pathways and ultimately cellular responces. G-protein coupled receptors are found only in 
eukaryotes including yeast, plants, chaonoflagellates and animals.7 G protein-coupled 
receptors are involved in many diseases, and are also the target of around half of all modern 
medicinal drugs. The ligands that bind and activate these receptors include phermones, 
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hormones and neurotransmitters. They vary in size from small molecules to peptides to large 
proteins.7 
There are two principal signal transduction pathways involving the G-protein coupled 
receptors, the cAMP signal pathway and the phosphatidylinositol pathway.8 GPCRs can be 
grouped into 6 classes based on sequence homology and functional similarity.9,10 
• Class A (Rhodopsin-like)  
• Class B ( Secretin receptor family)  
• Class C (Metabotropic glutamate/phermone)  
• Class D ( Fungal mating pheromone receptors)  
• Class E (Cyclic AMP receptors)  
• Class F ( Frizzled/Smoothened)  
The very large rhodopsin A group has been further subdivided into 19 subgroups (A1-A19).9 
1.4.1 Molecular structure of GPCRs 
Dixon and coworkers characterized and cloned β-adreno receptor as a first receptor of GPCRs 
family.4 Most GPCRs consists of a single poly peptide chain of 400-500 residues and about 
40-60 kDa of molecular mass, whose general anatomy is shown in fig 4B.4 They all poses 
seven trans membrane α-helices, and the helices are connected via three intracellular and 
extracellular loops, ICL 1-3 and ECL 1-3, respectively. Both the extra cellular N-terminus and 
the intracellular C-terminus vary greatly in length and sequence. The other highly variable 
region is the long third cytoplasmic loop. Site directed mutagenesis experiments show that the 
cytoplasmic loop is the region of the molecule that couples to the G-protein. Therefore 
deletion or modification of this section results in receptors that still bind ligands but cannot 
associate with G-proteins or produce response. Usually, a particular receptor subtype couples 
selectively with a particular G-protein and it has been proven, by genetic engineering, that the 
third cytoplasmic loop is one of the structural elements conferring G-protein selectivity.4 
1.4.2 G-Proteins and their role 
The guanine nucleotide-binding proteins (G proteins), are a family of proteins involved in 
second messenger cascades. G-proteins are so called because they function as "molecular 
switches", alternating between an inactive GDP and active GTP bound state, ultimately going 
on to regulate downstream cell processes. G-proteins belong to the larger group of enzymes 
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called GTPases5 and are important signal transducing molecules in cells. In fact, diseases such 
as diabetes, allergies, depression, cardiovascular defects and certain forms of cancer, among 
other pathologies, are thought to arise due to disorder of G-protein signaling.5 They are the go 
between proteins, the so called G-proteins because of their interaction with the guanine 
nucleotides, GTP and GDP. G-proteins are currently the object of much interest. Alfred G. 
Gilman and Martin Rodbell got nobel prize in physiology in the year 1994 for their discovery 
of G-proteins and their role in signal transduction.6 
1.4.3 G-Protein cycle and Classification of G-Proteins 
1.4.4 Types of G proteins 
G-proteins can be roughly classified into two distinct families of proteins.7 The first category 
‘heterotrimeric’ or the "large" G-proteins that are activated by G-protein-coupled receptors 
are made up of an α subunit, and a βγ dimer. The second category, "small" G-proteins (20-25 
kDa), belong to the Ras superfamily of small GTPases. These proteins are homologous to the 
α- subunit which is found in heterotrimers and are in fact monomeric. However, they also 
bind to GTP, GDP and are involved in signal transduction. Heterotrimeric G-proteins share a 
common mode of action, that is activation in response to a conformation change in the G-
protein-coupled receptor, followed by exchange of GTP for GDP and finally dissociation in 
order to activate further proteins in the signal transduction pathway. However, the specific 
mechanism differs between different types of G-proteins.8 
1.4.5 G-protein cycle 
Receptor activated G-proteins are bound to the inner surface of the cell membrane. They 
consist of Gα and the tightly associated Gβγ subunits. There are four main families of Gα 
subunits, Gαs, Gαi/o, Gαq/11 and Gα12/13.8 These groups differ primarily in effector recognition, 
but share a similar mechanism of activation. 
When agonist (ligand) binds to GPCR, it induces a conformational change and promotes GDP 
dissociation. This allows an interaction between the activated protein and the nucleotide-free 
G-protein, forming a ternary complex (step 1). These G-proteins consist of a Gα-subunit and a 
Gβγ-dimer. The next step is GDP exchanges with GTP on the Gα subunit, that allows the 
receptor to function as guanine nucleotide exchange factor (step 2). This exchange reduces the 
affinity of Gα subunit to the Gβγ dimer leading to a disruption of the ternary complex as a 
result the G-protein dissociates to Gα-GTP and the Gβγ dimmer (step 3). The dissociated Gα-
GTP and the Gβγ dimer activates or inhibits several effector proteins causing a variety of 
intracellular effects (step 4). After a certain period, the Gα-GTP subunit undergoes hydrolysis 
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into Gα-GDP and Pi and the intrinsic activity of Gα subunit deactivates (step 5). Finally 
reassociation of Gα-GDP and βγ heterodimer closing the G-protein cycle (step 6).9 
Figure 5. Activation of G-protein cycle
Adapted from Seifert et al, Life Sciences, 2003, 73, 2263
 
1.5 Two state activation model of GPCRs and ligand classification 
The two-state model of GPCR activation is an elegant way to explain and describe the actions 
of GPCR ligands.10 According to this model, a GPCR can be in an active state R*
 
and an 
inactive state R, which are in equilibrium. Agonists are substances which can bind to the 
receptor and stabilize the active conformation. Neutral antagonists do not alter the 
equilibrium, but only block the binding site of the natural ligand. The active state is able to 
bind to a G-protein and cause GDP/GTP exchange, whereas the inactive state hardly interacts 
with G-proteins. However, since both receptor states are in equilibrium, there always exist 
some active receptors with no agonist bound. This phenomenon is known as “constitutive 
activity” and it is supposed to be (to a variable extent) a common feature of all wild type 
GPCRs and in some cases the cause of diseases.10 The concept of constitutive activity leads to 
a totally new class of receptor ligands called “inverse agonists” which are able to stabilize the 
inactive form of the receptor, and thus reduces the constitutive activity.9 The formylpeptide 
receptor is a known example for a constitutively active receptor.9 
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Figure 6. Two state model of GPCR activation I
R R*
Adapted from Seifert et al, Life Sci 2003, 73, 2263
 
Figure 7. Two state model of GPCR activation II
Adapted from Seifert et al Life Sci 2003, 73, 2263
 
Ligands can be classified as full agonists, partial agonists, antagonists, partial inverse agonists 
and full inverse agonists based on the biological response they provoke.13 
Full agonists: An agonist is a substance that binds to a receptor and triggers 100% response 
in the cell. 
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Partial agonists: Partial agonists are compounds that induce a submaximal response even if 
they fully occupy the receptor. 
Antagonists: Antagonist is a ligand that binds to a receptor without causing activation but 
impairs agonist binding. 
Inverse agonists: Inverse agonists are ligands that reduce the constitutive activity. 
1.6 Histamine 
Histamine was first discovered in 1910 by the British physiologist Sir Henry Hallett Dale as a 
contaminant of ergot, generated by bacterial action.11 It was first synthesized before its 
physiological significance was known and due to its wide range of biological activity, it has 
become one of the most important biogenic amines in medicine and biology. The word 
'histamine' comes from Greek, histos, which means tissue. Most of the early studies on the 
biological actions of histamine were carried out by Sir Henry Dale and his colleagues. Dale 
had shown that a local anaphylactic reaction was result of an antigen-antibody reaction in 
sensitized tissue. He subsequently demonstrated that histamine could largely mimic both in 
vitro and in vivo anaphylactic responses.11  
Histamine is an important chemical mediator and neurotransmitter on a broad range of 
physiological and pathophysiological conditions. Its specific effects are mediated by four 
different aminergic G-protein coupled receptor (GPCR) subtypes (H1-H4) in central and 
peripheral tissues.15 The biogenic amine is known to participate in allergic, inflammatory, 
gastric acid secretion, immunomodulation, and neurotransmission conditions.15 
Histamine is used to maintain homeostasis (the body's natural balance of chemicals, 
temperature, metabolic rates). It is also a neurotransmitter and plays a role in our immune 
system by acting as a chemoattractant. Histamine imbalances in our body cause a variety of 
effects. Histamine shortage (Histapenia) causes effects ranging from heavy body hair growth 
and headaches to anaphylactic shock and paranoia. Histamine abundance (Histadelia) in the 
body also causes a variety of effects ranging from the mundane (such as phobias, symptoms 
of seasonal allergies - such as runny nose, inflammation, soreness, etc - and an increased 
metabolism) to the serious (like chronic depression).11  
1.6.1 Metabolism of histamine 
The histamine N-methyltransferase (HNMT) plays an important role in metabolism of 
histamine within the human airways and gut. It is the only enzyme responsible for the 
termination of neurotransmitter actions.12 The HNMT inactivates histamine by transferring a 
methyl group from S-adenosyl-L-methionine to the imidazole ring. Inactive Nг- 
methylhistamine is excreted in urine or can be further oxidized by diamine oxidase (DAO) or 
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monoamine oxidase (MAO) into Nг-methyl-imidazole-aldehyde, which can be further 
oxidized into its corresponding acid (Fig. 8). The histamine metabolism pathway starting with 
DAO is only relevant in Peripheral Nervous System (PNS).13 
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1.6.2 Synthesis and storage 
Histamine is a basic amine, 2-(4-imidazolyl)-ethyl-amine and is synthesized in the body from 
histidine by the enzyme histidine decarboxylase (Figure 9). It is found in most tissues of the 
body and skin. On the other hand histamine is present in high concentrations in the lungs and 
in the gastrointestetinal tract. At the cellular level, it is found largely in mast cells and 
basophils.13 Its synthesis in Golgi apparatus can be blocked by α–fluoromethylhistidine.14 
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1.6.3 Release 
Histamine is released from mast cells by a secretory process during inflammatory or allergic 
reactions. The mast cell membrane has receptors both for a special class of antibody (IgE) and 
for complement components C3a and C5a. The cell can be activated to secrete mediators 
through these receptors and also by direct physical damage. The secretory process is intiated 
by a rise in intra-cellular calcium. This follows cross linking of receptors which intiates an 
increase in calcium permeability and a release of calcium from intracellular stores. Some 
neuropeptides release histamine, though the concentrations required are fairly high.4  
Agents which increase cAMP formation (example β-adrenoreceptor agonists) inhibit 
histamine secretion, so it seems that, in these cells, cAMP dependent protein kinase is an 
intracellular ‘‘braking’’ mechanism. Replenishment of the histamine content of mast cell or 
basophil, after secretion, is a slow process which may take days or weeks, where as turnover 
of histamine in the gastric ‘histaminocyte’ is very rapid.4  
Histamine is metabolized by diamine oxidase and by the methylating enzyme imidazole N-
methyl-transferase. Sensitivity to the effects of histamine varies between tissues and species. 
The guinea pig is very sensitive and mouse is very insensitive to this agent. Human sensitivity 
lies between these two extremes.4 
1.6.4 Actions 
1.6.5 Gastric secretion 
Histamine stimulates the secretion of gastric acid via H2-receptor. In clinical terms this is the 
most important action of histamine, since it is implicated in the pathogenesis of peptic ulcer.4  
1.6.6 Smooth muscle effects 
Histamine acting on H1-receptors causes contractions of the smooth muscle of the ileum, the 
bronchi, bronchioles and the uterus. The effects on the ileum is not as marked in man as it is 
in the guinea pig.4 The response of guinea pig ileum to histamine is the basis of the standard 
bioassay for histamine. Bronchial construction by histamine is also more marked in guinea 
pigs  than in man, though the histamine may be one of the many factors causing reduction of 
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air-flow in the first phase of bronchial asthma. Uterine muscle in most species is contracted 
and in human this is only significant if a massive release of histamine is produced by 
anaphylaxis during pregnancy, which may lead to abortion.4 
1.6.7 Cardiovascular effects  
Histamine expands blood vessels by an action on H1-receptors in man and by a combined 
action on H1 and H2-receptors in some experimental animals. The effect may be partly 
endothelium-dependent. It increases the rate and output of the heart by action on cardiac H2-
receptor. This is a direct effect which may be coupled to an indirect, reflex response if there is 
a fall in blood pressure.4 
When injected intradermally, histamine causes a reddening of the skin and a wheal with a 
surrounding flare. This combination of effects was described by Sir Thamos Lewis over 60 
years ago and was termed the ‘triple response’.4 The reddening is due to vasodilation of the 
small arterioles, precapillary sphincters and the wheal is due to increased permeability of 
postcapillary venules. These effects are mainly due to activation of H1-receptor.4 
 
1.7 Histamine Receptors 
Histamine produces its action by an effect on specific receptors, which comprise four main 
types, H1, H2, H3 and H4 that can be distinguished by means of selective agonist or antagonist 
drugs. Even though all histamine receptor subtypes belong to one family of rhodopsin-like 
class A GPCRs, they strongly differ in receptor distribution, ligand binding, signaling 
pathways and functions (Table 1).15 
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Table 1.Molecular pharmacology profile of histamine receptor subtypes15 
 
  
hH1R 
 
hH2R 
 
hH3R 
 
hH4R 
 
Chromosomal 
gene location 
 
 
3p25 
 
5q35.2 
 
20q13.33 
 
18q11.2 
 
Amino acids 
 
487 
 
359 
 
445 
 
390 
 
Isoforms 
   
+ 
 
+ 
 
G-protein coupling  
 
Gq/11 
 
Gs 
 
Gi/Go 
 
Gi/Go 
 
Signal 
transduction 
 
PLC↑ 
Ca2+ ↑ 
 
cAMP↑ 
 
cAMP↓ 
Ca2+ ↑ 
MAPK↑ 
 
cAMP↓ 
Ca2+ ↑ 
MAPK↑ 
 
 
Tissues  
 
Lung, brain, 
vessels  
 
Heart, stomach, 
brain 
    
 Neurons 
 (CNS, PNS) 
 
Mast cells, 
eosinophils 
 
 
Physiological 
relevance 
 
Contraction of 
smooth 
muscles, food 
intake, sleep-
wake regulation 
 
 
Gastric acid 
secretion 
 
Sleep, food 
intake 
 
Chemotaxis 
 
Pathophysiological 
relevance  
 
Allergic 
reaction 
 
Gastric ulcer 
 
Cognitive 
impairment, 
seizure, 
metabolic 
syndrome 
 
 
Inflammation, 
immune 
reaction 
 
1.7.1 The histamine H1 receptor 
The histamine H1 receptor was cloned from cattle in 199116 and then from human in 1993.17 
The human histamine H1 receptor, (hH1R) is a 56 k Da protein with 487 amino acids.18 The 
histamine H1 receptor is expressed in smooth muscle, endothelial cells, the adrenal medulla, 
gastrointestinal tract, the heart and the central nervous system (CNS).18 
Histamine H1 receptor  preferentially couples to a pertussis-toxin insensitive Gαq/11-protein.19 
Signal transduction of the histamine H1 receptor involves calcium mobilization via the 
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activation of phospholipase C. H1 receptor activation inhibits immediate responses of type I 
allergic reaction like redness, itching and swelling (‘‘triple response’’). On the other hand the 
H1 receptor-mediated effects are food and water intake, convulsion, attention and sleep 
regulation taken as a central ones. Rhinitis, asthma, anaphylaxis and urticaria can be taken as 
peripherially.15 
 The histamine H1-receptor is an important therapeutic target for allergic conditions.18 
Histamine H1 receptor agonists are mainly used as pharmacological tools instead of 
therapeutic drugs.19 The moderate potent H1 receptor agonist betahistine (Aequamen®) is used 
in therapy for Meniere’s disease.24 Replacement of imidazole ring with thiozole or aromatic 
rings lead to H1 receptor agonist compounds.15 The 2-substituted histamine derivates (e.g. 
histaprodifen series) led to compounds with higher affinity and efficacy.15  
Therapeutically H1 receptor antagonists are more important than the agonists. Sedation was 
one of the drawback with the application of first generation H1 antihistamines such as 
bamipine, dimetindene, diphenylhydramine, and mepyramine (Figure 10). Newer second 
generation H1-antihistamines do not penetrate the blood-brain barrier or poorly penetrates and 
prevent the sedation. Some of the newer non-sedative antagonists are hydroxyzine--cetrizine, 
terfenadine---fexofenadine, ebastine---carebastine, loratidine---desloratidine.15 Many 
histamine –mediated effects cannot be blocked by H1 antihistamines.25 H1R antagonists such 
as cetirizine (14, Zyrtec®) and fexofenadine (16, Telfast®) are top selling blockbuster drugs.14 
The high affinity H1R antagonist [3H] mepyramine is the most commonly used radioligand.26 
The ligands (agonists and antagonists) for H1 receptor was shown in figure 10. 
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The histamine H1R is characterized by a large third intracellular loop and a relatively short C 
terminal tail.14 Molecular modeling and site-directed mutagenesis suggest that, histamine can 
bind to the hH1R by forming an ionic interaction between its protonated amino group and the 
conserved Asp-107 of TM3. Lys-191 in TM5 is possibly interact with Npi of the imidazole 
ring, whereas the Asn-198 is believed to form a hydrogen bond with Nτ-H. In place of Asn-
198, (Figure 11)27-29 Nτ-H may interact with Thr-194. 
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1.7.2 The histamine H2 receptor 
The human histamine H2-receptor, (hH2R) is a 40 kDa protein with 359 amino acids.18 The 
histamine H2 receptor is found in gastric parietal cells, vascular smooth muscle, suppressor T 
cells, neutrophils, brain and cardiac tissues. It is mainly involved in stimulation of gastric acid 
secretion. It couples to a Gs-protein, resulting in an increase in cAMP turnover.30-33  Signal 
transduction of the histamine H2 receptor involves increased cAMP accumulation via 
activation of adenylate cyclase.  
Furthermore histamine mediates smooth muscle relaxation in airway, uterine and blood 
vessels via the H2R.34,35 H2R has numerous functions in the immune system, for example, it 
has been shown to inhibit T-cell proliferation36,37 to block the histamine release from mast 
cells and to modulate cytokine production.38-40  
H2 receptor activates positive inotropic and chronotropic effects on atrial and ventricular 
tissues. On the other hand H2 receptor activation in the CNS, can inhibit nerve cells and block 
the long-lasting after hyperpolarization and thus increase working memory. Because of their 
positive inotropic effect, H2R agonists are of potential therapeutical interest for the treatment 
of congestive heart failure. The histamine H2 receptor is an important therapeutic target in the 
treatment of gastric ulcers.18 
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The H2 receptor agonists dimaprit and its rigid aromatic analogue amthamine have been 
developed, of which the latter shows improved selectivity and potency as compare to that of 
histamine.15 The guanidin derivatives like impromidine or arpromidine have much higher 
affinities and poses positive inotropic and vasodilatory effects. Further developments led to 
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metiamide and then to cimetidine as the first compound for the therapy of gastric ulcer.15 
Ranitidine, nizatidine, famotidine and roxatidine were compounds with much higher affinities 
and larger interaction potential.15 H2R antagonists are mainly used for the treatment of 
heartburn and peptic ulcer for example cimetidine 31.41 
Unlike the H1R, the H2R possesses a substantially shorter third intracellular loop and a longer 
palmitoylated C-terminus.14 The endogenous ligand histamine is assumptive to bind in its Npi-
tautomeric form to amino acids located in TM3 and TM5 of the hH2R. The protonated amino 
group interacts with Asp-98 of TM3 and the imidazole Npi-H forms a hydrogen bond with 
Asp-186 of TM5. Imidazole Nτ interacts with Tyr-182 likewise located in TM5 (Figure 
13).42,43 In contrast to Tyr-182, Thr-190 may participate in histamine binding.44 
N
N
NH
HH
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1.7.3 The histamine H3 receptor 
The human histamine H3-receptor, (hH3R), was cloned by Lovenberg et al. in 1999.20 It is a 
49-kDa protein with 445 amino acids.18 The histamine H3 receptor anatomically localized 
primarily to the CNS with prominent expression in basal ganglia, hippocampus, cortex and 
straital area.15 In the periphery H3 receptors can be found with low density in gastrointestinal, 
bronchial and cardiovascular system.15 Several therapeutic indications for the histamine H3 
receptor have been suggested, for example, sleep, wakefulness, cognition, memory processes, 
attention-deficit hyperactivity disorder, obesity.15 
It is a presynaptic autoreceptor on histaminergic neurons for controlling the synthesis and 
release of histamine. As a heteroreceptor it modulates the release of several other 
neurotransmitters.45,46  
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The H3R receptor couples to Gαi/o-proteins and has been demonstrated to influence several 
signal transduction pathways.47 For example forskolin-induced cAMP production, inhibition 
of adenylyl cyclase (AC), stimulation of mitogen-activated protein kinase (MAPK), 
phospholipase A2 (PLA2), inhibition of Na+/H+ antiporter and K+ induced Ca+2 mobilization 
take place (Table 1). In contrast to the H1R and H2R, gene encoding the H3R contains two48 or 
possibly three49 introns resulting in at least 20 hH3R isoforms.50 This leads to the assumption 
that signaling fine tuning may be controlled by formation of isoforms or receptor 
oligomerization. 
As H3 autoreceptor activation stimulates the negative feed-back mechanism, reduced central 
histaminergic activity is observed.15 Involvement in cognition, sleep-wake status, energy 
homeostatic regulation and inflammation has attracted pharmaceutical research for numerous 
therapeutic approaches in different peripheral but mainly central diseases.15 
H3R agonists perhaps therapeutic value for the treatment of insomnia,51 pain,52 
inflammation,53,54 or migraine.55 Potent stimulation of H3 receptors has been observed by 
histamine derivatives. The methylated histamine derivates, Nα-methyl histamine and the more 
potent and selective (R)-α-methyl histamine are used for receptor characterization and are also 
available as tritiated radioligands.15 Although uncountable experiments with these tools have 
been reported, selectivity concerning H4 receptors may be a problem with some investigations. 
Imetit, immepip, imifuramine and recently immethridine have been introduced as useful 
agonists.15 
H3R antagonists are of potential therapeutical interest for the treatment of obesity, epilepsy 
and myocardial dysfunction, as well as cognitive and sleep disorders.56 
The floating change from agonist to antagonist is even more complex with histamine H3 
receptors than with any other histamine receptor subtype. Due to high constitutive activity of 
H3 receptors inverse agonists can be found as well as neutral antagonists.15 
Proxyfan was the first compound as agonist for H3 receptors.15 First generation of H3 receptor 
antagonists were monoalkyl-substituted imidazole derivatives like ciproxifan, thioperamide or 
clobenpropit.15 Numerous therapeutic indications are claimed in which cognitive impairment, 
attention-deficiet hyperactivity disorder, schizophrenia, narcolepsy, seizure and obesity are 
mostly mentioned.15 Promising compounds like BP2.649, GSK-189254 and JNJ-17216498 
have already entered clinical phase.15 H3R antagonists have been extensively studied by many 
pharmaceutical companies as drug candidates for the treatment of obesity,57 schizophrenia,58 
attention-deficit hyperactivity disorder,59  narcolepsy60 or Alzheimer’s disease.61,62 
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Yao and coworkers reported that, histamine is assumed to interact with the conserved Asp-
114 of TM3 via the protonated amino group.63 Asp-80 in TM2 apparently forms a hydrogen 
bridge with Nτ-H, which is crucial for receptor activation. The imidazole Npi is likely to 
interact with Asn-404 in TM7 (Figure 15).63 In contrast, Uveges and colleagues suggested that 
the imidazole ring could interact with Glu-206 in TM5.64 
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1.7.4 The histamine H4 receptor 
The human histamine H4-receptor, (hH4R), was cloned and characterized in the year 2000 
through homology searching for new GPCRs in human genomic databases.65-67 The human 
H4-receptor (hH4R) is a 44 kDa protein with 390 amino acids. The deduced amino acid 
sequence showed homology particularly to the human histamine H3 receptor, with about 40% 
overall identity and even more (58%) within the trans-membrane domains. The genomic 
structure of the H4 receptor is comparable to that the H3 receptor with two large introns and 
three exons with large interspecies variations from 65-72% homology in sequences.18 
The histamine H4 receptor shows several hallmarks of the biogenic amine subfamily of 
GPCRs. An aspartate residue (Asp 61) in the second transmembrane domain (TM 2) and a 
DRY motif at the end of TM 3 (Asp 111-Tyr 113), which are important for receptor 
activation; and also another aspartate residue (Asp 94) in TM 3, which is the putative binding 
site for the primary amine; other hallmarks includes a disulfide bridge between the first (Cys 
87) and the second (Cys164) extracellular loops; tryptophan residues (Trp 140 and Try 316) 
in TM 4 and TM 6; proline residues (Pro186 and Pro 318) in TM 5 and TM 6; an asparagine 
residue (Asn 350) and an NPXXY motif (Asn 354-Tyr358) in TM 7; and a potential 
palmitoylation site in the C-terminus region (Cys 374) (Figure 16).66,75 
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 Figure 16. Human histamine H4 receptor
Modified from Mol. Pharmacol. 2001, 59, 427
 
The histamine H4-receptor has been found in bone marrow and leukocytes, particularly in 
immune cells such as eosinophils, mast cells, dendritic cells, basophils and T-cells.68-71 On the 
other hand its expression can be found with moderate levels in spleen, small intestine and also 
with low level in brain.15 
About the physiological and pathophysiological role of the H4R is not much known. The H4R 
has been shown to trigger chemotaxis and to induce Ca2+-mobilization in mast cells,79 
eosinophils. In addition, stimulation of the H4R results in actin polymerization, shape change 
and up regulation of adhesion proteins in eosinophils.72,73 The H4 receptor seems to be present 
in most tissues at low level and connected to cells of hematopoietic linage. Furthermore, the 
H4R was found to be expressed in synovial cells of patients suffering from rheumatoid 
arthritis. The observed variations in the expression levels of the H4R perhaps related to 
severity and duration of the rheumatoid arthritis.74 These findings suggested that this H4R 
may play a crucial role in inflammatory and immunological processes.  
Like the H3 receptor, the H4 receptor is also coupled to Gαi/o proteins. H4 receptor activation 
leads to a pertussis-toxin-sensitive decrease in the forskolin-induced cAMP production. On 
the other hand the H4 receptor activation inhibits cAMP responsive element-binding protein 
(CREB)-dependent gene transcription.67,68, 69,75 In addition, H4 receptor stimulation results in 
the pertussis-toxin-sensitive activation of downstream mitogen-acitvated protein kinase 
(MAPK) pathways.65 H4 receptor-mediated Ca2+ signalling in mast cells is sensitive to both 
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pertussis toxin and the phospholipase C β inhibitor U73122. Furthermore phospholipase C is 
activated via Gβγ subunits that dissociate from Gαi/o proteins following H4 receptor 
stimulation in mast cells (Figure 17).71 
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Figure 17. Signal transduction of histamine H4-receptor
Adapted from Trends in Pharmacological Science 2005, 26, 462
 
Many compounds with reported affinity for H3 receptor, also have affinity for H4 receptor.15 
This is the case especially for imidazole containing compounds even though there are 
numerous exceptions.15 Considering the high sequence similarity with the H3 receptor it is not 
surprising that the H4 receptor is activated by several H3 receptor agonists, including immepip 
(H4 receptor, Ki=9 nM), imetit (H4 receptor,Ki=5 nM) and (R)-α-methylhistamine (H4 
receptor, Ki=146 nM). Furthermore, the H4 receptor is activated by the H2 and H3 receptor 
antagonist burimamide (H4 receptor, Ki=180 nM) and the H3 receptor antagonist clobenpropit 
(H4 receptor, Ki=13 nM). Thioperamide, an inverse agonist at H3 receptors, is also an inverse 
agonist at the H4 receptor (H4 receptor, Ki=27 nM).72-75   
Recently, OUP16 has been described as a full agonist with moderate affinity and selectivity 
for the H4 receptor.76 Furthermore, 4(5)-methylhistamine has been identified as a more potent 
and selective H4 receptor agonist than OUP16.76 Following high throughput screening and 
medicinal chemistry input, JNJ7777120 and its analogue JNJ10191584 have been identified 
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as H4 receptor antagonists with high affinity and selectivity.76 But in contrast to the 
nonselective H3 and H4 receptor inverse agonists these compounds act as neutral antagonists. 
The first highly selective and orally active H4 receptor ligand described has been the 
antagonist JNJ 7777120. Unfortunately this compound is rapidly metabolized in liver 
microsomes and has a limited half-life of about 1-2 hours in vivo.15 Numerous heterocyclic 
compounds such as indolylpiperazines, 2-aminopyrimidine derivatives are developed as H4 
receptor antagonists (Figure 18).78-80 
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Antagonists show general anti-inflammatory potency in models of asthma, arthritis, colitis 
and pruritus. Further results in autoimmune disorders, allergic conditions and nociceptive 
responses can be expected in the near future.76 Shin et al.81 and Jongejan et al.82 reported the 
molecular modeling and site-directed mutagenesis for the binding mode of histamine H4 
receptor. 
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It was assumed that the histamine can interact via its protonated amino group with Asp-94 in 
TM3 of the hH4R, whereas the imidazole ring is considered to mainly interact with Glu-182 
of TM5. Jongejan et al. proposed the imidazole Npi to form a hydrogen bond with the 
protonated Glu-182 and the imidazole Nτ-H to interact with Ser-320 of TM6 (Figure 19 A).82 
In contrast, Kiss and coworkers suggested a reverse binding mode of histamine at the hH4R to 
be more favorable and it was expected that the protonated amino group to interact with Glu-
182. Asp-94 is presumed to form a hydrogen bond with the imidazole Nτ-H and Thr-323 of 
TM6 to interact with the imidazole Npi (Figure 19 B).83 Furthermore, the authors describe a 
possible binding mode of the cyanoguanidine-type H4R agonist OUP-16 at the hH4R. The 
imidazole Nτ-H of this compound is considered to interact like histamine with Asp-94, 
whereas an N-H group of the cyanoguanidine moiety apparently forms a hydrogen bond with 
Glu-182. Furthermore, a hydrogen bond between the nitrile group and Thr-323 is expected 
(Figure 19 C).83 In addition, very recently the importance of Phe-169 in the second 
extracellular loop of the hH4R for agonist binding has been demonstrated.84 
The histamine H1 and H2 receptors have been successful targets of block buster drugs for 
treating allergic diseases and gastric ulcer, respectively. The development of ligands (agonist, 
antagonists) for histamine H3 and H4 receptor are essential and highly interest for these new 
therapeutic targets. There are very few chiral compounds known as histamine receptor ligands 
and the development of chiral compounds is particular interest in synthetic point of view.  
Different advances in histamine receptors ligands have ever attracted pharmaceutical 
developments. Where as ligands for histamine H1 and H2 receptors have been introduced long 
back into market, the run for the first selective H3 and H4 receptor ligands in the market is 
highly topical. Numerous pharmaceutical companies and academic institutions have programs 
with diverse lead structures and some even with first candidates in to clinical trails.15 
Histamine receptor subtypes have been important drug targets for many decades. Histamine 
H3 and H4 receptors have led to a strong renewal of the interest in this biogene amine as well 
as to intensified research on the ligands and the potential therapeutic indications. Although at 
present histamine related development in pharmaceutical industry is mainly fixed on these 
receptor subtypes, basic research on re-uptake mechanism, isoform activation, receptor cross-
talk etc, may open new fields for novel therapeutic applications of new ligands.15 
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Aim of the work                 
In this part of work, a new strategy for the enantioselective synthesis of tetrahydrofuran 
imidazole based human histamine H3 and H4 receptor potential agonists was designed based 
on the lead structures 35 (imifuramine) and 45 (OUP-16) (Figure 2.1). The application of γ-
butyrolactones as starting materials towards analogues of 35 and 45 was shown for the first 
time by enantioselective synthesis. Analogues of imifuramine and their cyanoguanidine 
derivatives were aimed to be synthesized with an extended side chain as well as additional 
functional groups to gain insight into structure-activity relationships. The development of 
agonists for the recently discovered histamine H3 and H4 receptors would be an important step 
towards therapeutics for the treatment of insomnia, pain, migraine, inflammation and 
immunological disorders.  
Figure 2.1 Histamine H3 and H4 receptor agonists developed by Kurihara et al
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Based on the histamine H3 and H4-receptor agonists 35 (imifuramine) and OUP-16 (lead 
structures) this part of work was designed to use the γ-butyrolactone 55 as starting material 
(Figure 2.2). Protection of aldehyde functional group of γ-butyrolactone 55 followed by 
reduction of lactone would give the corresponding lactol. Treatment of this anomeric lactol 
with bisprotected imidazole may afford the corresponding diols possibly as two diastereomers 
which can be cyclized by Mitsunobu reaction to obtain the cyclic building blocks 56 and 57. 
Side chain modification of allyl group of 56 and 57 by hydroboration, phthalimidition 
followed by reductive cleavage of phthalimide and deprotection of protecting groups would 
give the amines 58 and 60 for the histamine H3 receptor potential agonists. Introduction of 
cyanoguanidine moiety on 58 and 60 could afford the target molecules 59 and 61 for the 
histamine H4 receptor potential agonists. Deprotection of cyclic acetal group of the building 
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blocks 56 and 57 followed by reductive amination may obtain the amines 62 amd 63.             
γ-Butyrolactone (GBL)-55 may provide variety of tetrahydrofuran-imidazole derivatives (56-
63, Figure 2.2) as structurally and biologically important class of human histamine H3 and H4 
receptor potential agonists. 
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Figure 2.2 Tetrahydrofuran imidazole based potential agonists for histamine H3 and H4 receptors
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As explained above by using the same synthetic strategy GBL 64 may afford the cyclic 
buiding blocks, which can be converted to variety of histamine H3 and H4 receptor potential 
agonists (Figure 2.3). Compounds 65 to 72 could be obtained from cyclic building blocks of 
GBL 64 by side chain modification and different functionalization. Since imidazole 
acylguanidine derivatives are also known as histamine H3 and H4 receptor agonists, it is also 
possible to convert the four amines 65-70 in to their corresponding acylguanidine derivatives. 
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Chapter 2 
2. Enantioselective synthesis of histamine H3 and H4 receptor 
potential agonists based on γ-butyrolactones  
2.1. Stereoselective Synthesis of γ-Butyrolactones (GBLs) 
Functionalized γ-butyrolactones have attracted substantial attention in recent years due to 
their synthetic importance as building blocks in natural product synthesis1 as well as in 
medicinally active synthetic compounds. The development of new methods for the synthesis 
of chiral γ-butyrolactones has been one of the current interests in asymmetric synthesis.2 
Recent examples include the transformation of (i) chiral natural products3 (ii) chiral allylic 
alcohols4 (iii) chiral propagyl alcohols5 (iv) and stoichiometric or catalytic use of 
organometallic reagents.6 In most of these methods, a multistep process that is more than four 
steps is required to reach the desired γ-butyrolactones. 
Several research groups have synthesized γ-butyrolactones, a few methods are described here 
briefly. 
The recent synthesis of both syn- and anti-lactones by asymmetric aldol reactions was 
demonstrated by Hajra and coworkers.7-9 The authors reported that the formation of both syn- 
and anti-aldol products from the same set of reactants is possible by simply inverting the 
addition sequence of the base and aldehyde using Evans type chiral auxiliary  (N-acyl-2-
oxazolidinones). Under the conventional method, addition of TiCl4, base, followed by 
aldehyde (Method A), the aldol reaction of 73 with variety of aldehydes at low temperature 
and in situ lactonization of 77 (syn-aldol product) provided trans-4,5-disubstituted-γ-
butyrolactone 79 in good yields and high diastereoselectivity via intermediate 78.7-9 However 
under the inverse method, addition of TiCl4, aldehyde, followed by base (Method A′), the 
aldol reaction of 73 with variety of aldehydes at low temperature furnished 74 (anti-aldol 
product) with high diastereoselectivity and in good yield. In situ lactonization of 74 and 77 
gave the corresponding lactones 75 and 78 having chiral auxilaries in there. The selective 
removal of the chiral auxiliaries of lactones 75 and 78 provided γ-butyrolactones 76 and 79 as 
a general approach for the synthesis of (+)- and (-)-4,5-trans- and cis-paraconic acids, for 
example (+)- and (-)- methylenolactocins (4,5-trans) and phaseolenic acids (4,5-cis) has been 
demonstrated (Scheme 2.4). 
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Hoppe and coworkers reported a chiral homoenolate reagents of type 80 that reliably adds to 
aldehydes through cyclic Zimmerman-Traxler transition states10 81 to form the homoaldol 
adducts 82 or ent-82 with essentially complete γ-regio- and anti-diastereoselectivity. 
Covalently bound ‘‘cations’’ M gave rise to complete transfer of chirality from position 1 in 
80 to position 3 in the addition products 82 and ent-82. Depending on whether the 
heterosubstituent X takes a pseudoaxial or a pseudoequatorial position [(Z)-81 or (E)-81]11 an 
opposite sense of chirality is induced in the products 82 and ent-82, with enantiomeric γ-
hydroxy carbonyl compounds 80 and ent-80, respectively, being formed after hydrolysis 
(Scheme 2.5). 
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Hoppe et al introduced α-metallated 2-alkenyl N,N-diisopropylcarbamates as versatile 
homoenolate reagents. Because of the strongly activating properties of N,N-
diisopropylcarbamoyloxy groups, these are easily prepared by facile deprotonation and the 
cation is fixed in the α-position by chelation. Exchange of lithium by 
tetra(isopropoxy)titanium dramatically enhances the regioselectivity and diastereoselectivity 
of the aldehyde addition.12 
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Scheme 2.5 Synthesis of GBLs by Hoppe et al
84 85 86
87 88
N
N
 
Hoppe type enantioenriched lithiated carbamates are configurationally stable at -78 °C and 
can be obtained by deprotonation of the optically active precursors or through kinetic 
resolution of the racemic carbamates by n-butyllithium/(_)-sparteine (89).13 It is known that, 
the removal of the (pro-S) protons of the carbamates such as 84 by butyllithium/sparteine is 
kinetically favoured, as found for the O-alkyl derivatives,14,15 however a rapid epimerisation 
takes place even at -78 °C. The sparteine complex (S)-85 crystallised from the 
pentane/cyclohexane solution with simultaneous dynamic kinetic resolution, resulting in up to 
92% de in the solid. The metal exchange proceeded with inversion of the configuration and 
gave rise to the allyltitanium intermediate (R)-86, which was stable in solution. The 
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homoaldol adducts of aldehydes and ketones were obtained with 90% ee. These are easily 
transformed into optically active γ-lactones such as 88 (Scheme 2.6).16                                                       
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17-19
 used cyclopropane derivatives such as (rac)-90 for the synthesis of 
substituted (rac) γ-butyrolactones 93 (Scheme 2.6). Vicinally donor-acceptor-substituted 
cyclopropanes like 90 that serve as 1,3-dipolar synthon  in 92 for many synthetically valuable 
transformations.20 Since the two charges of synthon 92 are in 1,3-relationship, many reactions 
employing 91 may be regarded as processes involving a formal umpolung of reactivity and 
often provide products not easily available by alternative methods.21 Deprotonation of  D-A 
(donar-acceptor)  substituted cyclopropanes such as  (rac) - 90 with LDA at -78 °C, reacted 
with carbonyl compounds approaches the enolate exclusively, at the less hindered side giving 
the cis compound (rac) - 91 (aldol product). Deprotection and ring opening of aldol product 
91 to γ-oxo esters (rac) - 92 can be accomplished under mild conditions with acids or fluoride 
sources. Similarly, crude hydroxyalkylated cyclopropanes are transformed to γ-lactols or its 
equivalents to the acyclic tautomers (rac) - 92 which under lactonization gave highly 
functionalized (rac) GBLs 93. Reiser et al reported,22-24 the synthesis of anti disubstituted γ-
butyro- lactonaldehyde 97 with diastereo and enantioselectively, using copper (I)-catalyzed 
asymmetric cyclopropanation of furan-2-carboxylic ester, followed by ozonolysis, Sakurai 
allylation with allyltrimethylsilane and finally base mediated retroaldol-lactonization 
sequences. Cyclopropane carbaldehyde 94 can be synthesized by copper(I)-bis(oxazolines)-
catalyzed cyclopropanation of furan-2-carboxylic esters followed by ozonolysis of 
cyclopropane ester. The selective nucleophilic addition of 94 which undergoes highly 
diastereoselective additions giving rise the Felkin-Anh adduct 95. Base mediated 
retroaldol/lactonization cascades of 95 leads to γ-butyrolactone 97 with high 
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diastereoselectivity (95:5) (Scheme 2.6).22-24 The advantage of this methodology is that γ-
butyrolactones of either enantiomer can be achieved by copper(I)- bis(oxazolines)-catalyzed 
cyclopropanation of furan-2-carboxylic esters depending on the choice of chiral ligand (R,R or 
S,S bisoxazolines) used. Here it is note worthy to remember that both the analogues of OUP-
16 and OUP-13 of the first selective H4 receptor agonists can be achieved by both 
enantiomers of the γ-butyrolactones 55 and 64. 
2.2 Synthesis of chiral bis(oxazoline) ligands  
Bis(oxizolines) have proved to be privileged structures because they promote a great number 
of metal-catalyzed transformations with extraordinary selectivity. Evans and coworkers 
discovered that C2-symmetric bis(oxazoline) copper complexes such as (box) Cu (I) & (II) 
both are effective promoters of enantioselective cyclopropanation, Diels-Alder, aldol, ene, 
Michael and amination reactions.25,26 Chiral bis(oxazolines) were also used in our group 
extensively for the above mentioned asymmetric reactions.26,27  Most commonly, 
bis(oxazolines) can be obtained from aminoalcohols by a two step condensation/cyclization 
sequence with acid chloride as described here.27 Bis(4-isopropyloxazoline) available as either 
enantiomer from inexpensive L- or D- Valine, is an attractive alternative for large scale 
applications of enantioselective reactions.  
Here synthesis of both (R,R) and (S,S)- iPr-BOX ligands (104 & 108) is described. The (R,R)-
iPr-BOX ligand (104) was derived from D-valine (101) and the (S,S)-iPr-BOX ligand (108) 
was prepared from the cheaper amino acid L-valine (105). 2,2-dimethylmalonyl dichloride 
100 was prepared by oxidation of 2,2-dimethyl propane-1,3-diol (98) followed by oxalyl 
chloride treatment of corresponding 2,2-dimethyl malonic acid 99. D-Valinol 102 was 
prepared from D-valine 101 and similarly L-valinol (106) was prepared from L-valine 105 by 
sodiumborohydride reduction in presence of iodine. These valinols 102 and 106 were coupled 
with 100 to obtain the corresponding C2-symmetric diamides 103 and 107. Tosylation of 
diamides 103 and 107 followed by their subsequent cyclization obtained the corresponding 
enantiomeric pure chiral bioxazoline ligands 104 and 108 (Scheme 2.7).27 
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Following the synthetic strategy developed in our group the disubstituted γ-butyrolactones 55 
and 64 can be obtained starting with the copper(I)-bis(oxazolines)-catalyzed cyclopropanation 
of furan-2-carboxylic ester 109 (Scheme 2.8). From the same starting material 109 the two 
enantiomers of cyclopropane esters 110 and 113 can be synthesized depending on the choice 
of chiral bis(oxazolines). The methodology was standardized up to 100 g scale with 99% ee. 
Ozonolysis of 110 followed by reductive workup leads to the aldehyde 111, which undergoes 
highly diastereoselective additions with nucleophiles to 112 followed by a 
retroaldol/lactonization cascade to 55. Similarly the other enantiomer of GBL 64 can be 
obtained from 113 (Scheme 2.8). The stereochemical outcome of the sequence of 
cyclopropanation, ozonolysis to the cyclopropylcarbaldehyde and subsequent 
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allylation/retroaldol-lactonization depends on the stereochemistry of the bis(oxazoline)-ligand 
(BOX) initially used for the cyclopropanation. 
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There are four important reactions during the enantioselective synthesis of γ-butyrolactones.  
1) Cyclopropanation 
2) Ozonolysis 
3) Sakurai Allylation 
4) Lactonization 
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Each of those above reaction is described in detail. 
2.3 Cyclopropanation 
W. H. Perkin reported the first synthesis of cyclopropane derivatives in 1884.28 The 
cyclopropanation of olefins using the transition metal-catalyzed decomposition of α-
diazoesters is one of the most extensively studied methods.29
 
Both inter and intramolecular 
versions of this reaction have been developed. The nature of the starting diazo reagent as well 
as the type of the reaction (inter- or intramolecular) plays a key role in the appropriate 
selection of the most efficient catalyst for a given transformation. The simple α-diazoesters 
can be prepared on gram scale and reacted in presence of the metal catalyst and alkenes.30
 
Cu, 
Rh, Ru and Os metal carbenes are known to react faster with electron rich alkenes among the 
wide range of catalysts, whereas Pd metal carbenes are optimal for electron-deficient alkenes. 
The mechanism of the transition metal-catalyzed decomposition of α-diazocarbonyl 
compounds is believed to proceed via formation of the metal carbene complex31
 
in most cases. 
In 1966 Nozaki reported the first example of an enantioselective copper catalyzed 
intermolecular cyclopropanation.32 
The copper (I) complex of bis(oxazoline) 104, disclosed by Evans in the early 1990s,
 
is still a 
standard to which new bis(oxazoline) ligands are compared.33,34 In 1990 Wenkert et al 
reported the cyclopropanation of furan-2-methyl carboxylic ester with Rh2(OAc)4 leading to 
exo-cyclopropane
 
furoic ester in 55% yield.35 In difference to metal carbene complexes such 
as pybox ruthenium carbene and porphyrene-osmium carbene, the copper carbene complexes 
have not yet been characterized by X-ray crystallography. However the NMR study of 
copper-carbenes in solution was successfully carried out by Hofmann36 et al, which is entirely 
consistent with Pfaltz’s37 mechanistic postulation for mono semicorrin copper (I) complex. 
According to Pfaltz’s method the cyclopropanation is carried out using bis(semicarrinato) 
copper (II) complex as a precatalyst. Activation of this complex either by heating or addition 
of phenyl hydrazine in the presence of alkyl diazoacetate, the complex is reduced to loose one 
semicorrin ligand, and the resulting one reacts as an active catalyst for the cyclopropanation. 
The regioselective cyclopropanation of furoic ester proceded only at the sterically less 
hindered double bond. This copper catalyzed cyclopropanation promoted highly enantio- and 
diastereoselectively in the presence of chiral bisoxazoline ligand, orienting the ester group 
exclusively on the convex face of the bicyclic frame work. The treatment of furoic ester 109 
with ethyldiazoacetate in the presence of bisoxazoline 108 under above mentioned conditions 
(Scheme 2.9) leads to the cyclopropane carboxylate 110 obtained in pure form upon 
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crystallization (99% ee) in 41% yield up to 100g scale without loss of enantioselectivity in the 
course of scale up.  
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The stereochemical outcome of  the copper-bisoxazoline catalyzed cyclopropanation of furan-2-
carboxylic methyl ester with ethyl diazoacetate can be explained by model studies of Pfaltz37 and 
Andersson.38  
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The (bisoxazoline) copper (I) complex first reacts with the ethyl diazoacetate and forms a metal-
carbene intermediate. Now there are two possibilities to interact the double bond of furoic ester 
either from bottom or from top side of this intermediate since it has trigonal planar geometry. 
Depending on the direction of attack, the ester group at the carbenoid center either moves forward 
or backward relative to the plane bisecting the bisoxazoline ligand. In the case of approach A, the 
repulsive steric interaction builds up larger between the ester group and the isopropyl group of the 
bisoxazoline ligand. However, the double bond of furan preferentially approaches from sterically 
less hindered side, where there is only a smaller repulsive interaction is present with  hydrogen in 
case of approach B. Therefore, approach B is expected to be favoured over A (Figure 2.3). 
2.4 Ozonolysis 
   The cleavage of an alkene or alkyne with ozone to form the organic compounds in which the 
carbon-carbon multiple bond has been replaced by a double bond to oxygen is called as 
ozonolysis. 39,40  The reaction outcome depends on the type of multiple bond being oxidized 
and also the work up conditions. 
   2.4.1 Ozonolysis of alkenes 
   In a typical procedure, ozone is bubbled through a solution of alkene in dichloromethane at     
-78 °C until the solution turns blue, indicating the consumption of olefin. The intermediate 
ozonide is converted to a carbonyl derivative by adding a reductive or oxidizing reagent 
depending on the choice of product. Reductive work up conditions are commonly used than 
oxidative conditions. Alkenes can be oxidized with ozone to form aldehydes, ketones, 
alcohols, or carboxylic  acids. The use of dimethyl sulfide, triphenyl phosphine or zinc dust 
produces aldehydes or ketones, while the use of sodium borohydride produces alcohols. The 
use of hydrogen peroxide produces carboxylic acids. Recently, the use of amine N-oxides has 
been reported to produce aldehydes directly.41 Dichloromethane is commonly used as solvent 
for this reaction. Methanol is often used as a 1:1 cosolvent to facilitate timely cleavage of the 
ozonide. In an industrial scale ozonolysis of oleic acid produces azelaic acid and pelargonic 
acids. 
  2.4.2 Mechanism of ozonolysis 
   In the generally accepted mechanism proposed by Rudolf Criegee in 1953,42 the alkene and 
ozone form an intermediate molozonide in a 1,3-dipolar cycloaddition. Then the molozonide 
reverts to its corresponding carbonyl oxide (also called as Criegee intermediate) and aldehyde 
or ketone in a retro-1,3-dipolar cycloaddition. The oxide and aldehyde or ketone react again in 
a 1,3-dipolar cycloaddition to produce a stable ozonide intermediate (a trioxolane). Evidence 
for this mechanism is found in isotopic labeling. When 17O-labelled benzaldehyde reacts with 
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carbonyl oxides, the label ends up exclusively in the ether linkage of the ozonide (Scheme 
2.10).43 
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The reaction of bicyclohexene 110 with ozone in dichloromethane at -78 ºC, followed by 
reductive work up conditions in presence DMS gave rise to the highly functionalized 
cyclopropane carbaldehyde 111 in quantitative yield (Scheme 2.11). 
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2.5 Sakurai Allylation 
The Sakurai allylation also known as the Hosomi-Sakurai reaction44 is the chemical reaction 
of carbon electrophiles such as aldehydes and ketones with allylsilanes catalyzed by a strong 
Lewis acid (LA). Lewis acid activation is essential for the completion of reaction. Strong 
Lewis acids such as TiCl4, BF3.OEt2, SnCl4 and AlCl(Et)2 are all effective in promoting this 
reaction. A wide variety of aliphatic, alicyclic and aromatic carbonyl compounds can undergo 
smoothly and a regiospecific transposition occurs in the allylic part. The reaction is a type of 
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electrophilic allyl shift with the formation of an intermediate beta-silyl carbocation. Driving 
force is the stabilization of carbocation by the beta-silicon effect. 
The high reactivity of allylsilane toward electrophiles has been explained by σ (Si-C)-pi 
conjugation. The synthetic utility of this reaction is displayed by the regiospecific 
transformation of the allylic group to a carbonyl function, in which the carbon-carbon bond 
formation occurred exclusively at a γ-carbon of allylsilanes. The reaction mechanism 
involves a nucleophilic attack of the allylsilane to the carbonyl carbon polarized partially by 
LA through a cyclic process would be most favorable, because the regiospecificity and the 
trans preference in the stereochemistry of the products are observed actually (Scheme 2.12) 
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Scheme 2.12 Sakurai allylation with Lewis acids
 
Sakurai allylation of cyclopropane carbaldehyde 111 in the presence of Lewis acid BF3.Et2O 
gave the corresponding cyclopropane allyl alcohol 112 (Scheme 2.12). 
Scheme 2.13 Sakurai allylation of cyclopropane carbaldehyde
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2.5.1 Determination of Stereochemistry 
The stereoselective addition of nucleophiles to a prochiral center will be influenced by an 
adjacent chiral centre. It is an important transformation in asymmetric synthesis of organic 
chemistry. The diastereoselective addition of nucleophiles to α chiral carbonyl compounds 
was postulated by D.J. Cram45 and developed by Felkin and Anh.46-49 According to Felkin-
Anh model,50 the carbonyl group orients orthogonally to the adjacent large group (L), 
therefore, two possible reactive conformations must be considered. Generally the priority of L 
group is determined by steric bulkiness. However in the Felkin-Anh model electron 
withdrawing substituents are considered as L for electronic reasons independent for their 
steric bulkiness.  
Substituted cyclopropyl carbonyl compounds are most stable in bisected conformations for 
stereoelectronic reasons. Of the two possible bisected conformations, the s-trans 
conformation is favoured with respect to s-cis due to steric repulsion  between carbonyl group 
and cyclopropyl moiety in the latter case. The addition of nucleophiles to the s-cis 
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conformation leads to the Felkin-Anh product and the conformation of s-trans leads to the 
anti Felkin-Anh product. Even though the s-trans conformation is favoured, when bulky 
nucleophiles approach the steric repulsion between the nucleophile and cyclopropyl group 
dominates its diastereoselectivity (Figure 2.4). 50 
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Figure 2. 4 Plausible nucleophilic attack on cyclopropane carbaldehyde
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2.6 Retroaldol reaction 
The aldol reaction is reversible, cleavage of a β-hydroxy carbonyl is called the reverse aldol 
or retro-aldol reaction.51 Equlibrium between the β-hydroxylcarbonyl products and the 
carbonyl reactants lie toward the products with alkyl aldehydes and toward the reactants with 
alkyl and aryl ketones (Scheme 2.14). 
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2.6.1 Formation of the anti-substituted lactones 
The addition of allyl trimethyl silane to cyclopropyl carbaldehyde (111) gave the Felkin-Anh 
product (112) (Scheme 2.13). This cyclopropane derivative (112) has several properties that 
are useful for further synthetic transformations. The hydroxyl group at C-4 is located in a γ-
position to the ester group at C-2 of the cyclopropane moiety, the vicinal donor-acceptor 
relationship between the hydroxyl group at C-1 and the ester group at C-2 could make feasible 
ring opening of cyclopropane. These two features made a possibility for the development of 
retroaldol/lactonization sequences of allyl cyclopropane to trans-disubstituted γ-
butyrolactone. The base mediated Sakurai allylation product 112 either with Ba(OH)2 or Et3N 
upon retroaldol/lactonization sequence was afforded γ-butyrolactone 55 (Scheme 2.15). 
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2.7 Introduction to tetrahydrofuran-imidazole based histamine H3 
and H4 receptor agonists 
Kurihara et al developed a series of chiral compounds related to aminomethyl tetrahydrofuran 
imidazoles (Figure 2.5), which have been examined in vitro for both the human histamine H3 
and H4 receptors.52 Among them, the (2S,5S)-isomer 54 showed approximately 300-fold 
higher selectivity at the H3 receptor than the H4 receptor. On the other hand, (2R,5S)- and 
(2R,5R)- cyanoguanidines OUP-13 (46) and OUP-16 (45) bound to the H4 receptor had >40-
fold selectivities over the H3 receptor and they are the first selective H4 receptor agonists. 
Thus the imidazole-tetrahydrofurane amines 116, 117, 35, 54 are H3 agonists and their 
cyanoguanidine derivatives 118, 46, 45, 119 are H4 receptor agonists.52 
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Figure 2.5 Histamine H3 and H4 receptor agonists developed by Kurihara et al
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About the physiological and pathophysiological role of the H4R is not much known. Recently, 
OUP-16 has been described as a full agonist with moderate affinity and selectivity for the H4 
receptor. Furthermore, to investigate the possible physiological functions of the H4 receptor, a 
more potent and selective ligands are required. Because of more sequence homology between 
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H3 and H4 receptor than any other subtypes of histamine receptors, most H3 receptor ligands 
can bind to the H4 receptor as well. For example, the classical “selective” H3 receptor agonist, 
(R)-α-methylhistamine shows H4 agonistic activity and thioperamide, the H3 antagonist 
prototype, has moderate affinities for the H4 receptor. Very few ligands have so far been 
reported that can selectively target the human H4 receptor. Imifuramine was found as eutomer 
exhibiting H3 agonistic activity.52,53,54 
The competitive binding affinities (pKi value) for the hH3-receptor of the cyanoguanidines 
(118, 46, 45, 119) were significantly lower than that of the THF-amines (116, 117, 35, 54). 
(Table 1). The pKi values of 35, 54 for the binding to the hH3 receptor were 10-fold higher 
than that of the other compounds and were 6.64 ± 0.12, 6.66 ± 0.14 respectively. The trans-
isomers (35, 54) of amino compounds exhibited about 10-fold higher affinity than their cis-
isomers (116, 117). In a functional H3 receptor assay, the compounds 116, 117, 35 and 54 
acted as full agonists (0.9 < α < 1.0, Table1).52     
Table 1. pEC50 values and affinity values of THF-imidazoles for human H3 receptora 
a
 The pEC50 values were determined by the inhibition of the forskolin-stimulated (1 µM) 
cAMP production, expressing the human H3 receptor. All values shown are means ± SEM of 
at least four experiments. H3 receptor competition binding was performed using [3H] Nα-
methylhistamine (1 nM). 
Among them, 35 had the highest agonistic activity. As shown in Table 2, 35, 46 and 45 
competed for [3H] histamine binding to the hH4 receptor with pKi values of 6.05 ± 0.04, 6.65 
± 0.06, and 6.90 ± 0.17 respectively. Moreover, 116, 118, 46, 45, and 119 all showed agonist 
Functional activity   
Compound 
 
configuration 
     pEC50 efficacy(α) 
 
binding pKi 
 
Histamine 
(R)-α-methylhistamine 
116 
117 
35 
45 
118 
46 
45 
119 
 
 
 
     
    2S,5R 
    2R,5S 
2R,5R 
2S,5S 
2S,5R 
2R,5S 
2R,5R 
   2S,5S 
 
    8.39 ± 0.06 
9.91 ± 0.05 
6.09 ± 0.05 
6.11 ± 0.08 
7.35 ± 0.07 
6.98 ± 0.05 
NE 
4.99 ± 0.08 
5.50 ± 0.08 
˂4 
 
 
1.00 
0.85 ± 0.05 
0.95 ± 0.04 
1.06 ± 0.04 
1.04 ± 0.05 
0.91 ± 0.04 
˂0.1 
0.43 ± 0.03 
0.79 ± 0.06 
 
 
 
 
7.47 ± 0.11 
     
    5.77 ± 0.03 
    5.69 ± 0.05 
6.64 ± 0.12 
6.66 ± 0.14 
5.09 ± 0.08 
 5.15 ± 0.17                       
 5.66 ± 0.09 
 4.73 ± 0.13 
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properties with high intrinsic activities (0.9 < α < 1.0). Among them, 45 most potently 
inhibited the 1 µM forskolinstimulated responses with an apparent pEC50 value of 7.11 ± 
0.05 (Table 2). 35, 54, 46 and 45 exhibited receptor selectivity for either the hH3 or hH4 
receptor. THF-Amine compounds 35, 54 showed selective H3 agonistic activity, which was 
approximately 45-, 300-, fold higher than for the H4 receptor, respectively. In contrast, the 
cyanoguanidine analogues 46 and 119 exhibited full agonistic activities at the H4 receptor 
with 45- and 41-fold higher potency than at the H3 receptor, respectively.52 
Table 2. pEC50 values and affinity values of THF-imidazoles for human H4 receptora 
Functional activity  
Compound 
 
 
 
configuration 
 
      pEC50 
 
    efficacy(α) 
 
 
binding pKi 
Histamine 
(R)-α-methylhistamine 
116 
117 
35 
54 
118 
46 
45 
119 
 
 
   
2S,5R 
2R,5S 
2R,5R 
2S,5S 
2S,5R 
2R,5S 
2R,5R           
2S,5S 
7.68 ± 0.05 
6.26 ± 0.07 
5.12 ± 0.05 
5.26 ± 0.07 
5.70 ± 0.05 
4.51 ± 0.01 
5.12 ± 0.06 
6.65 ± 0.03 
7.11 ± 0.05 
4.67 ± 0.03 
1.00 
1.01 ± 0.01 
   1.02 ± 0.07 
   0.88  ± 0.06 
   0.70 ± 0.01 
0.60 ± 0.04 
1.07 ± 0.01 
1.01 ± 0.01 
   0.99 ± 0.01 
 1 .06 ± 0.02 
 
 
5.19 ± 0.07 
5.60 ± 0.10 
6.05 ± 0.04 
4.89 ± 0.06 
5.09 ± 0.07 
6.65 ± 0.06                       
6.90 ± 0.17 
4.69 ± 0.12 
a
 The pEC50 values were determined by the inhibition of the forskolin-stimulated (1 µM) 
cAMP production, expressing the human H4 receptor. All values shown are means ± SEM of 
at least four experiments. H4 receptor competition binding was performed using [3H] 
histamine (10 nM). 
The substitution of an amino group of tetrahydrofuranylimidazoles with a cyanoguanidine 
moiety led to a decrease in the agonistic activity at the H3 receptor and an increase in the H4 
receptor selectivity. The 46 (OUP-13) and 45 (OUP-16), having the 2R-configuration, were 
highly selective compounds at the H4 receptor. On the other hand, 54 having the 2S,5S-
configuration, behaved as the most selective H3 receptor agonist in THF-imidazole series. 
These results suggest that the stereochemistry of the tetrahydrofuranylimidazoles is useful for 
the investigation of selective ligands for hH3 and hH4 receptors.52 
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2.7.1 Synthesis of histamine H3 and H4 agonists by Kurihara and coworkers 
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Kurihara et al reported the synthesis of trans- and cis-4(5)-(5-aminomethyltetrahydrofuranyl) 
imidazole [(+)-35 and 117], which was the clue to the development of H3 or H4 ligands, 
starting from L-glutamic acid.53-56 Reduction of 120 with DIBAL-H followed by treatment of 
bisprotected imidazole 122 with 121 in presence of n-butyl lithium obtained 123 as 1:1 
inseparable diastereomeric mixture (Scheme 2.16). The Mitsunobu cyclization of 123 using 
the expensive reagent TMAD obtained 124 as again 1:1 inseparable mixture of trans and cis 
cyclization product, due to indistinguishable activation between two hydroxy groups of a 
chiral 1,4-diol intermediate 123. Deprotection of TBDMS with TBAF followed by flash 
chromatography afforded 125 and 129 whose NOE experiments did not show significant 
difference and relative configurations were not established at this stage. On the other hand 
optical rotation measurements did not show any variations. Latter stage using chiral HPLC 
proved that 125 and 129 was obtained with low optical purities of 1:1.2 (9% ee) and 1:1.5 
(20% ee) (Scheme 2.16). Debenzylation of 125 and 129 using Pd(OH)2/C furnished the 
primary alcohols 126 and 130. Phthalimidation of 126 and 130 using DEAD-Ph3P gave rise to 
127 and 131 respectively. To determine the relative configuration at this stage phthalimide 
127 was recrystalized and analyzed by X-ray crystallography as racemic mixture, and its 
configuration between C2 and C5 was found to be trans. Reductive cleavage of phthalimides 
127 and 131 with hydrazine hydrate, followed by acidic hydrolysis using 1.5 N HCl produced 
amines 35 and 117. Introduction of cyanoguanidine on 35 and 127 led to the histamine H4 
receptor agonists 45 (OUP-16) and 46 (OUP-13).55 
The findings of imifuramine, and their cyanoguanidine derivatives OUP-16 and OUP-13 as 
important therapeutic targets of recently discovered histamine receptors and the synthetic 
drawbacks for the enantioselective version, encouraged us to synthesize trans- and cis-
tetrahydrofuranylimidazole derivatives for improvement of more potent and receptor selective 
histamine H3 and H4 agonists using the γ-butyrolactone based enantioselective synthesis.  
Kurihara and coworkers reported the efficient and β -stereoselective synthesis of 4(5) (2-
deoxyribofuranosyl)imidazoles (137-140) and 4(5)-(β-D-ribofuranosyl) imidazole (142) 
where they have used Mitsunobu reaction as key step for the cyclization of diols 133-136, and 
141. The cyclization of diols, 133 and 134 having bisprotected imidazoles (sulfonamide and 
TBDMS groups) using TMAD reagent on C1-S and C1-R diols gave only poor yields 12% 
and 7% and no enantioselectivity (Scheme 2.17).57,58  
The cyclization of unsubstituted imidazole diol 141, under Mitsunobu conditions (Bu3P-
TMAD) obtained 142 with β-stereo selectivity in 92% yields. The authors reported the 
feasible mechanism for the Mitsunobu cyclization (TMAD-Bu3P system) of the diols bearing 
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an unsubstituted imidazoles (NH free imidazole diols) via diazafulvene intermediate (Scheme 
2.18).58 Mitsunobu cyclization of diols 133-136 bearing monosubstituted or disubstituted 
imidazole proceeded via a SN2 process of the standard Mitsunobu reaction. 
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The intact-imidazole moiety is thus shown to be indispensable for the exclusive formation of 
β-anomers. Intramolecular hydrogen bonding between the nitrogen in the imidazole and OH 
groups in the sugar moiety should be essential to the determination of the ratio of α- vs β-
glycosylation. Epimerization between α and β-anomers did not take place under the present 
reaction conditions. From these results, β-selectivity may be explained as in Scheme 2.18.58 
Reaction of the TMAD-Bu3P adduct with 141R forms the zwitterion 143R. Preferential 
elimination of Bu3PO from 143R leads to isoimidazole 144. Spontaneous cyclization assisted 
by a hydrogen bond gives the β-anomer (142β), which is stabilized by intramolecular 
hydrogen bonding. Although the S-isomer (141S) similarly leads to the active species 145, it 
exclusively gave the β-anomer via rotomer 144 which is thermodynamically more stable. The 
remarkable stereoselectivity (β/α ratio 26/1) of the ribofuranosylimidazoles 142 is facilitated 
by electronic repulsion in 145. The somewhat low selectivity (α/β ratio 5.4/1) of the 2′-deoxy 
compounds 137-140 may be due to lack of the OBn group at C-2′.58 
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2.8 Enantioselective Synthesis of histamine H3 and H4 receptor potential 
agonists using γ-butyrolactone (GBL)-55 
The retrosynthetic analysis for ‘enantioselective synthesis of human histamine H3 and H4 
receptor potential agonists’ was briefly explained here based on γ-butyrolactone. The OUP-16 
analogue 61 can be obtained by introduction of cyanoguanidine on amine 60 and similarly 59 
can be obtained from 58. The amines 60 and 58 could be obtained by the deprotection of 
TBDMS and sulphonamide groups from 156 and 157 respectively. Synthesis of amines 156 
and 157 would be possible from the corresponding building blocks 150 and 151 by 
hydroboration followed by phthalimidation and subsequent cleavage of phthalimide. 
Treatment of 147 with bisprotected imidazole 122 in presence of n-butyl lithium may obtain 
the diols as possibly diastereomers which can be cyclised by Mitsunobu reaction to afford the  
building blocks 150 and 151. The lactol 147 can be obtained from the γ-butyrolactone 55 by 
 59 
protection of aldehyde with ethylene glycol and followed by DIBAL-H reduction (Scheme 
2.19). 
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2.8.1 Results and discussion 
2.8.2 Synthesis of lactol  
The aldehyde 55 was protected with ethylene glycol in the presence of catalytic amount of 
para-toluenesulfonic acid according to the known procedure.59 Under the conditions 
mentioned below the aldehyde 55 gave 146 in 85% yield. DIBAL-H reduction of 146 at -78 
°C for 2h, upon dilution with EA and the addition of saturated potassium sodium tartrate gave 
the corresponding lactol 147 in 90% yield (Scheme 2.20).60 
O
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Reagents and conditions: i) ethylene glycol ( 5 eq), p-TsOH ( 0.25 eq), benzene, 90 °C, 85% 
ii)1.5 eq DIBAL-H (1M solution in DCM), -78 °C, 2h, 90%
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Scheme 2.20 Synthesis of lactol
 
2.8.3 Synthesis of bisprotected imidazole 
The bisprotected imidazole 122 was prepared in two steps according to the reported procedure 
by Chadwick and co-workers.61 Treatment of imidazole (158) with N,N-dimethyl 
chlorosulfonamide and triethyl amine in benzene afforded the sulfonamide 159 in 80% yield. 
Further treatment of 159 with nBuLi at -70 °C in anhydrous THF gave the bisprotected 
imidazole 122 in 73% yield (scheme 2.21).61,62 
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122
Scheme 2.21 Synthesis of Bisprotected imidazole
 
2.8.4 Synthesis of Imidazole-Diols 
The bisprotected imidazole 122 was treated with nBuLi in THF at -70 °C to generate the anion 
which was subsequently reacted with lactol in THF to afford the diastereomers of the diols 
148 and 149. The anion generated at C-5 of bisprotected imidazole (122) was reacted on the 
anomeric carbon of the lactol 147 to form the C-C bond in diols 148 and 149.55 These diols 
were separated by silicagel column chromatography for further reactions to use single 
diastereomers (Scheme 2.22). The diols 148 and 149 were also used as mixture of 
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diastereomers for further synthetic transformation. Cyclization of these diols 148 and 149 was 
done under suitable Mitsunobu reaction conditions as explained broadly in section 2.8.5.  
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2.8.5 The Mitsunobu reaction  
The Mitsunobu reaction is a redox combination of a trialkyl or triarylphosphine and a dialkyl 
azodicarboxylate for the substitution of primary or secondary alcohols with a broad range of 
nucleophiles.63 Since its discovery in 1967 by Oyo Mitsunobu, this reaction is popularly 
known because of its versatility and effectiveness.64,65 This mild reaction converts a hydroxyl 
group into a potent leaving group which can be displaced by a wide variety of nucleophiles. It 
has a privileged role in organic synthesis, particularly often used as a key step in natural 
product syntheses and medicinal chemistry because of its scope, stereospecificity.63 This mild 
reaction converts a hydroxyl group into a potent leaving group which is able to displace by a 
wide variety of nucleophiles for the synthesis of broad range of compounds from esters, 
ethers, amines, azides, cyanides, thiocyanides, thioesters, and thioethers (Scheme 2.23).63 
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Scheme 2.23 Mitsunobu reaction with various nucleophiles
 
The Mitsunobu reaction has been proved to be a diverse, useful and practical method for C-O, 
C-N, C-C and C-X bond formation, among other uses in organic synthesis. It is also used for 
the inversion of asymmetric alcohols, formation of cyclic ethers, epoxides, amines, β-
 62 
lactams,66,67 macrolactonization,68 nucleosides synthesis,69 dehydration70 and carbon chain 
elongation.71 Its mild reaction conditions and excellent stereoselectivity make it an excellent 
reaction that serves its purpose well. There is no doubt that it will continue to be an important 
synthetic tool for the practicing organic chemist. Some advantages and disadvantages about 
this reaction are described below. 
Advantages  
1) A mild, one-pot reaction 2) Typically gives good yields and high stereospecificity  
3) Tolerates many functional groups 4) A wide range of nucleophiles are accepted.  
Disadvantages  
1) Byproducts are difficult to remove 2) Not very atom economical 3) Some of the 
reagents are expensive.  
Here are some Mitsunobu reagents known in the literature as shown below (Figure 2.6).72  
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Chiral secondary alcohols undergo a complete inversion of configuration unless they are 
sterically very congested.73-75 The nucleophile is normally a relatively acidic compound 
containing an O-H, S-H, or an N-H group with pKa having less than or equal to 15, preferably 
below 11. The preferred phosphorus (III) component is triphenylphosphine (Ph3P) or 
tributylphosphine (n-Bu3P), both are inexpensive and commercially available. Generally, the 
Ph3P-DEAD/DIAD system is useful for acidic nucleophiles with pKa < 11. For those having a 
pKa > 11, more active coupling reagents such as 1,1-(azodicarbonyl)dipiperidine (ADDP), 
4,7-dimethyl-3,5,7-hexahydro-1,2,4,7-tetrazocin-3,8-dione (DHDT) and N,N,N′,N′-
tetramethylazo dicarboxamide (TMAD). Modification of the organic group on the 
 63 
azodicarboxylate can afford these reagents. Recently Tsunoda and coworkers76 have reported 
the above DEAD alternatives of increased basicity that allow carbon nucleophiles having 
higher pKa’s to be used as nucleophiles.77,78 
The mechanistic details of the Mitsunobu reaction, particularly at the intermediate stages, are 
still a subject of debate and intensive studies.63,75,79,80 A feasible pathway of the esterification 
process is shown in Figure 2.7. The first step is the irreversible formation of the Morrison-
Brunn-Huisgen (MBH) betaine intermediate 167 by phosphine and azodicarboxylate (166), 
the identity of betaine has been established by multinuclear NMR.63 MBH 167 is able to 
deprotonate the nucleophile in step 2 and the resulting carboxylate anion deprotonates the 
alcohol forming an alkoxide which can attack the betaine at phosphorus eventually forming 
the pentacoordinated phosphorane 169 and oxyphosphonium ion 170 (step 3).63 In step 4 the 
carboxylate anion participates in a bimolecular nucleophilic displacement of 
triphenylphosphine oxide which proceeds with inversion. It is generally accepted that the 
oxyphosphonium ion 170 is the active intermediate which undergoes SN2 displacement. The 
other species probably play a spectator roles although 172 (acylphosphonium salt) may indeed 
be the active intermediate when the attempted inversion of hindered secondary alcohols yields 
esters with retained stereochemistry.81 Finally the hydrazine RO2CNH-NHCO2R and 
phosphine oxide Ph3P(O) are formed as byproducts in Mitsunobu reaction. 
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Acids of lower pKa have been shown to give higher yields of inverted products when the 
alcohol is sterically hindered. The proposed reason for this increased activity is the evidence 
that acids of lower pKa tend to favor the oxyphosphonium intermediate 170 over the less 
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reactive phosphane 171.82,83 The intermolecular formation of aliphatic ethers is unfortunately 
hindered by the fact that the betaine intermediate is not basic enough to sufficiently 
deprotonate the weakly acidic hydroxyl group. However, formation of cyclic ethers via 
intramolecular condensation proceeds in good yields.84,85 
The difficulty with the Mitsunobu reaction is that the isolation and purification of the desired 
product requires separation from phosphine oxide and hydrazinedicarboxylate byproducts. 
Various ways of addressing this problem have been developed by modifying 
triphenylphosphine or azo dicarboxylate reagents to facilitate isolation and purification of the 
products. Few methodologies are established with their own limitations, including acidic or 
basic aqueous workup, applying novel ring opening metathesis (ROM) protocols, post 
reaction sequestration (solution or solid-phase reaction), and polymer assisted phase-
switching or solid phase immobilization.86,87 The use of polystyryldiphenylphosphine resin 
can circumvent the problem of removal of triphenylphosphine oxide because the resulting 
phosphine oxide is also anchored to the polymer and it can be readily filtered off.63 Reduction 
of the phosphine oxide back to reusable resin can be effected by treating it with 
trichlorosilane.63,88 Polymer-supported triphenylphosphine prepared from bromopolystyrene 
has also been used for esterification reactions.89,90 
Zaragoza and Stephensen have reported that fmoc protected amino acids esterified with Wang 
resin reacted with aliphatic alcohols in the presence of n-Bu3P-ADDP/i-Pr2NEt or Et3N to 
yield O-alkyl carbamates that are suitable for robotic synthesizers.63,91 Here the substrate was 
polymer bound, but not the reagents.63 They also noted that primary alcohols gave good 
results, but yields using secondary alcohols were not satisfactory.63 Peroxisome proliferator-
activated receptors (PPARs) have great potential as pharmaceutical targets for many 
applications.63 Humphries et al have disclosed a method for the synthesis of PPAR agonists 
using the PS-PPh3-ADDP reagent system.63,92 A solid phase synthesis of AChE inhibitors was 
developed by Leonetti et al.93 where they used n-Bu3P-ADDP in CH2Cl2. Recently, a polymer 
bound azodicarboxylate and anthracene tagged phosphine for the Mitsunobu reaction leading 
to phthalimides, esters, as well as ethers has been reported by Lan et al.94 The authors pointed 
out that the azodicarboxylate and its corresponding hydrazine product could be readily 
separated from the desired products by simple filtration.63 Curran and co-workers have been 
developed new approaches to circumvent the problem of separation by using new fluorous 
tagged azodicarboxylate reagents, and fluorous phosphine in the Mitsunobu reaction.95,96 The 
byproducts could be separated either by fluorous flash chromatography or fluorous solid-
phase separation.63,95 
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In our case, the Mitsunobu cyclization was first carried out under standard Mitsunobu 
conditions by using Diethylazodicarboxylate (DEAD) and triphenylphosphine (PPh3). The 
expected product was not formed, but only a complex mixture of reagents and starting 
material was observed (Figure 2.24). The reaction also did not work with DIAD (diisopropyl 
azodicarboxylate) and tributylphosphine. To investigate this problem the reaction was studied 
in detail to achieve the target product with desired stereochemistry. The search for a suitable 
Mitsunobu reagent revealed tetraethyl azodicarboxylate (TEAD) 174 as an alternative to 
tetramethyl azodicarboxylate (TMAD) 162 and azodicarboxylate dipyrrolidine 176 as an 
alternative to azodicarboxylate dipiperidine (ADDP) 164. When DEAD was treated with 
diethyl amine at 0 °C in ether, TEAD was formed as minor product only about 10% yield. 
The major product was isolated as hydrazine derivative. This can be explained by addition of 
diethyl amine to nitrogen of the azo centre rather then the ester carbonyl (Scheme 2.25).97 
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The cyclization of the diols was done with the above prepared TEAD reagent but the product 
was formed with very low yield. To overcome all these problems the reaction was tested with 
tetramethylazodicarboxylate (TMAD). The diol was treated with 3 eq of TMAD in presence 
of tributylphosphine in benzene at room temperature to obtain the cyclized product in about 
70% yield (Scheme 2.26). The same condition was applied to convert diol 149 to 151 cis 
isomer which gave little bit lower yield compare to trans isomer. 
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Toy and co-workers have introduced PhI(OAc)2, an additional component to use only a 
catalytic amount (10 mol %) of the expensive azodicarboxylate reagents.98 This methodology 
was applied here to convert 148 to 150 by using 10 mol % of TMAD, 3 equivalents of 
tributylphosphine and 3 equivalents of  PhI(OAc)2 however, only 30% yield of 150  was 
observed under these conditions and as the major product the undesired 178 was isolated 
(Scheme 2.27). PhI(OAc)2 converts hydrazine byproducts back to the azodicarboxylate but 
acetic acid is a byproduct which may interfere in the expected reaction. As long as acetic acid 
does not interfere in the expected reaction, this methodology could be a very useful one. This 
idea of “organocatalytic” cycle is quite novel and needs further exploration to view the scope 
of this reaction to avoid the stoichiometric use of expensive azodicarboxylate reagents. 
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The treatment of DEAD (160) with pyrrolidine at 0 °C in anhydrous ether did not give the 
expected product 176 even as minor product, instead only the hydrazine by product 177 was 
observed (Scheme 2.28). 
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The final attempt for the suitable Mitsunobu reagent was investigated by treating DEAD (160) 
with piperidine at 0 °C in ether to form the corresponding reagent azodicarbonyl dipepiredine 
(ADDP) which was successful and the product 164 was obtained in good yield (Scheme 
2.29).97 
N N COOEtEtOOC N
N N
O
N
O
Expected product
160 164
ADDP
Reagents and conditions: i) Piperidine, dry ether, 0 °C, 2h, 74%
i
Scheme 2.29 Preparation of Azodicarbonyldipepiredine (ADDP)
 
Tsunoda et al.78 reported 1,1′-(azodicarbonyl)-dipiperidine (ADDP)-Bu3P and N,N,N′,N′- 
tetramethylazodicarboxamide (TMAD)-Bu3P as new reagent systems for the Mitsunobu 
reaction, and Kurihara et al. applied these methods to the cyclization of unsubstituted 
imidazole diols.55 Treatment of the mixture with ADDP-Bu3P afforded the β-anomer having 
an unsubstituted imidazole in modest yield. The authors also reported that (TMAD)-Bu3P 
system obtained the products in good to excellent yield. 
As mentioned in scheme 2.26 when TMAD-Bu3P system used as Mitsunobu conditions the 
cyclization of substituted imidazole diols (148 and 149) afforded the products (150 and 151) 
in about 70% yield. Interestingly when ADDP-Bu3P system used as Mitsunobu conditions the 
cyclization of substituted imidazole diols (148 and 149) afforded the products (150 and 151) 
in about 80% yield as shown in scheme 2.30. These results clearly suggested us that use of 
inexpensive reagent ADDP gave more yield than expensive TMAD in our case. 
Yokoyama et al.99 reported synthesis of C-ribonucleosides having typical aromatic 
heterocycles, in which the cyclization of the corresponding diols proceeds through 
intramolecular SN2 reaction under Mitsunobu conditions. The orientation of the glycosidic 
linkage is controlled by the C1 configuration of the substrate: one isomer (1R) affords an α-
anomer and the other isomer (1S) gave β-anomer.55,58 Thus, Mitsunobu cyclizations of 148 
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(1S) and its diastereomer 149 (1R) are required selective formations of C1-oxyphosphonium 
intermediates to obtain products with high optical purities.55 
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Reagents and conditions: i)  ADDP (3 eq), Bu3P, benzene, rt,18h, 80%
R = SO2NMe2
i)
i)
Scheme 2.30 Mitsunobu cyclization of diols with ADDP
 
The cyclization of 148 and 149 proceded under Mitsunobu condition (ADDP-Bu3P) is 
stereoselective intramolecular SN2 reaction as reported by Yokoyama et al.99 The orientation 
of the glycosidation is controlled by the C1 configuration of the substrates 148 and 149, thus 
one isomer 148 (1S) gave β-anomer 150 (2R) and the other isomer 149 (1R) affords an α-
anomer 151 (2S) as shown in scheme 2.30.55 The stereochemistry of both 150 and 151 were 
determined by COSY and NOE experiments which supports that the configuration in 150 as 
2R and in 151 as 2S. The high optical purity of these products were confirmed by optical 
rotation and chiral HPLC, which shows that, this strategy is enantioselective for the synthesis 
of analogues of histamine H3 and H4 receptor agonists. The Optical purity of 150 was 
determined as [α]D 24 – 49.5 (c 1.0, CHCl3) and 151 as [α]D 24 + 15.7 (c 1.0, CHCl3). 
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The plausible mechanism for the cyclization of diols 148 and 149 was explained incontrast to 
diazafulvene intermediate and according to stereoselective cyclization of Mitsunobu reaction 
as reported by Yokoyama et al.99 This plausible mechanism also supports the Mitsunobu 
cyclization of diols bearing monosubstituted or disubstituted imidazole proceeds via a SN2 
process of standard Mitsunobu reaction as mentioned by Kurihara et al.58 In our case the diols 
148 and 149 having bisprotected imidazoles (sulfonamide and TBDMS protecting groups) are 
electron deficient aromatic rings (since sulfonamide is electron withdrawing group) which do 
not favour to undergo diazafulvene rearrangement (see Scheme 2.18). The feasible 
mechanism is suggested in scheme 2.31. ADDP and tributyl phosphin forms betain 
intermediate (MBH) 179 which can pick up a proton from 1-hydroxy group of 1S diol 148 
and affords alkoxide anion 180. This alkoxide anion can attack on phosphorous of 181 
eventually lead to the oxyphosphonium intermediate 182. This oxyphosphonium intermediate 
can undergo stereospecific SN2 type cyclization by concerted mechanism to obtain the 
 
2 11 11 
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required product 150 and delivers the byproducts tributyl phosphine and hydrazine derivative 
184 (Scheme 2.31). Similarly diol 149 undergo same mechanism to furnish 151. It is believed 
that the cyclization of diols 148 and 149 proceeds through normal intramolecular SN2 
mechanism as shown in scheme 2.31 which supports the stereoselective cyclization of 
Mitsunobu reaction as reported by Yokoyama et al.99  
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Scheme 2.31 Plausible mechanism of Mitsunobu cyclization of Imidazole diols
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Hydroboration of 150 and 151 did not work with catecholborane, 9-BBN and 
acetoxyborohydride. The hydroboration was studied in detailed to overcome the problem of 
reactions with 150 and 151. 
2.8.6 Hydroboration 
In 1936 diborane, B2H6, a rare substance, prepared in less than gram quantities in only two 
laboratories, that of Alfred Stock at Karlsruhe, Germany and of H. I. Schlesinger, at the 
University of Chicago, USA.100 The existence of simplest hydrogen compound of boron, not 
as BH3, but as B2H6, was considered to constitute a serious problem for the electronic theory 
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of G. N. Lewis.101 The reactions of diborane were under study at the University of Chicago by 
H. I. Schlesinger and Anton B. Burg, in the hope that a knowledge of the chemistry would aid 
in resolving the structural problem. 
Investigation of selective reductions by Brown and coworkers, a minor anomaly resulted in 
the discovery of hydroboration.102 Brown’s coworker, B. C. Subba Rao, was examining the 
reducing characteristics of sodium borohydride in diglyme catalyzed by aluminum chloride.103 
Investigation soon established that the reagent was adding an H-B, bond to the carbon-carbon 
double bond to form the corresponding organoborane.104,105 The process of producing 
organoboranes by the addition of a compound with a B-H bond to an unsaturated hydrocarbon 
is called as hydroboration. Subba Rao established that oxidation of such organoboranes, in 
situ, with alkaline hydrogen peroxide, proceeds quantitatively, producing alcohols.105-107 
It was soon established that the addition proceeds in an anti-Markovnikov manner. The 
reaction involves a cis-addition of the H-B bond. The addition takes place preferentially from 
the less hindered side of the double bond. No rearrangement of the carbon skeleton was 
observed, even in the molecules as labile as α-pinene. Most functional groups can tolerate 
hydroboration. The hydroboration of a simple olefines generally proceeds directly to the 
formation of the trialkylborane. However, in a number of instances it has been possible to 
control the hydroboration to achieve the synthesis of monoalkyl boranes, dialkylboranes, and 
cyclic, bicyclic boranes. Many of these reagents such as thexylborane, disiamylborane, 
dipinylborane (IPC2BH) and 9-borabicyclo-(3.3.1)-nonane (9-BBN) have proven to be 
valuable in overcoming problems encountered with the use of diborane itself.102,108,109 
2.8.7 Hydroboration of cyclic buiding blocks 
The transition metal catalyzed hydroboration of olefins represent conventional approaches 
towards regioselective synthesis of alcohols. There are few methods available efficiently for the 
rhodium-catalyzed olefin addition reactions.
110
 This method has been used in our research group 
for the conversion of allylic double bond of γ-butyrolactone derived olefins to the 
corresponding primary alcohols using catecholborane in presence of Wilkinson catalyst.111 
When olefins 146 and 186 were treated with catecholborane in presence of Wilkinson 
catalyst, obtained the primary alcohols 185112 and 187113 in 65% and 71% respectively. But 
under the same conditions olefin 150 did not proceed to obtain the alcohol 152 and only 
starting material was recovered quantitatively (Scheme 2.32). The reason may be due to the 
imidazole moiety in olefin 150, the catalyst may not be active enough to form the oxidative 
addition species to proceed the reaction.   
 75 
OO
O
O
OO
O
O
OH
OO
NHBoc
OO
NHBoc
OH
O
O
O
N
N
SO2NMe2
SiO
O
O
N
N
SO2NMe2
Si
OH
150 152
Reagents and conditions: i) Rh(PPh3)3Cl, Catechol borane, THF, H2O2, 0 °C-rt, 12h
Scheme 2.32 Hydroboration with catechol borane
          Did not form the product
only starting material was recovered
i)
i)
i)
146
65%
71%
0%
185
186 187
 
Periasamy and coworkers reported the conversion of olefins to alcohols by using 
acetoxyborohydride method.114,115 Simple addition of sodium borohydride to acetic acid could 
generate acetoxyborohydride in situ which can react with variety of olefins to obtain the 
alcohols. When olefin 150 was treated with acetoxyborohydride which was generated by 
addition of sodium borohydride to acetic acid, unfortunately this reaction did not work even 
after stirring the reaction mixture from 0 °C to room temperature for 24 hours. Under these 
conditions only the starting material was recovered quantitatively. Then the hydroboration of 
150 was done with 9-BBN but again only the starting material was recovered. It may be 
because of sterically bulky borane hydride not able to react with olefin 150 (Scheme 2.32). 
O
O
O
N
N
SO2NMe2
Si 150
Reagents and conditions:  i) AcOH/NaBH4,THF, 0 °C-rt, 24h ii) 9-BBN, THF, H2O2, rt,12h
N.R, SM recovery
N.R. = No Reaction; 
SM = Staring Material
Scheme 2.33 Hydroboration on cyclic building block
N.R, SM recovery
i) ii)
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Knochel et al. reported the remote C-H activation of phenyl substituted alkenes by using 
BH3.THF.116 The authors used diborane at 50 °C to obtain the alcohols in 24 hours. Under 
these conditions when olefin 150 was subjected to diborane the starting material was 
completely disappeared with in 8h at 50 °C, further addition of 2M NaOH followed by 
oxidation with hydrogen peroxide obtained the alcohol in very good yield.  Later the reaction 
was standardized without heating and only at room temperature with additional stirring of 2-3 
hours. Olefin 150 was treated with diborane at room temperature for 12 hours and further 
oxidation of organoborane with hydrogen peroxide obtained the alcohol 152 in 80% yield 
(Scheme 2.34). Under the same conditions olefin 151 furnished the alcohol 153. 
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Scheme 2.34 Hydroboration with diborane
 
2.8.8 Phthalimidation  
In 1972, Mitsunobu reported the formation of amines from alcohols via phthalimide and 
subsequent reduction with hydrazine.117 Amines are also accessible via Staudinger reductions 
of azides which are formed in excellent yields using HN3 under Mitsunobu conditions.118  The 
primary alcohols 152 and 153 were subjected to phthalimidation using phthalimide, 
diethylazodicarboxylate and triphenylphosphine under standard Mitsunobu phthalimidation 
conditions to get the phthalimides 154 and 155 as C-N bond forming reactions in 65% yield 
(Scheme 2.34). 
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2.8.9 Synthesis of amines 
The reductive cleavage of phthalimides was done under basic hydrolysis conditions.117 
Phthalimides 154 and 155 were treated with hydrazine hydrate in ethanol at room temperature 
obtained the primary amines 156 and 157 in 76% yield (Scheme 2.35). 
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Scheme 2.35 Synthesis of amines
 
2.9.0 Deprotection of TBDMS and Sulfonamide groups 
The deprotection of sulfonamide was done under acidic conditions using HCl as reported by 
Kurihara et al.53-56 Using HCl under the conditions mentioned by Kurihara et al when 156 and 
150 were subjected to acidic hydrolysis, only TBDMS was deprotected and sulfonamide did 
not deprotect. The reaction was done with 1.5 N HCl, there was only starting material left 
even after refluxing for 24h. Then the concentration was increased to 3N and 6N even after 
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refluxing 24h there is no product formation. Only starting material was recovered. The 
deprotection was also done with TFA119 and sulfuric acid120 but in both the cases only starting 
material was recovered. The deprotection of sulfonamide was done under basic conditions 
with KOH121 and also with K2CO3/thiophenol122 in both cases only starting material was 
recovered. The deprotection was also done with Na/liq ammonia,123 Na/Naphthalene,124     
Na-Hg125 in all three cases either starting material was recovered or only a complex mixture 
was observed. Then the reaction was done by using most of the known methods in the 
literature for the deprotection of sulfonamide like, TBAF,126 TMSI,127 1,3-diaminopropane in 
microwave,128 Mg in methanol129 and SmI2 in THF130 to get the target molecule. But in all the 
cases deprotection was not successful. 
The reaction was carried out on final target molecule, later on when it was not successful then 
the model studies were done on the cyclic building block and also on imidazole sulfonamide 
none of them were successful. The deprotection on simple imidazole sulfonamide gave very 
low yield (10%) with HCl (Schemes 2.36 and 2.37). The reaction profile was illustrated in the 
table 3. Deprotection of sulfonamide was not successful with various reagents and different 
reaction conditions as shown in the table 3. 
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Scheme 2.36 Deprotection of TBDMS and sulfonamide
Reagents and conditions: i) 1.5 N HCl, Ethanol, reflux, 12h
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Scheme 2.37 Deprotection of sulfonamide on model substrate
i)
Reagents and conditions: i) 1.5 N HCl, Ethanol, reflux, 12h
 R = TBDMS, 5%
 R = H, 10%
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Table 3. Deprotection of sulfonamide under different reaction conditions 
 
Reagent 
 
Solvent 
 
Temperature 
 
Product obtained 
1N, 3N, 6N, conc HCl THF 0 °C, RT, Reflux 
Only TBDMS 
deprotection 
1N, 3N, 6N, conc HCl Ethanol 0 °C, RT, Reflux 
Only TBDMS 
deprotection 
TFA DCM 0 °C, RT 
Only TBDMS 
deprotection 
Na/liq. NH3 Anhyd. THF -78 °C NMR is not clean 
Na-Hg (1.5% Na) Methanol reflux 
Starting material 
recovery 
Na/naphthalene 
1,2-dimethoxy 
ethane 
RT 
Traces of amount 
converted 
TMSCl/NaI Acetonitrile reflux Only SM 
1,3-diamino propane DMF 140 °C, Microwave Complex mixture 
Thiophenol/K2CO3 DMF RT SM recovery 
5% KOH Methanol RT 
Only TBDMS 
deprotection 
Mg (5eq) Methanol RT SM recovery 
SmI2 THF RT SM recovery 
TBAF THF RT Complex mixture 
 
2.9.1 Summary  
2.9.2 Synthesis of cyclic building blocks for the human histamine H3 and H4 
receptor potential agonists from GBL-55 
Protection of 55 with ethylene glycol followed by DIBAL-H reduction gave 147 as anomeric 
mixture (1:1) in 90% yield. Treatment of 147 with bisprotected imidazole 122 in the presence 
of n-butyl lithium afforded diols 148 and 149 in 90% yield. Diastereomers of these diols were 
separated by silica gel column chromatography. Treatment of these diols 148 and 149 with 
ADDP-Bu3P obtained the cyclized products 150 and 151 respectively (Scheme 2.38). 
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Preparation of suitable Mitsunobu reagents and analysis of stereochemistry of cyclic building 
blocks was achieved. 
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Scheme 2.38 Synthesis of building blocks for THF-Imidazole based H3&H4-receptors agonists
O
CHO
O
Reagents and conditions: i) ethylene glycol, TsOH, benzene, reflux, 85%; ii) DIBAL-H, CH2Cl2
 -78°C, 90%; iii) BuLi, THF -78°C, 90%; iv) TMAD, Bu3P, benzene, RT, 70% or  ADDP, Bu3P, 
benzene, RT, 80%
i) ii)
iv) iv
R = SO2NMe2
                                                                                                                                               
2.9.3 Towards the synthesis of human histamine H3 and H4 receptor 
potential agonists 
The forward synthesis having imidazole, tetrahydrofuran and amine side chain (linker, spacer 
and lipohilic groups) for the synthesis of histamine H3 and H4 receptor potential agonists was 
established by hydroboration of the cyclic building blocks 150 and 151 and subsequent 
phthalimidation and dephthalimidation.  
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Reagents and conditions: v) BH3.THF, THF, rt, 12h, 2M  NaOH/H2O2, 5h, 80% 
vi) Phthalimide, PPh3, DEAD, rt, 12h, 65% vii) N2H4.H2O, EtOH, rt 12h 76%.
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Hydroboration of 150 and 151 with BH3.THF to furnished the primary alcohols 152 and 153 
in good yields (80%). The primary alcohols 152 and 153 were subjected to phthalimidation 
using phthalimide, DEAD and PPh3 to get phthalimides 154 and 155 in 65% yield. 
Deprotection of phthalimides using hydrazine hydrate afforded the primary amines 156 and 
157 in 76% (Scheme 2.39). 
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2.9.4 Synthesis of OUP-13 analogues from γ-butyrolactone GBL-64 
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The OUP-13 analogue 72 can be synthesized from the corresponding amine 70 by 
introduction of cyanoguanidine. The amine 70 could be obtained by the deprotection of 
TBDMS and sulphonamide groups from 198. Hydroboration of 192 and subsequent 
Mitsunobu phthalimidation followed by reductive cleavage of phthalimide may afford 198. 
Aldehyde protection of GBL-64 with ethylene glycol followed DIBAL-H reduction of lactone 
would give the corresponding lactol 189. Treatment of this lactol with bis protected imidazole 
could provide diols as possible diastereomers which can be cyclized under Mitsunobu 
conditions to obtain two cyclic building blocks 192 and 193 (Scheme 2.40).The 
cyanoguanidine derivative of imidazole tetrahydrofuran 71 can be obtained from 193 by 
following the same sequence of 192 to 72. 
2.9.5 Synthesis of cyclic building blocks for the human histamine H3 and H4 
receptor potential agonists from GBL-64 
As explained in the section 2.8 earlier, following the same methodology by using the GBL 64 
the cyclic building blocks were synthesized.  
OO
O
O
OHO
O
O
N
N
R
Si
OH
O
O
OH
N
N
R
Si
OH
O
O
OH
O
O
O
N
N
SO2NMe2
SiO
O
O
N
N
SO2NMe2
Si
64 188 189
122, iii)
191190
193192
Scheme 2.41 Synthesis of building blocks for THF-Imidazole based H3&H4-receptors agonists
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Reagents and conditions: i) ethylene glycol, TsOH, benzene, reflux, 85%,  ii) DIBAL-H, CH2Cl2
 -78°C, 90%, iii) n-BuLi, THF, -78°C, 85%; iv) TMAD, Bu3P, benzene, rt, 68% or  ADDP, Bu3P, 
benzene, rt, 78%
i) ii)
iv) iv
R = SO2NMe2[α]D 24   8.4
[α]D 24   6.0
[α]D 24  + 4.0
[α]D 24  + 22.9
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Protection of 64 with ethylene glycol followed by DIBAL-H reduction gave 189 as anomeric 
mixture (1:1) in very good yield (90%). Bis protected imidazole 122 was prepared in two 
steps according to literature procedure. Treatment of 189 with bisprotected imidazole 122 in 
the presence of butyl lithium afforded diols 190 and 191 in 85% yield. Diastereomers of diols 
190 and 191 were separated by silica gel column chromatography. Treatment of these diols 
190 and 191 with ADDP/Bu3P as Mitsunobu conditions obtained the cyclized products 192 
and 193 (Scheme 2.41). Diastereomers of the chiral diols 190 [α]D 24 – 8.4 (c 1.0, CHCl3) and 
191 [α]D 24 + 4.0 (c 1.0, CHCl3) were separable by column chromatography in high optical 
purities. Cyclization of chiral diols 190 and 191 proceeded via stereoselective SN2 Mitsunobu 
reaction by using inexpensive ADDP reagent to afford cyclized products 192 [α]D 24 – 6.0 (c 
1.0, CHCl3) and 193 [α]D 24 + 22.9 (c 1.0, CHCl3) . The stereochemistry was analyzed in early 
stage on cyclic building blocks by COSY and NOESY experiments comparing with 
Kurihara’s method.  
2.9.6 Towards the synthesis of human histamine H3 and H4 receptor 
potential agonists from GBL-64 cyclic building blocks 
As explained in the section 2.82, following the same strategy the amines 198 and 199 were 
prepared. Hydroboration of the cyclic building blocks 192, 193 with BH3.THF followed by 
oxidation obtained the primary alcohols 194 and 195 in good yields (76%). The primary 
alcohols 194 and 195 were subjected to phthalimidation using phthalimide, DEAD and PPh3 
to obtain the phthalimides 196 and 197 in 62% yield. Deprotection of phthalimides using 
hydrazine hydrate afforded the primary amines 198 and 199 in 72% yield (Scheme 2.42). 
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2.9.7 Final steps towards the synthesis of histamine H3 and H4 receptor 
potential agonists  
Deprotection of sulfonamides 156, 157, 198, 199 would give the corresponding imidazole 
(NH free) amines 60, 58, 70 and 69 which are analogues to the imifuramine, and can be 
interesting to see the structure activity relationship. Upon introduction of cyanoguanidine 
groups on these amines 60, 58, 70 and 69 would lead to histamine H4 receptor agonists 61, 59, 
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72 and 71. In this way we can get a small library of molecules for histamine H3 as well as H4 
receptor agonists. This would be the first application of enantioselective GBLs to the 
histamine H3 and H4 receptor agonists as chiral drugs (Scheme 2.43). 
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2.9.8 Conclusion 
Application of γ-butyrolactones GBL-55 and GBL-64 for the enantioselective synthesis of 
tetrahydrofuran imidazole based histamine H3 and H4 receptor potential agonists were 
achieved for the first time. Deprotection of TBDMS and sulfonamides 156, 157, 198 and 199 
would supply variety of analogues for the histamine H3 receptor agonists (60, 58, 70 and 69). 
By introducing cyanoguanidine on these amines leads to H4 receoptor agonists 61, 59, 72 and 
71. This synthetic approach afforded analogues of both cis and trans tetrahydrofurane-
imidazoles, for example imifuramine, its enantiomer, OUP-16 and OUP-13 analogues for the 
histamine H3 and H4 receptor potential agonists. 
 
 87 
References 
1) Koch, S. S. C.; Chamberlin, A. R. J. Org. Chem. 1993, 58, 2725. 
2)  Fukuzawa, S-I.; Seki, K.; Tatsuzawa, M.; Mutoh, K. J. Am. Chem. Soc. 1997, 119, 1482. 
3) Ravid, U.; Silverstein, R. M.; Smith, L. R. Tetrahedron 1978,34, 1449. 
4) Brown, H. C.; Kulkarni, S. V.; Racherla, U. S. J. Org. Chem. 1994, 59, 365. 
5) Midland, M. M.; Nguyen, N. H. J. Org. Chem. 1981, 46, 4108. 
6) Sakamoto, S.; Yamamoto, Y.; Oda, J. J. Am. Chem. Soc. 1987, 109, 7188. 
7) Hajra, S.; Giri, A. K.; Karmakar, A.; Khatua, S. Chem. Comm. 2007, 2408. 
8) Hajra, S.; Giri, A. K.; Karmakar, A. Tetrahedran Lett. 2008, 49, 3625 
9) Hajra, S.; Giri, A. K. J. Org. Chem. 2008, 73, 3935. 
10) Zimmerman, H.E.; Traxler, M. D. J. Am. Chem. Soc. 1957, 79, 1920. 
11) Hoffmann, R. W.;  Wolff, J. J. Chem. Ber. 1991, 124, 563. 
12) Özlügedik, M.;  Kristensen, J.; Wibbeling, B.;  Fröhlich, R.; Hoppe, D. Eur. J. Org.            
Chem. 2002, 414. 
13) Hoppe, D.; Hense, T. Angew. Chem. Int. Ed. Engl. 1997, 36, 2282.  
14) Weisenberg, G. A.; Beak, P. J. Am. Chem. Soc. 1996, 118, 12218. 
15) Hoppe, D.;  Hintze, F.; Tebben, P. Angew. Chem. Int. Ed. Engl. 1990, 29, 1422. 
16) Hanko, R.; Rabe, K.;  Dally, R.; Hoppe, D. Angew. Chem. Int. Ed. Engl. 1991, 30, 1690.  
17) Reissig, H-U.; Christiane, B. J. Org. Chem. 1988, 53, 2440.                                            
18) Reissig, H-U.; Zimmer, R. Chem. Rev. 2003, 103, 1151. 
19) Reissig, H.-U. In The Chemistry of the Cyclopropyl Group; Rappoport, Z., Ed.; John  
Wiley & Sons: Chichester, 1987; Chapter 8, pp 375-443. 
20) Wenkert, E. Acc. Chem. Res. 1980, 13, 27. 
21) Seebach D. Angew. Chem, Int. Ed. Engl. 1979, 18, 239 
22) Böhm, C.; Schinnerl, M.; Bubert, C.; Zabel, M.; Labahn, T.; Parisini, E.; Reiser, O. Eur. 
J. Org. Chem. 2000, 2955. 
23) Böhm, C.; Reiser, O. Org. Lett. 2001, 3, 1315. 
24) R.B. Chhor.; B. Nosse.; S. Sörgel.; C. Böhm.; M. Seitz.; O. Reiser. Chem. Eur. J. 2003,  
9,120. 
25) Johnson, J. S.; Evans, D. A. Acc. Chem. Res. 2000, 33, 325. 
26) Schinnerl, M.; Seitz, M.; Kaiser, A.; Reiser, O. Org. Lett, 2001, 3, 4259. 
27) Evans, D.A.;  Woerpel, K.A.; Nosse, B.; Schall, A.; Shinde, Y.; Jezek, E.; Mahbubul                  
Haque, M.; Chhor, R.B.; Reiser, O. Organic Synthesis 2006, 83, 97. 
28) Perkin, Jr. W.H. Berichte der Deutschen Chemischen Gesellschaft 1884, 17, 54. 
 88 
29) Lebel, J.-F.  H.; Marcoux, C. M.; Andre, B. C. Chem Rev  2003, 103, 977. 
30) Ryan, P. W.; Andre, B.C. Org. Lett, 2002, 4, 4531. 
31) Jacobsen, E. N.; Pfaltz, A.; Yamamoto, H. Editors, Comprehensive Asymmetric Catalysis  
       I-III, Volume 2, 1999. 
32) Nozaki, H.; Moriuti, S.; Takaya, H.; Nayori, R. Tetrahedron Lett 1966, 7, 5239. 
            33) Evans, D. A.; Woerpel, K. A.; Scott, M. J.  Angew. Chem. Int. Ed. Engl. 1992, 31, 430. 
34) Evans, D. A.; Woerpel, K. A.; Hinman, M. M.; Faul, M. M. J. Am. Chem. Soc, 1991, 113,   
726 
35) Wenkert, E.; Guo, M.; Lavilla, T.; Porter, B.; Ramachandran, K.; Sheu, J.-H. J. Org.     
Chem 1990, 55, 6203. 
36) Straub, B. F.; Hofmann, P. Angew. Chem. Int. Ed. Engl. 2001, 40, 1288. 
37) Fritschi, H.;Leutenegger, U.; Pfaltz, A. Helv Chim Acta 1988, 71, 1553. 
38) Temme, O.; Taj, S. A.; Andersson, P. G. J. Org. Chem. 1998, 63, 6007. 
39) Claus, R. E.; Schreiber, S. L. Org. Syn., Coll. Vol. 1990, 7, 168                                       
40) Tietze, L. F.; Bratz, M. Org. Syn., Coll. Vol. 1998, 9, 314  
41) Schwartz, C.; Raible, J.; Mott, K.; Dussault P. H.  Org Lett, 2006, 8, 3199. 
42) Criegee, R. Angew. Chem. Int. Ed. Engl. 1975, 87, 745. 
43) Berger, S. Eur. J. Org. Chem. 1998, 1625. 
44) Hosomi, A.; Sakurai, H. Tetrahedron Lett. 1976, 17, 1295. 
45) Cram, D. J.; Wilson, D. R. J. Am. Chem. Soc. 1963, 85, 1245. 
46) Chérest, M.; Felkin, H.; Prudent, N. Tetrahedron Lett. 1968, 9, 2199. 
47) Anh, N. T. Top. Curr. Chem. 1980, 88, 145. 
48) Anh, N. T.; Eisenstein, O. Nouv. J. Chim. 1977, 1, 61. 
49) Anh, N. T.; Eisenstein, O. Tetrahedron Lett. 1976, 3, 155. 
50) Mengel, A.; Reiser, O. Chem. Rev.1999, 99, 1191. 
51) Augustine, R. L. Techniques and applications in organic synthesis, 1979, 1, pp1-84 
52) Hashimoto, T.; Harusawa, S.; Araki, L.; Zuiderveld, O. P.; Smit, M. J.; Imazu, T.;         
Takashima, S.; Yamamoto, Y.; Sakamoto, Y.; Kurihara,T.; Leurs, R.; Bakker, R. A.;  
Yamatodani, A. J. Med. Chem. 2003, 46, 3162. 
53) Harusawa, S.; Imazu, T.; Takashima, S.; Araki, L.; Ohishi, H.; Kurihara,T.; Sakamoto, Y.;    
Yamamoto, Y.; Yamatodani, A. J. Org. Chem. 1999, 64, 8608. 
54) Harusawa, S.; Imazu, T.; Takashima S.; Araki, L.; Ohishi, H.; Kurihara, T.; Yamamoto,      
Y.; Yamatodani, A. Tetrahedron Lett. 1999, 40, 2561. 
 89 
55) Harusawa, S.; Araki, L.; Imazu, T.; Ohishi, H.; Sakamoto, Y.; Kurihara, T. Chem.           
Pharma. Bull. 2003, 51, 325. 
56) Harusawa, S.; Araki, L.; Terashima, H.; Kawamura, M.; Takashima, S.; Sakamoto, Y.;  
Hashimoto, T.; Yamamoto, Y.; Yamatodani, A.; Kurihara,T.  Chem. Pharma. Bull. 2003, 
51, 832. 
57) Harusawa S., Murai Y., Moriyama H., Ohishi H., Yoneda R., Kurihara T. Tetrahedron    
Lett., 1995, 36, 3165.  
58) Harusawa, S.; Murai, Y.; Moriyama, H.; Imazu, T.; Ohishi, H.; Yoneda, R.; Kurihara, T. 
      J. Org. Chem. 1996, 61, 4405. 
59) Tetsuji, K.; Suzuki, T.; Masahiro, N.; Etsuko, S.; Katsuo, U. Heterocycles,1982, 19, 205. 
60) Pilli, R. A.; Riatto, V. B. Tetrahydron: Asymmetry 2000, 11, 3675. 
61) Chadwick D. J.; Ngochindo, R. I. J. Chem. Soc., Perkin Trans. 1, 1984, 481. 
62) Ngochindo, R. I. J. Chem. Soc., Perkin Trans. 1, 1990, 1645. 
63) Kumara Swamy, K. C.;  Bhuvan Kumar, N. N.; Balaraman, E;  Pavan Kumar, K.V. P. 
Chem. Rev. 2009, 109, 2551. 
64) Mitsunobu, O.; Yamada, M. Bull. Chem. Soc. Jpn. 1967, 40, 2380. 
65) Mitsunobu, O.; Yamada, M.; Mukaiyama, T. Bull. Chem. Soc. Jpn. 1967, 40, 935. 
66) Mattingly, P. G. K., Jr. J. F.; Miller, M. J. J. Am. Chem. Soc. 1979, 101, 3983. 
67) Brain, C. T. C., A.; Nelson, A.; Tanikkul, N.; Thomas, E. J. Tetrahedron Lett. 2001, 
      42, 1247.  
68) a) Meyers, A. I.; Amos, R. A. J. Am. Chem. Soc. 1980, 102, 870. 
      b) Butera, J.; Rini, J.; Helquist, P. J. Org. Chem. 1985, 50, 3676. 
     c) Liu, L.; Tanke, R. S.; Miller, M. J. J. Org. Chem. 1986, 51, 5332. 
69) Chong, Y. G., G.; Chu, C. K. Tetrahedron: Asymmetry 2000, 11, 4853. 
70) Goundry, W. R. F.; Lee, V.; Baldwin, J. E. Synlett 2006, 2407. 
71) Lai, J.-Y. Y., J.; Hawkins, D.; Falck, J. R. Tetrahedron Lett. 1995, 36, 5691. 
72) Tsunoda, T.; Kaku, H.; Ito, S. July, 2005, TCIMAIL, number 123  
      (http://www.tci-asiapacific.com/tcimail/backnumber/article/123drE.pdf) 
73) Dodge, J. A.; Trujillo, J. I.; Presnell, M. J. Org. Chem. 1994, 59, 234. 
74) Ahn, C.; Correia, R.; DeShong, P. J. Org. Chem. 2002, 67, 1751 
75) Guanti, G.; Banfi, L.; Basso, A.; Bevilacqua, E.; Bondanza, L.; Riva, R. Tetrahedron:         
Asymmetry 2004, 15, 2889. 
76) Tsunoda, T.; Yamamiya, Y.; Ito, S. Tetrahydron Lett. 1993, 34, 1639. 
 90 
77) Tsunoda, T.; Kaku, H. N, N, N’, N’-Tetramethyl-azodicarboxamide. ‘‘Electronic     
Encyclopedia of Reagents for Organic Synthesis’’ eds, by L. A. Paquette, et al., Wiley, 15 
October 2003. 
78) Tsunoda, T.; Otsuka, J.; Yamamiya, Y.; Ito, S. Chem. Lett 1994, 539. 
79) Ahn, C.; Correia, R.; DeShong, P. J. Org. Chem. 2003, 68, 1176. 
80) Shi, J. Y.; Hughes, D. L.; McNamara, J. M. Tetrahedron Lett. 2003, 44, 3609. 
81) Grynkiewicz, G. Rocz. Chem. 1976, 50, 1449. 
82) Camp, D. J., I. D. J. Org. Chem 1989, 54, 3045.  
83) Camp, D. J., I. D. J. Org. Chem 1989, 54, 3049.  
84) Carlock, J. T. M., M. P. Tetrahedron Lett. 1978, 19, 5153.  
85) Guianvarc′h, D. B., R.; Fourrey, J.-L. Tetrahedron Lett. 2001, 42, 647.  
86) Nam, N.-H.; Sardari, S.; Parang, K. J. Comb. Chem. 2003, 5, 479 
87) Tunoori, A. R.; Dutta, D.; Georg, G. I. Tetrahedron Lett. 1998, 39, 8751. 
88) Amos, R. A.; Emblidge, R. W.; Havens, N. J. Org. Chem. 1983, 48, 3598. 
89) Thomas, G. L.; Ladlow, M.; Spring, D. R. Org. Biomol. Chem. 2004, 2, 1679. 
90) Thomas, G. L.; Bo¨hner, C.; Ladlow, M.; Spring, D. R. Tetrahedron 2005, 61, 12153 
91) Zaragoza, F.; Stephensen, H. Tetrahedron Lett. 2000, 41, 2015. 
92) Humphries, P. S.; Do, Q.-Q. T.; Wilhite, D. M. Beilstein J. Org. Chem. 2006, 2, 21. 
93) Leonetti, F.; Cappa, A.; Maccallini, C.; Carotti, A. Arki Voc 2004, 272. 
94) Lan, P.; Porco, J. A., Jr.; South, M. S.; Parlow, J. J. J. Comb. Chem. 2003, 5, 660. 
95) Dandapani, S.; Curran, D. P. J. Org. Chem. 2004, 69, 8751. 
96) Curran, D. P.; Wang, X.; Zhang, Q. J. Org. Chem. 2005, 70, 3716 
97) Smissman, E. E.; Makriyannis, A. J. Org. Chem., 1973, 38, 1652 
98) But, T. Y. S.; Toy, P. H. J. Am. Chem. Soc. 2006, 128, 9636. 
99) Yokoyama, M.; Toyoshima, A.; Akiba, T.; Togo, H.; Chem. Lett., 1994, 265. 
100) Mehrotra, R. C.; Singh, A. Organomettalic Chemistry, A Unified Approach, Second      
Edition, 2000, PP 552 
101) Stock, A. Hydrides of Boron and Silicon, 1933, Cornell University Press, Ithaca, New    
York 
102)  Nobel Lecture, 8 December, 1979 by H. C. Brown 
        (http://nobelprize.org/nobel_prizes/chemistry/laureates/1979/brown-lecture.pdf) 
103)  Brown, H. C.; Subba Rao, B. C. J. Am. Chem. Soc. 1956, 78, 2582. 
104) Brown, H. C. Hydroboration, W. A. Benjamin, New York, 1962. 
105) Brown, H. C.; Subba Rao, B. C. J. Am. Chem. Soc. 1956, 78, 5694. 
 91 
106) Brown, H. C.; Subba Rao, B. C. J. Org. Chem. 1957, 22, 1136. 
107) Brown, H. C. Boranes in Organic Chemistry , 1972, Cornell University Press, Ithaca, 
New York. 
108) Negishi, E.; Brown, H. C. Synthesis, 1974, 77. 
109)  Brown, H. C.; Lane, C. F. Heterocycles, 1977, 7, 454. 
110) Evans, D. A.; Fu, G. C.; Anderson, B. A. J. Am. Chem. Soc. 1992, 114, 6679. 
111) Brewer, M.; Rich, D. H. Org. Lett. 2001, 3, 945. 
112) Chinna A.K. Reiser, O. unpublished results.  
113) Mohammad Mahbubul Haque, Ph.D thesis 2005, University of Regensburg 
114) Narayana, C.; Periasamy, M. Tetrahydron Lett. 1985, 26, 1757. 
115) Narayana, C.; Periasamy, M. Chem. Commun, 1987, 1857. 
116) Varela, J.A.; Pena, D.; Goldfuss, B.; Polborn, K.; Knochel, P. Org. Lett. 2001, 3, 2395. 
117) Mitsunobu, O. W., M.; Sano, T. J. Am. Chem. Soc. 1972, 94, 679-680. 
118) Loibner, v. H. Z., E. Helv. Chim. Acta. 1976, 59, 2100-2113 
119) Guianvarc'h, D.; Fourrey, J-L.; Maurisse, R.; Sun, J-S.; Benhida. R. Org. Lett., 2002, 4,    
4209 
120) Witt, O.; Truttwin, H. ibid., 1914, 47, 2788 
121) Sundberg, R. J.; Laurino, J. P. J. Org. Chem., 1984, 49, 249. 
122) Wilson, M. E.; Nowick, J. S. Tetrahedron Lett, 1998, 39, 6613 
123) Iserloh, U.; Dudkin, V.; Wang, Z.;  Danishefsky, S. J. Tetrahedron Lett. 2002, 43, 7027. 
124) Bergmeier, S. C.; Seth, P. P. Tetrahedron Lett. 1999, 40, 6181. 
125) Forshee, P. B.; Seibert, J. W. Synthesis, 2006, 756. 
126) Yasuhara, S.; Sakamoto, T. Tetrahedron Lett. 1998, 39, 595. 
127) Sabitha, G.; Subba Reddy, B. V.; Abraham, S.; Yadav, J. S. Tetrahedron Lett. 1999, 40, 
1569. 
128) Jagt, R. B. C.; Toullec, P. Y.; Geerdink, D.; de Vries, J. G.  Feringa, B. L.; Minnaard, 
A.J. Angew. Chem. Int. Ed. 2006, 45, 2789. 
129) Nyasse, B.; Grehn, L.; Ragnarsson, U. Chem Commun, 1997, 1017. 
130) Ankner, T.; Hilmersson, G. Org. Lett, 2009, 11, 503.  
 
 
 
 92 
Aim of the work 
The application of furan methyl carboxylate 109 and acetyl furan 248 towards the histamine 
H3 and H4 receptor agonists (Figure 3.2) was shown in Figure 3.1. As explained in schemes 
3.6 and 3.16, Cu-(I)-(bisoxazoline) catalyzed asymmetric cyclopropanation and N- 
bromosuccinimide (NBS) mediated ring opening of cyclopropane derivatives upon functional 
group transformation can afford compounds 244, 246, 247, 256, 273-276. By changing the 
position of amino methyl group, keeping the methoxy group and extending the spacer length 
between tetrahydrofuran and imidazole for the synthesis of derivates of histamine H3 and H4 
receptor potential agonists was shown (Figure 3.1 and 3.2).  
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by cyclopropane ring opening methodology
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Compounds 35, 45, 46, 54, 116-119 can be synthesized from imidazole aldehyde 258 (Figure 
3.2). Protection of NH followed by Grignard reaction with butenyl bromide can afford the 
olefin having alcohol functionality. Sharpless asymmetric dihydroxylation followed by 
Mitsunobu cyclization may give the corresponding cyclic building blocks. Upon functional 
group transformation of olefins to amines followed by introduction of cyanoguanidine would 
furnish the histamine H3 and H4 receptor agonists as shown in scheme 3.20. 
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Chapter 3 
3. Synthesis of histamine H3 and H4 receptor potential agonists by   
NBS mediated cyclopropane ring opening methodology 
3.1.1 Introduction to cyclopropane ring opening methodology 
1,2-Cyclopropanated sugar derivatives undergo ring opening reactions to give 2-C branched 
sugars when subjected to solvolysis in the presence of stoichiometric or catalytic amount of 
metal salts (Hg or Pt),1 strong acids,2 or halonium ions.3 Among them halonium ion mediated 
ring opening reactions can proceed under mild conditions (NIS or NBS) and leads to useful 
biologically active compounds such as natural products, unnatural amino acids and 
carbohydrate derivatives. Several applications and modifications to the NIS strategy have 
been reported.4-6 Compared with the organomercury intermediates, the halomethylene 
appendage obtained directly from the NIS/NBS protocol opened a window for more 
environmentally responsible elaboration.7 
The development of a novel cyclopropane solvolysis strategy for incorporating the geminal 
methyl groups of the epothilones A and B, has been reported by Danishefsky and co-workers 
using N-iodosuccinimide (NIS).8 The important key intermediate 202 for the synthesis of 
epothilones A (203) and B (204) was efficiently prepared by NIS mediated ring opening of 
cyclopropane 200 in methanol. The methyl glycoside 201 underwent reductive deiodination to 
afford the geminal methyl groups of artificial glycoside 202 (Scheme 3.1). 
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Scheme 3.1 Cyclopropane ring opening with NIS, a key intermediate 3.59 for the total synthesis 
of epothilones  A and B by Danishefsky et al
X = I
X = H
Bu3SnH, AIBN
two steps 80%
200 201
202
203
204
 
The cyclopropane 205 (Scheme 3.2) was obtained from reductive dehalogenation of 
corresponding dichlorocyclopropane derivative. Several attempts by Ley and co-workers  to 
open either the dichlorocyclopropane or the analogous dehalogenated cyclopropane with 
carbon nucleophiles proved unsuccessful.9 Finally cyclopropane ring opening of 205 was 
achieved with N-iodosuccinimide (NIS) and methanol to furnish 206 as anomeric mixture 
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after reduction of the iodide in 82% yield (in 2 steps). The synthesis of the highly substituted 
E and F pyran fragment 207 of altohyrtin A from tri-O-benzyl-D-glucal is achieved by 
cyclopropanation and NIS ring opening methodology (Scheme 3.2).9 
OBnO
BnO
OBn
NIS, MeOH
Bu3SnH, AIBN
82% two steps
OBnO
BnO
OBn
OMe O
O
BnO
BnO
OBn
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E and F Pyran fragment 
     of Altohyrtin A
Scheme 3.2 NIS opening of cyclopropane for the synthesis of E and F pyran fragment 3.63 by Ley et al
205 206 207
 
Nagarajan et al10 discovered a different cyclopropane reactivity between diastereomers 208 
and 210 (Scheme 3.3). Reaction of α-cyclopropane 208 with either NIS or NBS occurred 
rapidly and provided an anomeric mixture of 209 in 91% yield.  
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O
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O
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Scheme 3.3 NIS or NBS ring opening of cyclopropane sugar derivatives by Nagarajan et al
 
 
In contrast, reaction under identical conditions with β-cyclopropane 210 results in slower 
formation of 211 with pronounced anomeric selectivity. The same trend in reactivity was also 
observed on diastereomeric substrates 212 and 214 in which the free C(6) hydroxyl group is 
available to participate in an intramolecular nucleophilic attack to furnish 213 and 215 
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(Scheme 3.3). The authors extended the methodology to the formation of halogenated 2-C 
disaccharides by inclusion of sugar alcohols in the reaction.11 
Very recently, an efficient method for the synthesis of C(2) branched glycolamino acid 
derivatives 218 has been developed by Chandrasekaran and co-workers through direct NIS 
mediated ring opening in methanol (Scheme 3.4).12 D-glucal derived cyclopropane 216 
afforded the iodosugar 217 as a single diastereomer in 75% yield upon treatment with 
NIS/MeOH. The SN2 reaction of this iodosugar with NaN3 in DMF followed by reduction of 
sugar azide gave rise the glycoamino acid derivative 218 (Scheme 3.4). Furthermore the 
authors extended this methodology for efficient synthesis of fused perhydrofuro[2,3-b]pyrans 
(and furans)13 and also to nucleosides synthesis.14 
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Scheme: 3.4 General strategy for the synthesis of glycoamino acids by Chandrasekaran et al
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Following the above synthetic methodology Reiser and co-workers also synthesized unnatural 
amino acid derivatives of substituted tetrahydrofuran by NBS mediated cyclopropane ring 
opening reactions.15,16 When furan cyclopropane derivatives  219-221 were treated with NBS 
in methanol, the tetrahydrofuran-bromo compounds 222-224 were obtained in 78-82%. This 
methodology was applied for the synthesis of unnatural amino acid derivatives 225-227 
(Scheme 3.5). 
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Scheme 3.5 Cyclopropane ring opening with NBS for the synthesis of unnatural 
amino acid derivatives by Reiser et al
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3.1.2 Enantioselective synthesis of histamine H3 and H4 receptor 
potential agonists by furan cyclopropane ring opening 
methodology. 
3.1.3 Retrosynthetic analysis based on cyclopropanation of furan 
Introduction of acyl or cyanoguanidine groups into 244 can furnish potential histamine H4 
receptor agonists 257 or 256. Treatment of 243 with formamidine acetate in presence of 
ammonia (7N in methanol) may afford 244 by formation of imidazole ring and subsequent 
deprotection of Cbz group. This bromomethyl ketone 243 could be obtained from the 
corresponding acid 237 upon treatment with acid chloride, followed by diazomethane and 
HBr.  
O
CO2Et
OMe
NHCbz
O
Br O
CO2Et
OMe
NHCbz
HO
O
O
CO2Et
OMe
NH2
MeO
O
OMeOOC
CO2Et
OMe
Br
H
OMeOOC
CO2Et
H
H OMeOOC
 Histamine H4 receptor 
    potential agonist
Histamine H3 receptor 
potential agonists
109229
235237243
256
233
or
Histamine H4 receptor 
  potential 
 
agonists
257
Scheme 3.6 Retrosynthetic analysis for histamine H3 and H4 receptor potential agonists based on 
cyclopropane ring opening metholodogy
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Protection of amine 235 with Cbz chloride followed by selective hydrolysis of methyl ester 
can afford 237. The SN2 reaction of 233 with sodium azide and subsequent reduction with 
Pd/C may afford amine 235 as possible precursor for histamine H3 receptor agonist. 
Hydrogenation of 229 with Pd/C followed by NBS opening of cyclopropane ring in methanol 
could furnish the cyclopropane ring opening product 233. The cyclopropane ester 229 can be 
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obtained from the copper(I)-bis(oxazolines) catalyzed cyclopropanation of furan-2-carboxylic 
ester 109 (Scheme 3.6). 
3.1.4 Asymmetric cyclopropanation and hydrogenation 
Cu(I)bisoxazoline catalyzed asymmetric cyclopropanation of methylfuran carboxyalte 109 at    
0 °C gave the cyclopropane carboxylate 229 in 41% yield (Scheme 3.7). The hydrogenation 
of 229 was done by using 10% Pd/C in ethyl acetate at room temperature under balloon 
pressure to afford product 230 in moderate yields up to 50%. Change of solvents and Pd/C 
(5% Pd/C in ethylacetate, methanol) did not improve the yield of 229. Within 15 minutes it 
was observed by TLC analysis that at least three byproducts were forming in addition to 
remaining starting material 229 and the desired product 230. Continuation of the reaction for 
more than 15 minutes, increased the amounts of unwanted side products. 
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Scheme 3.7 Asymmetric cyclopropanation and hydrogenation
Reagents and conditions: i) (R,R)- iPr(bisoxazoline), Cu(OTf)2, PhNHNH2, EDA, 41%,
 ii) H2, 10% Pd/C, EtOAc, rt, 30 min, 50%
i) ii)
 
To overcome the above problem, the methyl ester of 229 was selectively hydrolyzed by using 
1 equivalent of lithium hydroxide to the corresponding carboxylic acid 231 in excellent yield. 
Upon treatment of acid 231 under the same reaction conditions (10% Pd/C, H2, EtOAc) used 
for 229 to 230 with longer reaction time gave the hydrogenation product 232 in quantitative 
yield with no side products being observed (Scheme 3.8). 
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H
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229 231 232
Scheme 3.8 Selective hydrolysis of methyl ester and hydrogenation on acid
Reagents and conditions: i) LiOH (1 eq), THF, H2O, 0 °C, rt, 12h, 96%,
 ii) H2, 10% Pd/C, EtOAc, rt, 12h, 98%
i) ii)
 
3.1.5 NBS mediated cyclopropane ring opening reactions 
By following the cyclopropane ring opening methodology, treatment of 232 or 230 with NBS 
in methanol gave the corresponding cyclopropane ring opening product 233 in good yield. 
Under these conditions it was observed that the free acid 232 was converted to its methyl ester 
in 233 (Scheme 3.9). Stereochemistry of 233 was analyzed by NOESY and COSY spectrum. 
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Scheme 3.9 Cyclopropane ring opening methodology
233
Reagents and conditions: i) NBS, MeOH, 0 °C-rt, 36h, 80%
i) i)
 
The SN2 reaction of 233 with sodium azide in DMF at room temperature yielded the 
corresponding azide 234 in quantitative yield. The reduction of azide was done in presence of 
H2 by using 10% Pd/C in ethyl acetate at room temperature gave the amine 235 with excellent 
yield (Scheme 3.10). 
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Scheme 3.10 Synthesis of α-aminoester
233 235
Reagents and conditions: i) NaN3, DMF, 15h, 97%, ii) H2, Pd/C, EtOAc, rt, 12h, 95%
i) ii)
 
3.1.6 Protection of amine and selective hydrolysis of methyl ester 
Protection of amine 235 with Cbz-chloride in presence of triethylamine in dichloromethane 
gave 236 in good yield. Once again the selective hydrolysis of methylester 236 was done with 
1 equivalent of lithium hydroxide to get the corresponding acid 237 in excellent yield 
(Scheme 3.11).17 
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Scheme 3.11 Protection of amine and hydrolysis of methyl ester
Reagents and conditions: i) CbzCl, Et3N, DCM, rt, 85%, ii) LiOH (1eq), THF, H2O, rt, 12h, 95%
i) ii)
235
 
3.1.7 Synthesis of neuraminidase (NA) NA B inhibitor by Wang et al 
Next it was envisioned to convert the carboxylic acid group of 237 into an imidazole ring via 
bromomethyl ketone intermediate following the method reported by Wang et al.  
(i) i-BuOCOCl, CH2N2, then HBr, 60.0%; (ii) formamidine, NH3, 45 °C, over night, 20.0%; 
(iii) 6N HCl, 4h, 95.8%.
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Scheme 3.12 Synthesis of influenza neuraminidase (NA) B inhibitor by Wang et al
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Recently, Wang et al synthesized 2,3-disubstituted tetrahydrofuran-5-carboxylic acids as 
inhibitors of influenza neuraminidase (NA) NA A (IC50 = 0.5µM) and NA B (IC50 = 1.0µM). 
The 3-carboxylate of 238 was converted into the bromomethyl ketone moiety via diazomethyl 
ketone giving compound 239. Condensation of 239 with formamidine in liquid ammonia in a 
sealed tube gave the imidazole derivative 240, which, upon acid hydrolysis of tert-butyl ester, 
afforded the desired compound NA B (241) (Scheme 3.12).17 
3.1.8 Synthesis of key intermediate bromomethyl ketone by Arndt-Eistert 
elongation 
Treatment of the acid 237 with oxalylchloride in dichloromethane gave the corresponding 
acid chloride 242 and this acid chloride was directly subjected to diazomethane and HBr to 
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obtain bromomethyl ketone 243 as reported by Wang et al (Scheme 3.12)17 but unfortunately 
the reaction failed to furnish product 243 (Scheme 3.13).  
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Scheme 3.13 Synthesis of bromomethyl ketone-tetrahydrofuran derivative
Reagents and conditions: i) oxalylchloride, DCM, rt, 70%, 
ii) CH2N2, ether, HBr, 0 °C, over two steps
i) ii)
242
 
3.1.9 Synthesis of histamine H3 and H4 receptor agonists by increasing the 
spacer length between imidazole and THF ring.                                                                                                 
Having the intermediate 237 in hand, it was coupled with histamine under standard reaction 
conditions (EDC, HOBt, NEt3)18 to obtain amide 245 for the synthesis of potential H3 receptor 
agonist. The deprotection of Cbz by using Pd/C under H2 atmosphere at room temperature 
gave the corresponding free amine 246 in good yield. This compound 246 was tested for the 
histamine H3 and H4 receptor agonist and it is only a very weak agonist for histamine H3 
receptor.19 Introduction of cyanoguanidine may obtain histamine H4 receptor potential agonist 
247 (Scheme 3.15). 
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Scheme 3.15 Synthesis of histamine-furane derivatives for H3 and H4 agonists
Reagents and conditions: i) Histamine, EDC, HOBt, NEt3, DMF, rt, 70%, ii) H2, Pd/C, 
EtOAc, 80% iii) (MeS)2C=NCN, MeOH, 40% MeNH2
i)
ii)
iii)
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3.2 Enantioselective synthesis of histamine H3 and H4 receptor 
potential agonists by imidazole-furan cyclopropane ring opening 
methodology. 
3.2.1 Retrosynthetic analysis for the Histamine H3 and H4 receptor agonists 
based on Imidazole-Furan.  
The possible histamine H4 receptor agonist 256 can be synthesized by the introduction of 
cyanoguanidine on amine 244. Amine 244 would be possible to obtain from 255 by reduction 
of azide followed by deprotection of Boc. 
Scheme 3.16 Retrosynthetic analysis based on imidazole-furane cyclopropane to 
histamine H3 and H4 receptor agonists
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NBS mediated ring opening cyclopropane 252 in methanol and subsequent SN2 reaction with 
sodium azide may furnish 255. Protection of 250 with Boc and subsequent asymmetric 
cyclopropanation followed by hydrogenation may give 252. Bromination of acetyl furane 248 
to the corresponding bromoacetyl furan and subsequent treatment with formamidine acetate in 
liq. ammonia can afford furan-imidazole 250 (Scheme 3.16).  
3.2.2 Preparation of furan-imidazole 
Bromination of acetylfuran 248 with 1 eq of bromine furnished bromoacetylfuran 249 with 
excellent yield.20 The treatment of bromoacetylfuran 249 with formamidine acetate in the 
presence of 7N ammonia at 45 °C, after 12 h stirring in an autoclave gave the corresponding 
imidazole furan 250 in 65% yield (Scheme 3.17) following Wang’s method.17 
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Scheme 3.17 Synthesis of furane-imidazole
Reagents and conditions: Br2 (1 eq), Et2O, rt, 30 min, 90%, 
ii) Formamidine acetate, liq. NH3, 45 °C, 12 h, 65%
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3.2.3 Synthesis of cyclopropane dihydrofuran-imidazole 
The NH protection of imidazole-furan was done by treating 250 with Boc anhydride and 
triethylamine in chloroform to obtain 251 in good yields. Subsequently, to obtain the desired 
product 252 the Cu (I) bisoxazoline catalyzed asymmetric cyclopropanation was tested under 
several conditions. 
Expected product did not form,  
only starting material was
 recovered quantitatively
Scheme 3.18 Synthesis of cyclopropane-dihydrofurane-imidazole
Reagents and conditions: i) (Boc)2O, NEt3, CHCl3, rt, 85%, ii) (S,S)-iPr-Box, Cu(OTf)2,
 PhNHNH2, N2CHCOOEt, 0 °C,
i) ii)
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When 251 was treated with (S,S)-isopropyl bisoxazoline, copper triflate, phenyl hydrazine and 
ethyl diazoacetate at 0 °C up to reaction timed of 3 days only the starting material was 
recovered along with dimerized products stemming from ethyl diazoacetate. The 
cyclopropanation of 251 was also done without using a chiral ligand just by addition of 
copper triflate, phenyl hydrazine and ethyldiazoacetate to see the racemic version of the 
reaction but even under these conditions the reaction did not work, neither at 0 °C nor at room 
temperature. Finally the cyclopropanation was also tested with dirhodiumtetraacetate as an 
alternative to the copper catalysts previously employed. In this case also only starting material 
was recovered (Scheme 3.18). 
3.2.4 Proposed synthesis of histamine H3 and H4 receptor potential agonists 
Hydrogenation of the double bond in 252 can be done with Pd/C under H2 atmosphere in 
ethylacetate to afford 253. Upon treatment of 253 with NBS in methanol may give 254 which 
can undergo SN2 reaction with NaN3 to obtain 255. Reduction of 255 with Pd/C in presence of 
hydrogen followed by deprotection of Boc in the presence of acid would furnish 244. 
Introduction of cyanoguanidine on 244 may afford 256 as possible H4 receptor agonist 
(Scheme 3.19). 
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Scheme 3.19 Proposed synthesis of histamine H3 and H4 receptor potential agonists
Reagents and conditions: i) H2, Pd/C, EtOAc, rt ii) NBS, MeOH, rt iii) NaN3, DMF, rt 
iv) H2, Pd/C, EtOAc, 3N HCl, v) (MeS)2C=NCN, MeOH, 40% MeNH2
i) ii)
iii)
iv)v)
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3.3 Synthesis of Imifuramine and OUP-16 as an alternative route 
to Kurihara’s synthesis21 
The histamine H4 receptor agonist (OUP-16) 45 can be obtained by introduction of 
cyanoguanidine on amine 35. In turn, it should be possible to obtain imifuramine 35 from 273 
by phthalimidation and dephthalimidation. Mitsunobu cyclization of 272 followed by 
debenzylation may afford the cyclized product 273. Sharpless asymmetric dihydroxylation of 
260 with AD-mix-α and subsequent benzylation of the primary hydroxyl group can furnish 
the corresponding diol 272. Protection of aldehyde 258 followed by Grignard reaction with 
butenyl bromide would furnish 260 (Scheme 3.20).   
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Scheme 3.20 Retrosynthetic analysis for imifuramine (H3 agonist) and OUP-16 (H4 agonist)
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3.3.1 NH protection and Grignard reaction of imidazole aldehyde   
The NH protection of imidazole aldehyde 258 was done with SEM-Cl in presence of triethyl 
amine in dichloromethane for 12 h to furnish 259 in good yield.22 The Grignard reaction of 
259 using butenyl magnesium bromide, (prepared in situ by addition of butenyl bromide to 
Mg in THF at 0 °C upon stirring for 30 minutes) from 0 °C to room temperature for   12 h 
furnished the alcohol 260 in 60% yield (Scheme 3.21). 
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Scheme 3.21 SEM protection and Grignard reaction with butenylbromide
Reagents and conditions: i) SEM-Cl, Et3N, DCM, 70%  
ii) Butenylbromide,  Mg, THF, 30 min at 0 °C,12h at rt, 60%
i) ii)
 
3.3.2 Sharpless asymmetric dihydroxylation 
In the 1980s, Sharpless discovered a combination of reagents that oxidize the C=C to almost 
pure single enantiomers of 1,2-diols.23 The oxidizing agent is osmium tetroxide (OsO4) in the 
presence of a reoxidizing agent, potassium ferricyanide (K3Fe(CN)6), a base such as 
potassium carbonate (K2CO3), and a chiral ligand that binds to OsO4 and directs the attack of 
OsO4 to either the top (β) face or bottom (α) face of C=C. These reagents are commercially 
available and are called AD-mix-α and AD-mix-β. Using (DHQD)2-PHAL as the chiral 
ligand, AD-mix-β directs attack of the OH groups to the β face of C=C. Using (DHQ)2-PHAL 
as the chiral ligand, AD-mix-α directs attack of the OH groups to the α face.24 
Pyne and coworkers (Scheme 3.22) reported the Sharpless asymmetric dihydroxylation on 
imidazole derived internal olefin as an important contribution.25-27 Catalytic asymmetric 
dihydroxylation (AD) of 261 at 0 °C for 4 days using commercially available AD mix-α or 
AD mix-β gave the syn-l,2-diols (1'S,2'S)-265 or (1'R,2'R)-263, respectively, in moderate 
yields. The enantiomeric purities of 265 and 263 were 98 and 99% respectively, as 
determined by 1H NMR analysis of their Mosher diester. Catalytic AD of the alcohol 262 with 
AD mix-β or AD mix-α gave triols 264 or 266, respectively, in good yield but in 95 and 90 % 
enantiomeric purities as determined by lH NMR analysis of their respective tri-Mosher esters 
(Scheme 3.22).25  
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i)ii)
Reagents and conditions: i) AD-mix-β, (DHQD)2PHAL, H2O/t-BuOH, 0 °C, 3 days
 ii) AD-mix-α, (DHQ)2PHAL, H2O/t-BuOH, 0 °C, 3 days
Scheme 3.22 Asymmetric synthesis of Imidazole triols by Pyne et al
 
Following the methodology developed by Pyne et al, the imidazole olefin 260 was aimed to 
be converted to the imidazole β-hydroxy triol 267 or imidazole α-hydroxy triol 268. However, 
the Sharpless asymmetric dihydroxylation (AD) using readily available AD-mix-β in tert-
butanol : water mixture (1:1) at 0 °C for 3 days did not afford the expected product 267. 
Under these conditions only the starting material was recovered. Likewise, Sharpless 
asymmetric dihydroxylation with AD-mix-α under the same conditions mentioned above did 
not proceed to obtain the product 268. Also in this case the starting material was recovered 
quantitatively. It was originally reported by Sharpless et al28 that an asymmetric 
dihydroxylation of olefins which are sluggish at 0 °C can be performed at room temperature 
as well. Nevertheless, when 260 was treated with AD-mix- α or AD-mix-β at rt for 3-5 days 
the imidazole α-hydroxy triol 268 or imidazole β-hydroxy triol 267 could still not be obtained. 
The free OH in 260 was protected with TBDMS to afford 269 and the asymmetric 
dihydroxylation was performed with both AD-mix-α and AD-mix-β at 0 °C as well as at room 
temperature, unfortunately in both cases the reaction did not proceed even after stirring for 5 
days, only starting material was recovered quantitatively (Scheme 3.23). 
N
N
OHSEM
OH
OH
Did not form this product
only staring material was 
recovered quantitatively 
after work up
N
N
OHSEM
N
N
OHSEM
OH
OH
Did not form this product
only staring material was 
recovered quantitatively 
after work up
N
N
OTBDMSSEM
Only starting material 
recovered quantitatively
Scheme 3.23 Sharpless asymmetric dihydroxylation
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Reagents and conditions: i) AD-mix-β, t-BuOH/H2O (1:1), 0 °C, 3days, ii) AD-mix-α, t-BuOH/H2O (1:1), 
0 °C, 3days, iii) TBDMS-Cl, imidazole, DMF, 70%
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3.3.3 Epoxidation and racemic dihydroxylation                                                   
Since the asymmetric dihydroxylation of 260 or 269 failed, it was decided to try routes that 
would install the diol unselectively either by direct dihydroxylation or via epoxide formation 
and subsequent opening with hydroxide. When 260 was treated with osmium tetroxide in 
presence of NMO at rt for 7 days the expected product 271 was not obtained and only the 
starting material was recovered. Treatment of 260 with m-CPBA in dichloromethane at rt for 
3 days also did not furnish either epoxide 270 or triol 271, only starting material was 
recovered (Scheme 3.24). 
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Reagents and conditions: i) m-CPBA, DCM, 0 °C-rt, 3days ii) K2OsO4.2H2O, 
NMO, t-BuOH/H2O (1:1), rt, 7 days
Scheme 3.24 Epoxidation and racemic dihydroxylation
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Conclusion 
The lower yield of hydrogenation of cyclopropane ester 229 was solved by hydrolyzing 
methyl ester to the acid 231, which underwent hydrogenation of its double bond in 
quantitative yield. The cyclopropane ring opening methodology was tried to apply towards the 
synthesis of histamine H3 and H4 receptor potential agonists with increased spacer length 
(Scheme 3.15) to give 245 and 246, which were found to be very weak agonists. Acetyl furan 
248 was converted to imidazole furan 250 in two steps (Scheme 3.17) and it may be a useful 
model study for the conversion of 243 to 244 (Scheme 3.14) as possible histamine H3 and H4 
receptor agonists. All attempts for asymmetric cyclopropanation of imidazole furan  failed. 
An alternative synthesis for imifuramine (35) and OUP-16 (45) was tried by Grignard reaction 
to 259 and Sharpless asymmetric dihydroxylation on 260. 
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Chapter 4 
4. Pharmacology  
4.1 Determination of histamine receptor agonism and antagonism 
in GTPase assays 
4.1.1 Generation of recombinant baculoviruses, cell culture and membrane 
preparation 
Receptors were N-terminally tagged with the FLAG epitope and C-terminally tagged with a 
hexahistidine tag. The cDNA of the human H3R was kindly provided by Dr. Robin Thurmond 
(Johnson & Johnson Research and Development, La Jolla, CA), and the cDNA of the human 
H4R was from the UMR cDNA Resource Center at the University of Missouri-Rolla (Rolla, 
MO). Baculoviruses for the human H3R and a fusion protein of the human H4R with the RGS-
protein GAIP were prepared in analogy to the procedures for the H1R and the H2R-GsαS fusion 
protein using the BaculoGOLD transfection kit (BDPharmingen, San Diego, CA) according to 
the manufacturer’s instructions.1,2  
Sf9 cells were cultured in 250- or 500-mL disposable Erlenmeyer flasks at 28 °C under 
rotation at 150 rpm in SF 900 II medium (Invitrogen, Carlsbad, CA) supplemented with 5 % 
(v/v) fetal calf serum (Biochrom, Berlin, Germany) and 0.1 mg/mL gentamicin (Cambrex Bio 
Science, Walkersville, MD). Cells were maintained at a density of 0.5 – 6.0 x 106 cells/mL. 
After initial transfection, high-titer virus stocks were generated by two sequential virus 
amplifications. In the first amplification, cells were seeded at 2.0 x 106 cells/mL and infected 
with 1:100 dilution of the supernatant from the initial transfection. Cells were cultured for 7 
days, resulting in the death of virtually the entire cell population. The supernatant fluid of this 
infection was harvested and stored under light protection at 4 °C. In a second amplification, 
cells were seeded at 3.0 x 106 cells/mL and infected with 1:20 dilution of the supernatant fluid 
from the first amplification. Cells were cultured for 48 h, and the supernatant fluid was 
harvested. After the 48 h culture period, the majority of cells showed signs of infections (e.g. 
altered morphology, viral inclusion bodies), but most of the cells were still intact. The 
supernatant fluid from the second amplification was stored under light protection at 4 °C and 
used as routine virus stock for membrane preparations. 
In infections for membrane preparation, cells were sedimented by centrifugation and 
suspended in fresh medium at 3.0 x 106 cells/mL. Cells were infected with 1:100 dilutions of 
high-titer baculovirus stocks encoding the histamine H3 and H4 receptors, histamine receptor 
fusion proteins, G-protein subunits and RGS proteins. Cells were cultured for 48 h before 
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membrane preparation. Sf9 membranes were prepared as described,2 using 1 mM EDTA, 0.2 
mM phenylmethylsulfonyl fluoride, 10 µg/mL benzamidine and 10 µg/mL leupeptin as 
protease inhibitors. Membranes were suspended in binding buffer (12.5 mM MgCl2, 1 mM 
EDTA and 75 mM Tris/HCl, pH 7.4) and stored at -80 °C until use. Protein concentrations 
were determined using the DC protein assay kit (Bio-Rad, Hercules, CA). 
4.1.2 Synthesis of [γ-32P]GTP. [γ-32P]GTP was synthesized by enzymatic 
phosphorylation of GDP according to a previously described procedure.3 [32P]Pi (8,500-9,100 
Ci/mmol orthophosphoric acid) was from PerkinElmer Life Sciences (Boston, MA, USA). All 
unlabeled nucleotides, glycerol-3-phosphate dehydrogenase, triose phosphate isomerase, 
glyceraldehyde-3-phosphate dehydrogenase, and lactate dehydrogenase were from Roche 
(Mannheim, Germany). 3-Phosphoglycerate kinase and Lglycerol-3-phosphate was from 
Sigma. 
4.1.3 Steady-state GTPase activity assay with Sf9 insect cell membranes 
expressing histamine H3 and H4 receptors  
H3R-regulated GTP hydrolysis was determined with membranes co-expressing human H3R, 
mammalian Giα2, Gβ1γ2 and RGS4. Human H4R activity was measured with membranes co-
expressing an H4R-RGS19 fusion protein with Giα2 and Gβ1γ2. Assay tubes contained Sf9 
membranes (10-20 µg of protein/tube), MgCl2 (H1R, H2R: 1.0 mM; H3R, H4R: 5.0 mM), 100 
µM EDTA, 100 µM ATP, 100 nM GTP, 100 µM adenylyl imidodiphosphate, 5 mM creatine 
phosphate, 40 µg creatine kinase and 0.2 % (w/v) bovine serum albumin in 50 mM Tris/HCl, 
pH 7.4, as well as ligands at various concentrations. In H4R assays, NaCl (final concentration 
of 100 mM) was included. Reaction mixtures (80 µL) were incubated for 2 min at 25 °C 
before the addition of 20 µL [γ-32P]GTP (0.1 µCi/tube). Reactions were conducted for 20 min 
at 25 °C and terminated by the addition of 900 µL of slurry consisting of 5% (w/v) activated 
charcoal suspended in 50 mM NaH2PO4, pH 2.0. Charcoal absorbs nucleotides but not Pi. 
Charcoal-quenched reaction mixtures were centrifuged for 7 min at room temperature at 
15.000 g. 600 µL of the supernatant fluid were removed, and 32Pi was determined by liquid 
scintillation counting. Enzyme activities were corrected for spontaneous degradation of [γ-
32P]GTP. Spontaneous [γ-32P]GTP degradation was determined in tubes containing all 
components described above, plus a high concentration of unlabeled GTP (1 mM) that, by 
competition with [γ-32P]GTP, prevents [γ-32P]GTP hydrolysis by enzymatic activities present 
in Sf9 membranes. Spontaneous [γ-32P]GTP degradation was <1 % of the total amount of 
radioactivity added. The experimental conditions chosen ensured that not more than 10% of 
the total amount of [γ-32P]GTP added was converted to 32Pi. All experimental data were 
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analyzed by non-linear regression with the Prism 4 program (GraphPad Software, San Diego, 
CA).3,4 
4.1.4 Pharmacology activity for human histamine H3 and H4 receptor 
agonists 
Agonist potencies and efficacies of KCA-compounds at hH3R and hH4R in the GTPase assay. 
Steady-state GTPase activity in Sf9 membranes expressing hH3R and hH4R was determined 
as described in section 4.1.3. Reaction mixtures contained ligands at concentrations from 1 
nM to 100 µM as appropriate to generate saturated concentration-response curves. Data were 
analyzed by nonlinear regression and were best fit to sigmoid concentration-response curves. 
Typical basal GTPase activities ranged between 2 and 4 pmol/mg/min, and the maximal 
stimulatory effect of HA (10 µM) amounted to 50 to 80% above basal. The efficacy (Emax) 
of histamine was determined by nonlinear regression and was set at 1.00. The Emax values of 
other agonists were referred to this value. Data shown are the means ± S.E.M. of a 
representative experiment each performed in duplicate (Table 4). 
4.1.5 Graphs. 
Representative dose/response curves of KCA-compounds tested in the steady-state GTPase 
assay. 
GTPase activity in Sf9 membranes expressing hH3R was determined as described in chapter 4 
and section 4.1.3. Reaction mixtures contained HA, KCA-compounds or THIO at the 
concentrations indicated on the abscissa to generate saturated concentration/response curves 
as far as possible. Data were analyzed by nonlinear regression and were best fit to sigmoid 
concentration/response curves. Data points are the means ± S.E.M. of a representative 
experiment performed in duplicates. A summary of the results of experiments with other 
KCA-compounds is shown in Table 4. 
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   Table:4  
hH3R + Gαi2 +              
β1γ +RGS4 
hH4R-GAIP +         
Gαi2 + β1γ2  
Compound 
 
Emax 
 
EC50/KB 
(nM) 
 
N* 
 
Emax 
 
EC50/KB 
(nM) 
 
N*  
 
O
O
O
N
N
SO2NMe2 KCA-203
 
n. a. n. a. 1 n. a. n. a. 1 
O
O
O
N
N
H KCA-294
 
n. a. n. a. 1 n. a. n. a. 1 
O
O
O
N
N
SO2NMe2
Si KCA-HBP
OH
 
n. a. n. a. 1 n. a. n. a. 1 
O
O
O
N
N
SO2NMe2
Si KCA-164E
NH2
 
n. a. n. a. 1 n. a. n. a. 1 
O OMeN
N
H
KCA-316
NHCbz
CO2Et
H
N
O
H
 
0.80 11810 1 n. a. n. a. 1 
O OMeN
N
H
NH2
CO2Et
H
N
O
H
KCA-319
 
0.20 27840 1 n.a. n.a. 1 
   * Number of independent experiments, n. a. : not active 
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Figure 4.1: Concentration/response curves of HA, THIO, KCA-203 and 
KCA-HBP on GTPase activity in Sf9 cell membranes expressing hH3R, 
Gαi2, Gβ1γ2 and RGS4. 
GTPase activity in Sf9 membranes was determined as described in chapter 4 and section 
4.1.3. Reaction mixtures containing membranes (10 µg of protein/tube) and ligands at 
concentrations indicated on the abscissa. Data shown are the means ± S.E.M. of a 
representative experiment performed in duplicates. Data were analyzed by nonlinear 
regression and were best fitted to sigmoidal concentration/response curves. 
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Figure 4.2: Inhibition curves of THIO, KCA-203 and KCA-HBP on HA 
pre-stimulated GTPase activity in Sf9 cell membranes expressing hH3R, 
Gαi2, Gβ1γ2 and RGS4. 
GTPase activity in Sf9 membranes was determined as described in chapter 4 and section 
4.1.3. Reaction mixtures containing membranes (10 µg of protein/tube), HA (100 nM) and 
ligands at concentrations indicated on the abscissa. Data shown are the means ± S.E.M. of a 
representative experiment performed in duplicates. Data were analyzed by nonlinear 
regression and were best fitted to sigmoidal inhibition curves. 
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Figure 4.3: Effects of KCA-316 and KCA-319 on GTPase activity in Sf9 cell 
membranes expressing hH3R, Gαi2, Gβ1γ2 and RGS4. 
Data are expressed as percentage change in GTPase activity induced by KCA-316 and KCA-
319 compared to the GTPase activities stimulated by HA or inhibited by THIO. Basal GTPase 
activity was set to 0% and the maximal stimulation of GTPase activity by HA (10 µM) was 
defined to be 100%. All other values were referred to HA. Data shown are the means ± 
S.E.M. of a representative experiment performed in duplicates. 
 
O OMeN
N
H
KCA-316
NHCbz
CO2Et
H
N
O
H
O OMeN
N
H
NH2
CO2Et
H
N
O
H
KCA-319
Human H3R
-10 -9 -8 -7 -6 -5 -4
-100
-50
0
50
100
150
HA
KCA-316
KCA-319
THIO
ligand (log M)
G
TP
 
hy
dr
o
ly
si
s
(%
 
o
f H
A-
st
im
u
la
te
d 
G
TP
as
e)
Figure 4.3 Pharmacology activity of KCA-316 and KCA-319 for hH3R
 
 
 
 
 
 
 
 
 
 117 
References 
 
1) Kelley, M. T.; Burckstummer, T.; Wenzel-Seifert, K.; Dove, S.; Buschauer, A.; Seifert, R. 
    Mol Pharmacol 2001, 60,1210. 
2) Houston, C.; Wenzel-Seifert, K.; Burckstummer, T.; Seifert, R. J Neurochem 2002, 80,  
     678. 
3) Stark, H.; Purand, K.; Hüls, A.; Ligneau, X.; Garbarg, M.; Schwartz, J.-C.; Schunack, W. J.         
Med. Chem. 1996, 39, 1220. 
4) Ghorai, P.;  Kraus, A.; Keller, M.;  Go¨tte, C.; Igel, P.; Schneider, E.; Schnell, D.;   
Bernhardt, G.; Dove, S.; Zabel, M.; Elz, S.; Seifert, R.; Buschauer, A. J. Med. Chem. 
2008, 51, 7193. 
 
 
 
 118 
Experimental Part 
Instruments and general techniques used 
1H NMR-Spectra were recorded Bruker Avance 300 (300 MHz), Bruker Avance 400 (400 
MHz) and Bruker Avance 600 (600 MHz). The chemical shifts are reported in δ (ppm) 
relative to all deuterated solvents chloroform (CDCl3, 7.26 ppm), dimethylsulfoxide (DMSO-
d6, 2.49 ppm), methanol-d4,
 
(CD3OD, 3.34 ppm) and tetramethylsilane (TMS, 0.00 ppm) as an 
internal standard. The spectra were analysed by first order, the coupling constants (J) are 
reported in Hertz (Hz). Characterization of signals: s = singlet, bs = broad singlet, d = doublet, 
t = triplet, q = quartet, m = multiplet, bm = broad multiplet, dd = doublet of doublet, dt = 
doublet of triplet, ddd = doublet of doublet of doublet, integration is determined as the relative 
number of atoms. Diastereomeric ratios were determined by comparing the integrals of 
corresponding protons in the 1H NMR spectra. 
13C NMR-Spectra were recorded on Bruker Avance 300 (75.5 MHz), Bruker Avance 400 
(100.6 MHz) and Bruker Avance 600 (150.9 MHz). The chemical shifts are reported in δ 
(ppm) relative to chloroform (CDCl3, 77.0 ppm), dimethylsulfoxide (DMSO-d6, 39.52 ppm), 
methanol-d4
 
(CD3OD, 49.0 ppm) and tetramethylsilane (TMS, 0.00 ppm) as an internal 
standard. 
2D-NMR-Spectra (COSY, NOESY, HMBC and HSQC) were recorded on Bruker Avance 
400 (400 MHz), Bruker Avance 600 (600 MHz). 
IR-Spectra were recorded with an AT1 Mattson Genesis Series FT-IR or a Bio-Rad 
Excalibur series FT-IR. 
MS-Spectra were recorded in Finnigan MAT 95, Varian MAT 311A, Finnigan TSQ 7000 
and Micromass Q TOF. 
Optical Rotations were measured on a Perkin-Elmer-Polarimeter 241 with sodium lamp at 
589 nm and also with KRUSS OPTRONIC GERMANY in the specified solvent. 
HPCL and GC Chiral HPLC (335 UV detector) was performed on a Kontron Instruments 
325 System. Chiracel OD/OD-H, AS and OJ columns were used (50x4.6 mm, 10 "m,) at the 
mentioned flowed rate and wavelength. Gas chromatography (GC) was measured on Fisons 
Instruments GC 8000 series (Data Jet Integrator, CP-chiralsil-DEX-CP column). 
Ozonolysis experiments were carried out using FISCHER process technology ozone 
generator. Microwave assisted reaction was done using Discover CEM. 
Thin layer chromatography (TLC) was performed on aluminum plates coated with silica 
gel (Merck silica gel 60 F 254, layer thickness 0.2 mm). Visualisation was accomplished by 
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UV-light (wavelength λ = 254 nm), Mostain, Molybdatophosphoric acid and a 
vanillin/sulphuric acid solution. 
Column chromatography was performed on silica gel (Merck Geduran 60, 0.063-0.0200 
mm mesh) and flash-silica gel 60 (0.040-0.063 mm mesh). 
Solvents: Dry solvents were prepared by following the standard methods. THF and toluene 
were distilled over sodium/benzophenone and stored over sodium wire. Dichloromethane and 
DMF were distilled over calcium hydride. Ethanol and methanol were distilled over 
magnesium and stored under nitrogen over 4 Å MS. HPLC grade solvents were used without 
further purification directly from MBRAUN MB SPS solvent purifier.  
All reactions with oxygen or moisture sensitive reactant were performed under 
nitrogen/Argon atmosphere.  
Synthesis of bis(oxazolines) 
(S-amino-3-methylbutan-1-ol (106))-2 
H2N
OH
 
10 g (85.3 mmol) of L-Valine 105 and 8.1 g (214 mmol) of sodium borohydride were taken in 
150 mL of anhydrous THF under nitrogen. 21.6 g (85.3 mmol) of iodine was taken in 60 mL 
of anhydrous THF and added dropwise to the above reaction mixturte at 0 °C slowly over a 
period of 1h, resulting in evolution of hydrogen gas. Then the reaction was refluxed for 20h 
and cooled to room temperature, then methanol was added cautiously until the stirred solution 
become clear. The reaction mixture was stirred for additional 30 minutes and solvent was 
evaporated under reduced pressure. This crude mixture was dissolved in 60 mL of 20% KOH 
and stirred for 4 hours and extracted with dichloromethane. The organic layer was dried over 
anhydrous sodium sulfate and concentrated under reduced pressure which obtained valinol as 
colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 0.91 (dd, J = 6.8, 4.2 Hz, 6H), 1.55 (dq, J = 13.5, 6.7 Hz, 
1H), 2.54 (ddd, J = 8.8, 6.4, 4.0 Hz, 1H), 3.27 (dd, J = 10.5, 8.8 Hz, 1H), 3.63 (dd, J = 10.5, 
4.0 Hz, 1H) 
13C NMR (75 MHz, CDCl3): δ = 18.46, 19.36, 31.68, 58.52, 64.79 
N,N′-bis((S)-1-hydroxy-3-methylbutan-2-yl)-2,2-dimethylmalonamide (107) 
N
H
HO N
H
O O
OH
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13 g of L-Valinol 106 (126.09 mmol) was taken in 130 mL of anhydrous dichloromethane and 
to this was added triethyl amine (44 mL, 5 eq) at 0 °C. 2,2-Dimethyl melonyl chloride (8.45 
mL, 1 eq) in dichloromethane was added dropwise to the above reaction mixture. The reaction 
mixture was stirred for 3h at room temperature. The reaction mixture was washed with 1N 
HCl, and the aqueous layer was extracted with dichloromethane, the combined organic layers 
are washed with saturated sodium bicarbonate, brine and dried over sodium sulfate. The 
solvent was removed under reduced pressure and the product was recrystallized in ethyl 
acetate. 
Rf  = 0.25 (EtOAc: MeOH, 95:5), [α]D 24 –6.0 (c 0.50, CH2Cl2), Mp 98-99 °C 
1H NMR (300 MHz, CDCl3): δ = 0.92 (d, J = 6.8 Hz, 6H), 0.96 (d, J = 6.8 Hz, 6H), 1.50 (s, 
6H), 1.82 (oct, 2H, J = 6.8 Hz), 2.66 (bs, 2H), 3.52 (m, 2H), 3.69-3.86 (m, 4H), 6.41 (d, J = 
8.6 Hz, 2H) 
13C NMR (75 MHz, CDCl3): δ = 18.81, 19.63, 23.72, 29.13, 50.20, 57.13, 63.52, 174.50 
(S)-4,5-dihydro-2-(2-((S)-4,5-dihydro-4-isopropyloxazol-2-yl)propan-2-yl)-4-
isopropyloxazole (108) 
O
N N
O
 
To a mixture of (–)-(S,S)-N,N'-Bis-(1-hydroxymethyl-2-methylpropyl)-2,2-dimethyl-
malonamide (107, 18.76 g, 620.0 mmol, 1.0 eq) and 4-dimethylamino pyridine (0.75 g, 6.2 
mmol, 0.1 equiv.) in dry CH2Cl2 (400 mL) was slowly added triethyl amine (37.6 mL, 270.0 
mmol, 4.4 equiv.) over 15 min. Subsequently a solution of tosyl chloride (23.65 g, 124.0 
mmol, 2.0 equiv.) in dry CH2Cl2
 
(50 mL) was added dropwise via the addition funnel. The 
reaction mixture was stirred for additional 48 h at room temperature where the color changed 
to yellow and cloudy precipitate occurred. The precipitate was dissolved in CH2Cl2
 
(150 mL). 
The reaction mixture was then washed with saturated NH4Cl (250 mL) followed by water 
(150 mL) and saturated NaHCO3
 
(200 mL). The combined aqueous layers were extracted with 
CH2Cl2
 
(3 x 200 mL) and the combined organic layers were dried over Na2SO4. After 
filtration and concentration in vacuo the residue was purified by hot n-pentane extraction to 
afford 108 (7.466 g, 44% yield) as a colorless oil. 
Rf  = 0.25 (CH2Cl2: MeOH, 19:1), [α]D 24 –107.5 (c = 1.0, CH2Cl2) 
1H NMR (300 MHz, CDCl3): δ = 0.85 (d, 6H, J = 6.8 Hz), 0.91 (d, 6H, J = 6.8 Hz), 1.51 (s, 
6H), 1.88-1.73 (m, 2H), 3.93-4.06 (m, 4H), 4.15-4.26 (m, 2H) 
13C NMR (75 MHz, CDCl3): δ = 17.30, 18.50, 24.41, 32.23, 38.52, 69.90, 71.54, 168.70 
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Synthesis of γ-butyrolactones. 
6-Ethyl 3-methyl (1S,5S,6S)-(−)-2-Oxa-bicyclo[3.1.0]hex-3-ene-3,6-dicarboxylate (110) 
O
CO2Et
H
HMeO2C
 
 
100 g (793.65 mmol) of methylfuroic ester (109) was taken in 2L, (3 neck) round bottom 
flask and cooled to 0 ºC under nitrogen. To this, 1.74 g (6.5 mmol) of bisoxazoline ligand 
(108), 1.895 g (5.2 mmol) copper triflate, 0.65 mL (6.5 mmol) phenyl hydrazine were added 
sequentially to the neat stirred methylfuroic ester. To the above mixture 1952 g (1.952 kg) of 
14% ethyl diazoacetate was added slowly dropwise with a special dropping funnel over a 
period of 16 days at 0 ºC. The reaction mixture was filtered through a pad of basic alumina 
and eluted with DCM until clearness of the eluent. Removing the solvent under reduced 
pressure afforded the crude product as yellow-brown oil. Crude product was devided into two 
parts for the column chromatography. Silica gel column chromatography (2 batches) of the 
crude product with 5% EA/PE obtained 69 g of cyclopropane ester 110 (41% yield). 
Crystallization in pentane/DCM mixture obtained 110 with 99% ee. 
Rf (SiO2, EA:PE 1:9, Moistain) = 0.35, Mp. 42 °C, [α]D 20 = –272 (c = 1.0, CH2Cl2) 
1H NMR (300 MHz, CDCl3): δ = 1.16 (dd, 1H, J = 2.7, 1.1 Hz), 1.23 (t, 3H, J = 7.1 Hz), 2.87 
(ddd, 1H, J = 5.3, 2.9, 2.7 Hz), 3.78 (s, 3 H), 4.12 (q, 2H, J = 7.1 Hz), 4.97 (dd, J = 5.3, 1.1 
Hz, 1H), 6.39 (d, J = 2.9 Hz, 1H) 
13C NMR (75 MHz, CDCl3): δ = 14.20, 21.50, 31.90, 52.10, 61.00, 67.50, 116.00, 149.30, 
159.50, 171.70  
IR (KBr): = 3118, 2956, 1720, 1617, 1428, 1380, 1297, 1166, 1124, 1041, 954, 831, 725 cm–1 
(2S,3R)-ethyl 2-((methoxycarbonyl)formoyloxy)-3-formylcyclopropanecarboxylate (111) 
CO2EtH
OHC
OC(O)CO2Me
 
17.88 g (84.33 mmol) of cyclopropane ester 110 was taken in 250 mL of anhydrous 
dichloromethane and cooled to -78 °C, ozone was passed the through controlled ozone 
generator till the blue colour solution was appeared (about 30-45 minutes). Then the excess 
ozone was expelled by passing oxygen through CaCl2 and KOH guard tubes for 15 minutes. 
To this 25 mL of DMS was added and the reaction was stirred for 24h. The reaction mixture 
was washed with sodium bicarbonate (25×4), dried over anhydrous sodium sulfate. The 
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solvent was removed under reduced pressure and the product obtained in quantitatively was 
crystallized in ether at -30 °C.  
Mp. 52 °C. [α]D 20 = –37.7 (c = 1.0, CH2Cl2) 
1H NMR (300 MHz, CDCl3): δ = 1.28 (t, J =7.1 Hz, 3H), 2.79 (ddd, J = 7.3, 6.0, 4.0 Hz, 1H), 
2.90 (dd, J = 6.0, 3.6 Hz, 1H), 3.91 (s, 3H), 4.19 (q, J = 7.1 Hz, 2H) 4.83 (dd, J = 7.3, 3.6 Hz, 
1H), 9.45 (d, J = 4.0 Hz, 1H) 
13C NMR (75 MHz, CDCl3): δ = 14.10, 26.40, 34.90, 54.00, 58.9, 62.00, 156.60, 156.90, 
168.10, 192.70  
IR (KBr): = 3066, 3015, 2963, 2892, 1785, 1751, 1735, 1706, 1445, 1345, 1313, 1210, 1167, 
1086, 1011, 963, 867, 790, 715, 613, 495 cm–1 
(2S,3S)-ethyl 2-((methoxycarbonyl)formoyloxy)-3-((S)-1-hydroxybut-3-enyl) 
cyclopropanecarboxylate (112) 
CO2EtH
OC(O)CO2MeOH
 
14 g (57.33 mmol) of cyclopropane carbaldehyde 111 was taken in 220 mL of anhydrous 
dichloromethane at -78 °C, to this 8.64 mL (68.79 mmol) of BF3.Et2O was added slowly. 
After 5 minutes, 13.7 mL (86 mmol) of allyl trimethylsilane was added dropwise and the 
reaction was stirred for 12h at -78 °C. Saturated sodium bicarbonate was added to the reaction 
mixture and allowed to room temperature. The organic layer was separated and the aqueous 
layer was extracted with dichloromethane (3×25 mL). The combined organic layers washed 
with brine and dried over anhydrous sodium sulfate. Removal of the solvent under reduced 
pressure obtained the cyclopropane allyl alcohol 112 in quantitative yield.  
1H NMR (300 MHz, CDCl3): δ = 1.25 (t, J = 7.0 Hz, 3H), 1.81– 1.92 (m, 1H), 2.15 (dd, J = 
6.2, 2.7 Hz, 1H), 2.31 – 2.51 (m, 4 H), 3.70 (ddd, J = 7.3, 7.3, 5.4 Hz, 1H), 3.88 (s, 3 H), 4.13 
(q, J = 7.0 Hz, 2 H), 4.72 (dd, J = 7.5, 2.8 Hz, 1H), 5.14 – 5.22 (m, 2 H), 5.76 – 5.93 (m, 1 H) 
13C NMR (75 MHz, CDCl3): δ = 14.1, 24.7, 31.3, 41.7, 53.8, 58.8, 61.3, 67.8, 118.8, 133.4, 
157.2, 157.2, 170.6 
(2S,3R)-2-allyl-tetrahydro-5-oxofuran-3-carbaldehyde (55) 
OO
CHO
 
16.4 g (61.194 mmol) of cyclopropane allyl alcohol 112 was taken in 260 mL of methanol 
and to this 9.65 g (30.6 mmol) of Ba(OH)2 in 310 mL of methanol was added dropwise at 0 
°C. The reaction was stirred for 6 hours and the solvent was removed under reduced pressure. 
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The crude mixture was diluted with dichloromethane and water. The layers were separated 
after long time. The separation of organic and aqueous layers was easy when Et3N was used 
as base instead of Ba(OH)2. The organic layer was dried over anhydrous sodium sulfate and 
the crude product was purified by column chromatography (1:1 EA/PE) to obtain 55 in 50% 
yield. 
TLC Rf (SiO2, EA:PE 1:1, Moistain) = 0.35 
1H NMR (300 MHz, CDCl3): δ = 2.35 – 2.59 (m, 2H), 2.71 (dd, J = 18.2, 9.9 Hz, 1H), 2.89 
(dd, J = 18.2, 7.5 Hz, 1H), 3.19 (dddd, J = 10.0, 7.3, 6.0, 1.2 Hz, 1H), 4.74 (dd, J = 11.9, 6.2 
Hz, 1H), 5.10 – 5.27 (m, 2 H), 5.75 (dddd, J = 17.3, 10.0, 7.0, 3.5 Hz, 1H), 9.69 (d, J = 1.2 
Hz, 1H). 
13C NMR (75 MHz, CDCl3): δ = 28.8, 39.2, 51.2, 78.0, 120.4, 130.9, 174.2, 197.4  
Synthesis of histamine H3 and H4 receptor potential agonists based on γ-butyrolactones. 
(5S,4R)-5-Allyl-4[1,3] dioxolan-2-yl-dihydro-furan-2-one (146)  
OO
O
O
 
The aldehyde 55 (3.9 g,   25.32 mmol) was dissolved in 120 mL of benzene and to this 7.05 
mL (126.6 mmol) of ethylene glycol and (0.962 g , 5.06 mmol) p-Toluene sulfonic acid were 
added under nitrogen.The reaction mixture was refluxed with Dean Stark apparatus for 24h. 
Then the reaction mixture was cooled to rt and diluted with diethyl ether and washed with 
NaHCO3 and brine. The aqueous layer was extracted with ether (3 × 40 ml). The combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure. The product 
was purified by column chromatography using EA/PE (20:80) as eluent to obtain 146 (4.25 g, 
yield 85%).  
TLC Rf  (EA:PE 1:1, Mostain) = 0.70 
1H NMR (300 MHz, CDCl3): δ =  2.32-2.60 (m, 5H), 3.80-4.0 (m, 4H), 4.47-4.54 (m, 1H), 
4.85 (d, 1H, J = 3.29 ), 5.10-5.20 (m, 2H), 5.68-5.84 (m, 1H) 
13C NMR (75 MHz, CDCl3): δ = 29.55, 39.20, 42.38, 65.41, 65.58, 79.66, 103.46, 119.25, 
132.03, 175.93  
HRMS: Reiser et al, Chem. Eur.J. 2003, 9, 260  
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(2R/S,4R,5S)-5-Allyl-4-[1,3]dioxolan-2-yl-tetrahydro-furan-2-ol (147)  
OHO
O
O
 
3.0 g (15.14 mmol) of 146 was dissolved in 160 mL of anhydrous dichloromethane under 
nitrogen and cooled to -78 °C. To this 22.7 mL (22.7 mmol) of DIBAL-H (1M solution in 
DCM) was added slowly drop wise. Then the reaction was stirred for 2 h. The reaction was 
quenched by the addition of ethyl acetate and warmed to room temperature. Then saturated 
solution of sodium potassium tartarate was added and the mixture was stirred for another 2 h. 
The layers were separated and the aqueous layer was extracted with dichloromethane. The 
combined organic layers were washed with brine, dried over sodium sulphate. Then the 
solvent was removed under reduced pressure to obtain lactol as anomeric mixture. A filter 
column (EA/PE 22:78) was done to get the pure product 147 in excellent yield (2.74 g, 90%). 
TLC Rf  (EA:PE 1:1, Mostain) = 0.65 
1H NMR (300 MHz, CDCl3) (from KCA-95): 1.92-2.05 (m, 1H), 2.10-2.22 (m, 1H), 2.25-
2.55 (m, 3H), 3.80-4.08 (m, 4H), 4.15-4.23 (m, 1H), 5.01-5.15 (m, 2H), 5.34-5.49 (m, 1H), 
5.70-5.95 (m, 1H)  
13C NMR (from KCA-95) (75 MHz, CDCl3): δ = 34.65, 35.59, 40.07, 41.38, 44.48, 45.33, 
64.90, 65.00, 65.10, 65.24, 65.38, 80.35, 98.34, 104.42, 105.07, 116.99, 117.62, 134.08, 
135.22  
HRMS calcd for C10H16O4Na (M+Na) 223.0946, found 223.0921 
(1R/S, 3R, 4S)-2-(tert-Butyl-dimethyl-silanyl)-5-(3-[1,3]dioxolan-2-yl-1,4-dihydroxy-
hept-6-enyl) imidazole-1-sulfonic acid dimethylamide (148,149)  
N
N
SO2NMe2
Si
OH
O
O
OH
 
The bis protected imidazole 122 (prepared according to literature procedure)61,62 9.77 g, 
(33.75 mmol) was dissolved in 100 mL of anhydrous THF and cooled it to -70 °C. To this 
21.1 mL (33.75 mmol)  of  1.6 M BuLi-hexane was added dropwise, then the resulting 
mixture was stirred for 30 min at -50 °C to precipitate the lithium salt. The reaction mixture 
was again cooled back to -70 °C and the THF solution of lactol 147 (2.5 g, 12.5 mmol in 50 
mL) was added slowly. The dry ice bath was removed and the reaction mixture was stirred at 
rt for 1 h. Then the reaction was quenched with water and THF was removed under reduced 
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pressure. The residue was dissolved in ethyl acetate and the organic layer was washed with 
water and brine. The solvent was dried over anhydrous sodium sulphate and concentrated 
under reduced pressure. The crude product was separated in quantitative yield by column 
chromatography using EA:PE 55:45 to 65:35 as eluent to obtain 90% (5.55 g) of diols.  
TLC Rf  (EA:PE 7:3, Mostain) = 0.56, 0.46 
1H NMR (300 MHz, CDCl3): δ = 0.37 (s, 6H), 0.98 (s, 9H), 2.01-2.08 (m, 2H), 2.10-2.32 (m, 
3H), 2.83 (s, 6H), 3.82-4.13 (m, 5H), 4.96 (d, 1H, J = 3.84 ), 5.06-5.16 (m, 3H), 5.74-5.89 (m, 
1H), 7.25 (s, 1H) 
13C NMR (75 MHz, CDCl3): δ = -3.59, -3.55, 18.42, 27.21, 30.03, 37.74, 38.88, 42.22, 63.18, 
64.70, 65.09, 70.77, 76.63, 105.86, 177.79, 130.05, 134.96, 137.50, 156.20  
HRMS: calcd for C15H26N3O6S (M+H) 376.1542, found 376.1539 
(2R/S,4R,5S)-5-(5-Allyl-4-[1,3]dioxolan-2-yl-tetrahydro-furan-2-yl)-2-(tert-butyl 
dimethyl -silanyl)-imadazole-1-sulfonic acid dimethylamide (150,151) 
O
O
O
N
N
SO2NMe2
Si
 
The diol (148,149) (3.55 g, 7.24 mmol)  was taken in 310 mL of benzene and to this tributyl 
phosphine 5.38 mL (21.74 mmol) and 5.48 g (21.74 mmol) of ADDP were added at rt under 
nitrogen atmosphere. Then the reaction was stirred over night (12h) at rt. Benzene was 
removed under reduced pressure and the residue was diluted (dissolved) with ethyl acetate 
from this the insoluble hydrazine by product was filtered through celite pad. The ethyl acetate 
layer was washed with water and brine. Then the solvent was dried over anhydrous sodium 
sulphate and concentrated under reduced pressure. The product was purified by column 
chromatography using (EA: PE 25:75) to obtain the cyclised product 2.67 g in 78% yield.  
The same reaction was done by using TMAD which gave only 68% yield.  
TLC Rf  (EA:PE 3:7, Mostain) = 0.70 
1H NMR (300 MHz, CDCl3): δ = 0.33 (s, 6H), 0.96 (s, 9H), 2.00-2.12 (m, 1H), 2.25-2.36 (m, 
3H), 2.41-2.51 (m, 1H), 2.82 (s, 6H), 3.79-3.99 (m, 5H), 4.83 (d, 1H, J = 4.11), 5.00-5.13 (m, 
3H), 5.73-5.88 (m, 1H), 7.20 (s, 1H) 
13C NMR (75 MHz, CDCl3): δ = -3.42, -3.63, 18.44, 27.30, 34.37, 34.45, 39.78, 46.51, 65.06, 
65.23, 71.16, 79.81, 104.71, 117.45, 130.10, 134.65, 135.02, 156.17 
HRMS: calcd for C21H36N3O5SSi (M-H) 470.2145: found 470.2137 
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(2R/S,4R,5S)-2-(tert-Butyl-dimethyl-silanyl)-5-[4-[1,3]dioxolan-2-yl-5-(3-hydroxy-
propyl)-tetrahydro-furan-2-yl]-imidazole-1-sulfonic acid dimethylamide (152,153) 
O
O
O
N
N
SO2NMe2
Si
OH
 
The diastereomeric mixture of olefin (150,151) (1 g, 21.23 mmol) was dissolved in 100 mL of 
anhydrous THF and to this 12.7 mL (12.7 mmol) of BH3.THF (1 M solution in THF) was 
added slowly drop wise under nitrogen atmosphere. Then the reaction was stirred over night 
at rt. The reaction was quenched with 2M NaOH and H2O2 and stirred it for another 4 h. The 
product was purified by column chromatography using EA:PE (80:20). The isolated product 
was 0.83 g, 80% yield as diastereomeric mixture having 152 and 153. 
TLC Rf  (EA:PE 100:0, Mostain) = 0.30 
1H NMR (300 MHz, CDCl3): δ = 0.34 (s, 6H), 0.93 (s, 9H), 1.15-1.17 (m, 3H), 1.75-1.85 (m, 
1H), 2.13-2.33 (m, 2H), 2.38-2.53 (m, 1H), 2.80 (s, 6H), 3.51-3.63 (m, 2H), 3.78-3.94 (m, 
4H), 4.76-4.86 (m, 1H), 7.23 (s, 1H) 
13C NMR (75 MHz, CDCl3): δ = -3.64, -3.47, -3.42, 18.42, 27.28, 29.69, 31.54, 32.49, 34.60, 
34.97, 37.47, 37.54, 47.38, 48.72, 62.62, 65.03, 65.23, 70.13, 71.18, 77.27, 79.69, 80.56, 
104.55, 104.69, 130.21, 130.48, 134.89, 135.38, 156.22, 156.30  
HRMS: calcd for (M+H) C21H40N3O6SSi 490.2407, found 490.2401 
(2R/S,4R,5S)-2-(tert-butyl-dimethyl-silanyl)-5-{5-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl) 
-propyl]-4-[1,3]dioxolan-2-yl-tetrahydro-furan-2-yl}-imidazole-1-sulfonic acid dimethyl 
amide (154,155)  
O
O
O
N
N
SO2NMe2
Si
N
O
O
 
The diastereomeric alcohol (152,153) (200 mg, 0.409 mmol) was disolved in 20 mL of 
anhydrous THF  and to this 90 mg  (0.61 mmol) of phthalimide, 214 mg (0.81 mmol) of 
triphenyl phosphene were added under nitrogen. To the above reaction mixture, 0.128 mL 
(0.81 mmol) of DEAD was added drop wise. Then the reaction was stirred overnight at rt. The 
solvent was removed under reduced pressure and the residue was diluted with ethyl acetate. 
The organic layer was washed with water and brine. The organic layer was dried over 
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anhydrous sodium sulphate and concentrated to give the crude product which was purified by 
column chromatography using EA: PE (30:70) as eluent. The isolated product is 165 mg, 65% 
yield as diastereomeric mixture having 154 and 155. 
TLC Rf  (EA:PE 1:1, Mostain) = 0.55 
1H NMR (300 MHz, CDCl3): δ = 0.35 (s, 6H), 0.98 (s, 9H), 1.60-1.90 (m, 4H), 2.04-2.2 (m, 
1H), 2.23-2.34 (m,1H), 2.41-2.54 (m, 1H),2.85 (s, 6H), 3.60-3.73 (m, 3H), 3.80-4.0 (m, 5H), 
4.80-4.86 (m, 1H), 7.26 (s, 1H), 7.65-7.72 (m, 2H), 7.79-7.83 (m, 2H) 
13C NMR (75 MHz, CDCl3): δ = -3.66, -3.64,  -3.44, -3.39, 14.32, 14.42, 18.43, 25.34, 25.56, 
27.30, 29.69, 32.22, 32.93, 34.35, 34.74, 37.39, 37.41, 47.32, 48.59, 65.12, 65.20, 69.81, 
70.77, 79.05, 79.79, 104.53, 104.70, 123.19, 130.23, 130.47, 132.11, 132.13, 133.75, 133.91, 
133.94, 134.24, 134.60, 135.09, 156.21, 156.34, 168.37 
HRMS: calcd for (M+H) C29H43N4O7SSi 619.2622 found: 619.2613 
(2R/S,4R,5S)-5-[5-(3-amino-propyl)-4-[1,3]dioxolan-2-yl-tetrahydro-furan-2-yl]-2-(tert-
butyl-dimethyl-silanyl)-imidazole-1-sulfonic acid dimethylamide (156,157) 
O
O
O
N
N
SO2NMe2
Si
NH2
 
The diastereomeric phthalimide (154,155) (130 mg, 0.21 mmol) was dissolved in 15 mL of 
ethanol and to this 0.066 mL (1.36 mmol) of hydrazine hydrate was added drop wise. Then 
the reaction was stirred over night at rt. Ethanol was concentrated under reduced pressure and 
the residue was diluted with ethyl acetate and washed with minimum amount of water and 
brine. The highly polar product was purified by column chromatography using ethyl acetate 
and then methanol as eluent. The isolated product was 78 mg, 76% yield having 
diastereomeric mixture 156 and 157. 
TLC Rf  (EA:PE 100:0, Ninhydrin) = 0.01, (MeOH:CHCl3 1:9) = 0.15 
1H NMR (300 MHz, CDCl3): δ = 0.38 (s, 6H), 1.00 (s, 9H), 1.45-1.80 (m, 5H), 2.00-2.38 (m, 
3H), 2.45-2.58 (m, 1H), 2.64-2.74(m, 2H), 2.87 (s, 6H), 3.43-3.51 (m, 2H), 3.56-3.74 (m, 
6H), 3.83-4.03(m, 5H), 4.83-4.92 (m, 1H), 7.3(s, 1H)  
13C NMR (75 MHz, CD3Cl3): δ = -3.65, -3.45, -3.40, 14.13, 18.44, 22.70, 26.08, 29.36, 29.50, 
29.63, 29.68, 30.44, 30.52, 31.93, 32.24, 33.09, 34.50, 34.84, 37.46, 42.00, 47.42, 62.92, 
65.01, 65.04, 65.18, 65.24, 70.01, 70.57, 71.03, 72.53, 76.61, 79.57, 80.44, 104.68, 104.80, 
130.17, 130.43, 135.04, 135.50, 156.20  
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1H NMR (300 MHz, CD3OD): δ = 0.38 (s, 6H), 0.96 (s, 9H), 1.5-1.83  (m, 5H), 1.99-2.16 (m, 
1H), 2.24- 2.40(m, 2H), 2.452.58 (m, 1H), 2.62-2.78 (m, 2H), 2.89 (s, 6H), 3.81-4.06 (m, 5H), 
5.12- 5.33(m, 1H), 7.28 (s, 1H)  
13C NMR (75 MHz, CD3OD): δ = -3.66, -3.64,  -3.44, -3.39, 14.32, 14.42, 19.20, 23.79, 
28.05, 30.67, 30.80, 33.12, 33.38, 34.27, 35.72, 36.25, 37.93, 37.97, 42.35, 63.06, 66.11, 
66.26, 66.37, 71.22, 71.62, 72.41, 81.09, 81.47, 105.82, 106.05, 130.85, 131.10, 136.95, 
137.54, 157.35.  
HRMS: calcd for (M+H) C21H41N4O5SSi 489.2567; found: 489.2559 
Synthesis of histamine H3 and H4 receptor potential agonists by furan cyclopropane ring 
opening methodology. 
(1S,5S,6S)-6-(ethoxycarbonyl)-2-oxa-bicyclo[3.1.0]hex-3-ene-3-carboxylicacid (231) 
OHOOC
CO2Et
H
H
 
11.60 g (54.71 mmol) of compound 229 was taken and dissolved in 150 mL of THF and 
cooled to 0 °C. To this 1.57 g of (65.66 mmol) lithium hydroxide in 100 mL of water was 
added slowly drop wise. Then the reaction was stirred over night. Completion of the reaction 
was checked by TLC and the reaction mixture was acidified to 2-3 pH with 1N HCl. Then the 
reaction mixture was diluted with ethyl acetate and separated the organic layer. The aqueous 
layer was extracted with EA (5 × 20 mL) and the combined organic layer was dried under 
anhydrous sodium sulfate. Removal of the solvent under reduced pressure followed by 
crystallization in chloroform/n-hexane (1:10) gave the pure product 231 in 96% yield. 
TLC Rf  (EA:PE 100:0, KMnO4) = 0.10  
1H NMR (300 MHz, CDCl3): δ =  1.17-1.20 (m, 1H), 1.26 ( t, 3H, J = 7.13 ) 2.84-2.92 (m, 
1H), 4.15 (q, 2H, J = 7.13), 4.97 (dd, 1H, J1 = 1.09, J2 = 5.21), 6.52 (d, 1H, J = 3.01), 11.17-
11.21 (bs, 1H)  
13C NMR (75 MHz, CDCl3): δ = 14.20, 21.49, 32.19, 61.34, 67.78, 118.74, 148.58, 163.70, 
171.93  
(1S,3R,5S,6S)-6-(ethoxycarbonyl)-2-oxa-bicyclo[3.1.0]hexane-3-carboxylicacid (232) 
OHOOC
CO2Et
H
H
 
4.6 g (23.23 mmol) of compound 231 was taken in 250 mL of ethylacetate and to this 460 mg 
of Pd/C (10%) was added. Then hydrogen balloon was kept and the reaction was stirred at 
room temperature over night. The reaction mixture was passed through the celite and the 
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solvent was removed under reduced pressure obtained 232 in 98% yield. The NMR of this 
product 232 is very clean without purification and there were no starting material and side 
products observed. 
TLC Rf  (EA:PE 100:0, Mostain) = 0.10 
1H NMR (300 MHz, CDCl3): δ =  1.22 (t, 3H, J = 7.13), 1.8-1.88 (s, 1H), 2.13-2.38 (m, 2H), 
2.60-2.777 (m, 1H), 4.04 (q, 2H, J1 = 7.04, J2 = 14.27), 4.32 (d, 1H, J = 5.76), 4.79 (dd, 1H, 
J1  = 3.84, J2 = 10.70), 9.5-10.5 (bs, 1H) 
13C NMR (75 MHz, CDCl3): δ = 14.15, 25.62, 28.10, 34.09, 60.82, 67.45, 78.61, 170.68, 
177.45 
(2R,4R,5R)-methyl 4-((S)-(ethoxycarbonyl)bromomethyl)-tetrahydro-5-methoxyfuran-2-
carboxylate (233) 
OMeOOC
CO2Et
OMe
Br
H
 
4.8 g (24.00 mmol) of compound 232 was taken in 200 mL of anhydrous methanol and to this 
6.4 g (36 mmol) of NBS was added at 0 °C and the reaction was stirred for 36 h.  The solvent 
was removed under reduced pressure and the crude product was purified by column 
chromatography in 5% EA/PE as eluent to obtain 233 in 80 % yield. 
TLC Rf  (EA:PE 1:9, Mostain) = 0.35 
1H NMR (300 MHz, CDCl3): δ = 1.23 (t, 3H, J = 7.13), 1.98-2.10 (m, 1H), 2.51-2.64 (m, 1H), 
2.76-2.87 (m, 1H), 3.28-3.32 (s, 3H), 3.71-3.75 (s, 3H), 4.12-4.25 (m, 3H), 4.56 (t, 1H, J = 
7.68), 4.83 (d, 1H, J = 1.92)   
13C NMR (75 MHz, CDCl3): δ = 13.87, 32.80, 46.64, 49.31, 52.37, 55.50, 62.33, 75.31, 
107.33, 168.66, 171.84  
HRMS: calcd for C11H17BrO6Na (M+Na) = 349.0106; found: 349.0104 
(2R,4R,5R)-methyl 4-((R)-(ethoxycarbonyl)azidomethyl)-tetrahydro-5-methoxyfuran-2-
carboxylate (234) 
OMeOOC
CO2Et
OMe
N3
H
 
3.6 g (11.11 mmol) of compound 233 was taken in 35 mL of analytical grade DMF and to this 
2.16 g (33.33 mmol) of sodium azide was added at room temperature under nitrogen. The 
reaction was stirred overnight and then the reaction mixture was quenched with water and 
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extracted with ethylacetate (5 × 20 mL). The solvent was removed under reduced pressure and 
the pure product was isolated by filtered column chromatography to obtain 234 in 97 % yield.  
TLC Rf  (EA:PE 1:9, Mostain) = 0.30 
1H NMR (300 MHz, CDCl3): δ = 1.25 (t, 3H, J = 7.13), 1.94-2.08 (m, 1H), 2.20-2.33 (m, 1H), 
2.39-2.54 (m, 1H), 3.37-3.42 (s, 3H), 3.67-3.72 (s, 3H), 3.98 (d, 1H, J = 10.97), 4.18 (q, 2H, 
J1 = 7.13, J2 = 14.27), 4.56 (t, 1H, J = 8.23), 4.96 (d, 1H, J = 4.11)  
13C NMR (75 MHz, CDCl3): δ =  14.15, 30.03, 46.07, 52.18, 54.81, 61.85, 61.96, 76.63, 
104.21, 169.37, 172.63  
HRMS: calcd for C11H17N3O6Na (M+Na) = 310.1015; found 310.1006 
(2R,4S,5R)-methyl 4-((R)-(ethoxycarbonyl)(amino)methyl)-tetrahydro-5-methoxyfyran-
2-carboxylate (235) 
OMeOOC
CO2Et
OMe
NH2
H
 
2.06 g (7.17 mmol) of compound 234 was taken and dissolved in 150 mL of distilled ethyl 
acetate and to this 200 mg of Pd/C (10%) was added at room temperature. Then the reaction 
was stirred under hydrogen atmosphere (balloon pressure) overnight. The completion of the 
reaction was checked by TLC. The reaction mixture was passed through celite and the solvent 
was removed under reduced pressure obtained 234 in 95 % yield. The product 235 was pure 
enough to proceed to the next step. 
TLC Rf  (EA:PE 100:0, Ninhydrin) = 0.25 
1H NMR (300 MHz, CDCl3): δ = 1.22 (t, 3H, J = 7.13), 2.00-2.40 (m, 3H), 3.38 (s, 3H), 3.69 
(s, 3H), 4.12 (q, 2H, J1 = 7.13, J2 = 14.27), 4.53 (t, 1H, J = 7.95), 4.98 (d, 1H, J = 3.84) 
13C NMR (75 MHz, CDCl3): δ = 14.21, 30.46, 48.69, 52.07, 54.79, 60.78, 61.01, 76.75, 
105.02, 172.97, 174.74  
HRMS: calcd for C11H19NO6Na (M+Na) = 284.1110, found: 284.1106 
(2R,4S,5R)-methyl 4-((R))-1-(benzyloxycarbonylamino)-2-ethoxy-2-oxoethyl)-5-
methoxytetrahydrofuran-2-carboxylate (236) 
OMeOOC
CO2Et
OMe
NHCbz
H
 
1.83 g (7.01 mmol) of 235 was taken in 120 mL of anhydrous THF and to this 1.45 mL (10.51 
mmol) of triethylamine was added under nitrogen atmosphere. To the above reaction mixture 
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1.2 mL (9.11 mmol) of carboxybenzoylchloride was added drop wise and the reaction was 
stirred at room temperature for 12 h. Then the reaction mixture was quenched with water and 
extracted with ethyl acetate (3 × 25 mL). The organic layer was washed sodium bicarbonate 
and brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under 
reduced pressure. The crude product 236 was separated by column chromatography as 25% 
EA/PE as eluent in 85% yield. 
TLC Rf  (EA:PE 1:1, Mostain) = 0.50 
1H NMR (300 MHz, CDCl3): δ 1.26 (m, 3H), 2.14-2.40 (m, 2H), 2.76-2.92 (m, 1H), 3.38 (s, 
3H), 3.74 (s, 3H), 4.07-4.27 (m, 2H), 4.59 (m, 2H), 5.12 (s. 2H), 5.82(d, 2H, J = 10.15) 7.27-
7.43 (m, 5H) 
13C NMR (75 MHz, CDCl3): δ = 14.11, 29.28, 44.45, 46.28, 52.20, 55.10, 61.58, 67.08, 
75.53, 105.34, 128.20, 128.74, 136.30, 137.49, 156.56, 171.16, 172.61 
(2R,4S,5R)-4-((R)-1-(benzyloxycarbonylamino)-2-ethoxy-2-oxoethyl)-5-
methoxytetrahydrofuran-2-carboxylic acid (237) 
OHOOC
CO2Et
OMe
NHCbz
H
 
1.5 g (3.79 mmol) of compound 236 was taken in 30 mL of THF and to this 100 mg (4.17) of 
lithium hydroxide in 100 mL of water was added at 0 °C. The reaction was stirred for 12 h 
and completion of the reaction was checked by TLC. Then the reaction mixture was acidified 
to 2-3 pH with 1N HCl. The reaction mixture was diluted with ethyl acetate and separated the 
organic layer. The aqueous layer was extracted with EA (5 × 15 mL) and the combined 
organic layer was dried over anhydrous sodium sulfate which obtained 237 in 95% yield. 
benzyl(R)-((2R,3S,5R)-5-(chlorocarbonyl)-tetrahydro-2-methoxyfuran-3-yl) 
(ethoxycarbonyl)methylcarbamate (242) 
O
CO2Et
OMeCl
O
H
NHCbz
 
291 mg (0.763 mmol) of compound 237 was taken in 40 mL of anhydrous DCM and to this 
two drops of DMF was added at 0 °C under nitrogen. To the above reaction mixture 0.2 mL 
(2.29 mmol) of oxalyl chloride was added and the reaction was stirred for 12 h. The reaction 
mixture was quenched with water and extracted with ethyl acetate (4 × 10 mL). The organic 
layer was washed with sodium bicarbonate and brine. Removal of the solvent under reduced 
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pressure gave the acid chloride 242 in good yield. The next step was done with this product 
without purification. 
benzyl(R)-((2R,3S,5R)-5-(2-(1H-imidazol-4-yl)ethylcarbamoyl)-tetrahydro-2-
methoxyfuran-3-yl)(ethoxycarbonyl)methylcarbamate (245) 
O
CO2Et
OMe
NHCbz
H
N
O
H
N
HN
 
30 mg (0.078 mmol) of 237 was taken in 5 mL of DMF and to this 0.012 mL (0.0866 mmol) 
of triethyl amine, 10.5 mg (0.094 mmol) of histamine, 11.70 mg (0.086 mmol) of HOBt and 
16.60 mg (0.086 mmol) of EDC were added sequentially and the reaction was stirred at room 
temperature 3 h. Then the reaction was quenched with water and extracted with ethyl acetate 
(5 × 10 mL) and the organic layer was washed with brine and dried over sodium sulfate. The 
solvent was removed under reduced pressure obtained 245 in 70% yiled.  
(R)-ethyl 2-((2R,3S,5R)-5-(2-(1H-imidazol-4-yl)ethylcarbamoyl)-tetrahydro-2-
methoxyfuran-3-yl)-2-aminoacetate (246) 
O
CO2Et
OMe
NH2
H
N
O
H
N
HN
 
30 mg (0.065 mmol) of 245 was taken in 4:1 mixture of ethylacetate and ethanol then treated 
with 5 mg of Pd/C (10%). The reaction was stirred under hydrogen atmosphere at room 
temperature for 8 h. The reaction mixture was passed through a small pad of celite and the 
solvent was removed under reduced pressure to obtain 246 in 80% yiled. 
Synthesis of histamine H3 and H4 receptor potential agonists by imidazole-furan 
cyclopropane ring opening methodology. 
2-bromo-1-(furan-2-yl)ethanone (249) 
O
O
Br
 
1.0 g (9.00 mmol) of 2-acetyl furan was taken in 5 mL of anhydrous ether and to this 0.46 mL 
(9.00 mmol) of bromine was added drop wise at 0 °C and the reaction was stirred for 30 min. 
The reaction mixture was poured in to ice cold water and extracted with ether (4 × 20 mL) 
and dried over anhydrous sodium sulfate. The removal of the organic solvent and purification 
by column chromatography using 6% EA/PE gave 249 in 90% yield. 
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TLC Rf  (EA:PE 1:9, Mostain) = 0.50 
1H NMR (300 MHz, CDCl3): δ = 4.30 (s, 2H), 6.58, (q, 1H, J1 = 1.64, J2 = 3.56), 7.32 (dd, 
1H, J1 = 0.54, J2 = 3.56), 7.63 (dd, J1 = 0.54, J2 = 1.64)  
13C NMR (75 MHz, CDCl3): δ = 30.11, 112.89, 119.20, 147.36, 150.29, 180.34 
5-(furan-2-yl)-1H-imidazole (250) 
O N
H
N
 
1.0 g (5.31 mmol) of 249 was taken in 40 mL of 7M liquid ammonia and to this 4.2 g (40.3 
mmol) of formamidine acetate was added and the reaction set up had put it in autoclave 
without any external pressure. The reaction was stirred over night at 45 °C in an oil bath. The 
solvent was evaporated slowly in a fume hood and the residue was removed by rotavapour. 
The crude product was purified by a filter column eluting with ethyl acetate gave the pure 
product 250 in 65% yield.  
TLC Rf  (MeOH:CHCl3 1:9) = 0.15 
1H NMR (300 MHz, CDCl3): δ = 6.49-6.41 (m, 1H), 6.51-6.54 (m, 1H), 7.34 (s, 1H), 7.38 (d, 
1H, J = 1.09), 7.72 (s, 1H), 12.53 (s, 1H)  
13C NMR (75 MHz, CDCl3): δ = 104.30, 111.35, 114.75, 131.55, 135.72, 141.07, 149.04 
tert-butyl 5-(furan-2-yl)-1H-imidazole-1-carboxylate (251) 
O N
N
O O
 
270 mg (2.01 mmol) of compound 250 was taken in 15 mL of chloroform and to this 0.41 mL 
(3.01 mmol) of triethyl amine was added. In 5 mL of chloroform 571 mg (2.60 mmol) of Boc 
anhydride was dissolved and added to the above reaction mixture slowly drop wise. The 
reaction was stirred at room temperature for 4 h. Then the reaction was quenched with water 
and the organic layer was extracted with chloroform. The organic layer was dried over 
anhydrous sodium sulfate and the removal of solvent was done under reduced pressure. The 
crude product was purified by column chromatography eluting in 25% EA/PE to obtain 251 in 
85% yield.        
TLC Rf  (EA:PE 4:6, Mostain) = 0.55 
1H NMR (300 MHz, CDCl3): δ = 1.61 (s, 9H), 6.41-6.46 (m, 1H), 6.69 (d, 1H, J = 3.01), 7.37-
7.40 (m, 1H), 7.51 (d, 1H, J = 1.09), 8.06 (d, 1H, J = 1.09)  
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13C NMR (75 MHz, CDCl3): δ = 27.88, 85.89, 106.11, 111.36, 111.55, 135.35, 137.36, 
141.72, 146.88, 148.70 
Synthesis of histamine H3 and H4 receptor potential agonists based on imidazole 
aldehyde. 
 
1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-5-carbaldehyde (259) 
N
N
O
H
SEM
 
1.0 g (10.4 mmol) of 258 was dissolved in 50 mL of anhydrous dichloromethane and to this 
1.73 mL (12.5 mmol) of triethyl amine was added drop wise. To this 2.2 mL (12.5 mmol) of 
SEMCl was added slowly drop wise under nitrogen and the reaction mixture was stirred for 
12 h. The reaction mixture was washed with water and extracted with dichloromethane (3 × 
15 mL). The organic layer was dried over anhydrous sodium sulfate and the solvent was 
removed under reduced pressure. The crude product was purified by column chromatography 
eluting with 40% EA/PE to obtain 259 in 70% yield.  
TLC Rf  (EA:PE 100:0, Mostain) = 0.50 
1H NMR (300 MHz, CDCl3): δ = -0.03 (s, 9H), 0.85-0.96 (m, 2H), 3.48-3.62 (m, 2H), 5.7 (s, 
2H), 7.83 (s, 1H), 7.88 (s, 1H), 9.79 (s, 1H)  
13C NMR (75 MHz, CDCl3): δ = -0.35, 19.26, 68.60, 94.74, 145.20, 180.82, 187.71 
1-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)pent-4-en-1-ol (260) 
N
N
OHSEM
 
49.20 mg (2.050 mmol) of Mg was taken in two neck RB was fitted with76.95, cooling 
condenser at and rubber septum under nitrogen and to this a pinch of iodine was added at 0 
°C. This mixture was stirred in 2 mL of anhydrous ether and 0.195 mL (1.921 mmol) of 
butynly bromide was added slowly drop wise. The reaction mixture was stirred for 30 min 
until the Grignard reagent is formed. To the above Grignard reagent 290 mg (1.281 mmol) of 
259 was added slowly drop wise in 20 mL of ether. When the addition is over immediately a 
white precipitate is formed then the cooling bath was removed and the reaction was stirred 
overnight at rt. The reaction mixture was quenched with saturated ammonium chloride and 
diluted with ethyl acetate. The layers were separated and the aqueous layer was extracted with 
ethylacetate (3 × 10 mL). The organic layer was dried over anhydrous sodium sulfate and 
concentrated under reduced pressure. The crude product was isolated by column 
chromatography eluting with 60% EA/PE gave 260 in 60% yield. 
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TLC Rf  (EA:PE 100:0, Mostain) = 0.10 or Rf  (MeOH:CHCl3 1:9, Mostain) = 0.4 
1H NMR (300 MHz, CDCl3): δ = -0.09 (s, 9H), 0.86-1.0 (m, 2H), 1.90-2.10 (m, 2H), 2.15-
2.35 (m, 2H), 3.45-3.60 (m, 2H), 4.62-4.82 (m, 2H), 4.94-5.15 (m, 2H), 5.36 (s, 2H), 5.80-
5.95 (m, 1H), 6.92-7.01 (bs, 1H), 7.49-7.55 (bs, 1H) 
13C NMR (75 MHz, CDCl3): δ = -0.34, 19.14, 31.66, 35.68, 37.53, 65.28, 67.60, 75.87, 
116.75, 128.79, 135.69, 139.84 
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The histamine H4 receptor has been characterized through homology searching of 
the genomic data base in 2000. The H4 receptor was found to have a similar amino 
acid sequence and pharmacological characteristics as the histamine H3 receptor. It 
has been suggested that the H4-receptor plays a role in the treatment of 
autoimmune, inflammatory and allergic disorders. Imifuramines and their 
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activity relationship. On the other hand we are also synthesising some analogues 
by cyclopropane ring opening methodology to change the position of aminomethyl 
and cyanoguanidine groups for the histamine H3 and H4 receptor agonists. 
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Enantioselective Synthesis of γ-butyrolactones 
 
OMeO2C OMeO2C
CO2Et
H
H
CO2Et
OC(O)CO2MeOHC
H O
O
CHO
Reagents and conditions: i) (S,S)- isopropyl Bisoxazoline,  Cu(OTf)2, PhNHNH2, ethyldiazoacetate, 0°C, 41%; 
ii) O3, DCM, -78°C, DMS, rt, 12h, 98%; iii) BF3.Et2O, allylTMS, DCM -78°C, 12h; iv) Ba(OH)2, MeOH, 0°C 50%
i) ii) iii), iv)
99% ee
 
 
Synthesis of Tetrahydrofuron-imidazole based building blocks 
for Histamine H3 and H4 receptor agonists                                                                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Towards the synthesis of histamine H3 and H4 receptor agonists                                                                             
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